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ABSTRACT 
Type 1 diabetes (T1D) develops in genetically susceptible individuals due to an auto-immune 
mediated destruction of pancreatic beta-cells. Disproportionately affecting non-Hispanic 
Caucasians, it is becoming more common among other races/ethnicities. With improvements in 
T1D management, patients can expect to live almost as long as people without T1D. 
Consequently, these patients will live longer with diabetes-associated complications, causing 
higher healthcare costs and reduced quality of life. When taken in consideration with a 
projected 3-5% annual increase in T1D incidence, preventing or delaying the onset and 
progression of diabetes complications deserves immediate public health attention. 
While most T1D-related complications are well researched, its deleterious effects on the 
brain have received less attention. Because the majority of T1D brain studies have focused on 
pediatric and young adult populations, the complex interplay between increasing age and T1D-
related brain abnormalities remains unclear. The goal of this research is to bring attention to 
the effects of childhood-onset T1D on brain structure and function in middle-aged adults who 
are also experiencing aging-induced cerebral insults. Data from a subset of middle-aged adults 
participating in the Pittsburgh Epidemiology of Diabetes Complications Study (EDC), diagnosed 
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with childhood-onset T1D between 1950-80, baseline 1986-88 and who underwent brain 
imaging and neuropsychological testing between 2010 and 2013 was used to address this goal, 
yielding some novel results.  
First, the presence and severity of white matter hyperintensities was dramatically 
greater in those with vs. without T1D. These lesions developed at a younger-than-expected age 
and were independent of traditional cardiovascular risk factors. Skin intrinsic fluorescence and 
smoking were identified as factors deserving further exploration. Second, adults with vs. 
without T1D scored worse on IQ, executive function and psychomotor tasks. Chronic 
hyperglycemia, proliferative retinopathy and polyneuropathy were related to worse task 
scores, suggesting a systemic effect of chronic hyperglycemia. Third, among those with T1D, 
reduced blood flow to the prefrontal cortex and superior parietal lobes was related to cognitive 
dysfunction; these regions are important for information processing and executive function, 
tasks found to be impaired in T1D participants. These results suggest that altered brain 
structure and function should be considered a T1D complication with important public health 
relevance.  
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1.0  INTRODUCTION 
Diabetes mellitus (DM), a disease marked by impaired glucose regulation, has afflicted humans 
for thousands of years, with the earliest written reference made by Egyptian physicians circa 
1500 B.C.1 The disease is classified into two primary categories, type 1 and type 2, although 
lesser known types also exist. Type 1 diabetes (T1D), formerly known as juvenile onset or 
insulin dependent diabetes, develops due to autoimmune-mediated destruction of pancreas 
beta-cells, resulting in loss of insulin production. Diagnosis of T1D typically occurs before age 20 
although it can be diagnosed at a more advanced age. Type 2 diabetes (T2D), formerly referred 
to as non-insulin dependent diabetes, develops due to the body’s inability to properly utilize 
insulin. It is most commonly diagnosed among individuals aged 40 and older after a period of 
insulin resistance. An alarming trend, however, of increasing T2D incidence rates in teens and 
children is occurring as physical inactivity and obesity rates are also increasing in youth.  
According to the Centers for Disease Control and Prevention (CDC), an estimated 1.7 
million new cases of DM, the majority of those being T2DM, were diagnosed among Americans 
age 20 and older in 2012.2 Improvements in diabetes management, combined with public 
health efforts to increase disease awareness and earlier diagnosis, have resulted in people 
living longer with the disease, as indicated by rising prevalence rates each year. Approximately 
29 million American adults, 9.3% of the population, were living with the disease in 2012; 
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alarmingly, an estimated 8 million of these people (28%) were unaware they had developed the 
disease.2 Type 1 diabetes makes up roughly 5% of all diabetes cases, with the overwhelming 
majority, 90-95%, being type 2.3   
 
 
Figure 1.1. Conceptual framework of diabetes pathogenesis, effects and complications 
 
Chronic hyperglycemia is associated with the development of specific complications in 
people with diabetes. These can be broadly categorized as microvascular and macrovascular 
complications. Diabetes is known to have negative effects on vision (retinopathy), kidney 
function (microalbuminuria, nephropathy and renal failure) and nerve function (neuropathy). It 
is also associated with higher rates of depression, certain cancers, infections (and delayed 
healing), non-traumatic amputations, especially of lower extremities, stroke, heart disease and 
death. Changes to brain structure and function, on the other hand, are less recognized 
complications of diabetes. Recent advances in neuroimaging techniques have greatly improved 
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researchers’ ability to investigate the effects of diabetes on brain structure and function, yet 
these results remain under debate.  
The primary aim of this paper is to demonstrate the deleterious effects of type 1 
diabetes on brain structure and function in middle-aged adults. To achieve this aim, this 
research will (1) characterize structural changes in the brains of adults with T1D and (2) 
demonstrate that these structural changes are associated with poorer performance in 
neurocognitive tasks. A secondary aim is to identify factors related to changes in brain structure 
and function that may be amenable to interventions. Brain imaging and comprehensive 
neuropsychological test data from a well-characterized population of adults with childhood-
onset T1D will be analyzed and compared to a similarly aged population without T1D to address 
these aims.  
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2.0  DIABETES MELLITUS 
This section briefly introduces the types of diabetes. It also presents the current understanding 
of the epidemiology and etiology (i.e., genetics and risk factors) associated with the two major 
types of diabetes.  
 
2.1 TYPE 1 DIABETES 
Type 1 diabetes, previously known as juvenile or insulin-dependent diabetes, refers to the 
condition in which the pancreas beta cells lose their ability to secrete insulin in sufficient 
amounts to maintain glucose homeostasis.3 Individuals with T1D require exogenous insulin to 
properly utilize glucose for energy. It is among the most frequently diagnosed metabolic 
disorders in children. 
2.1.1 Epidemiology 
Even though the majority of T1D cases are diagnosed before age 20, it can develop at any 
age.3,4 Symptoms vary somewhat, depending on the degree of beta cell destruction. Common 
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symptoms include polydipsia, polyuria, gastrointestinal distress or pain, lethargy and weight 
loss. In younger children, these signs may go unnoticed, with T1D diagnosed only after the child 
suffers a ketosis-induced coma.   
According to the Juvenile Diabetes Research Foundation (JDRF), as many as three million 
Americans are living with T1D, 85% of whom are adults (http://jdrf.org/about-jdrf/fact-
sheets/jdrf-and-diabetes-statistics/). The JDRF website also reports that approximately 80 
Americans are diagnosed with T1D each day, with an estimated 15,000 children and 15,000 
adults diagnosed annually. On a global scale, the International Diabetes Foundation (IDF) 
estimates that the world-wide incidence of T1D increases by 3% annually.5  
Type 1 diabetes is the only organ-specific autoimmune disease not occurring more 
frequently among females than males.6 While the overall incidence rates are fairly equal in 
children diagnosed prior to age 15, a male to female ratio of 2:3 is seen among those of 
Western European descent diagnosed between the ages of 15-40 years.7 Williams et al. (2002) 
tested 10,326 non-diabetic first-degree relatives of patients with T1D (diagnosed prior to age 
20) for islet cell antibodies (ICA). This population of individuals, all younger than 40 years of age 
and representing eight European countries (Austria, Greece, Hungary, Norway, Poland, Russia, 
Turkey and the United Kingdom), displayed similar rates of islet autoimmunity even though T1D 
rates vary tremendously across these countries. Levels of ICA were similar for males and 
females until age 10. Among individuals aged 10-20 years, however, islet autoimmunity was 
almost 2.5 times higher among males than females. This provides some explanation as to why 
T1D rates begin to show a sex difference around age 10.6   
 6 
Racial differences in T1D rates also exist. Based on data from 2002-2005, the SEARCH for 
Diabetes in Youth, a collaboration between the National Institutes of Health (NIH) and the CDC 
found that, in the US, non-Hispanic white youths had the highest incidence of T1D, 
24.8/100,000 per year among those under age 10, and 22.6/100,000 per year among those age 
10-19 years. Over this same time, incidence rates for non-Hispanic blacks under age 10 were 
16.5/100,000 per year, followed by 15/100,000 per year among Hispanics, 7/100,000 per year 
among Asian-Pacific Islanders, and 4/100,000 per year among American Indians. The same 
trend was observed for those aged 10-19 years; the incidence rate among non-Hispanic blacks 
was 15/100,000 per year, followed by 13.5/100,000 per year among Hispanics, 7.7/100,000 per 
year among Asian-Pacific Islanders and 5.2/100,000 among American Indians 
(http://diabetes.niddk. nih.gov/dm/pubs/statistics/).8  
 
2.1.2 Etiology 
There is no single cause of type 1 diabetes; it is a complex disease with suspected 
environmental triggering of the condition that only occurs among individuals with a genetic 
predisposition. The lifetime risk of T1D in the general population is estimated to be 0.4%, with 
higher risk conferred to individuals who have a first degree relative with T1D. Interestingly, 
having a father with T1D increases a child’s risk of developing the disease by 3-5% whereas 
having a mother with T1D increases the child’s risk by only 1-2%.9  
 
 7 
2.1.2.1 Genetics 
Type 1 diabetes is a complex, multigenic disorder that is not yet fully understood. In the early 
1970s, the human leukocyte antigen (HLA), located on the sixth chromosome, became the first 
gene to be associated with T1D.10 Roughly half of all T1D cases are associated with HLA, an 
antigen which encodes glycoproteins that allow the immune system to differentiate self from 
non-self.11 The HLA DR3 and DR4 alleles are most highly associated with the risk of developing 
T1D, with the highest susceptibility seen in those with the DR3/DR4 combination. Children with 
this genotype have a 5% risk of developing T1D by the age of 159 while the DR2 allele is 
protective against T1D.10,11 
In 1983, researchers found a genetic link between T1D and the insulin (INS) gene. This 
gene is found on the 11th chromosome and as the name implies, is involved in coding for insulin 
production. The class I allele appears to increase the risk of T1D while the class III allele is 
protective.10  
An additional six genes are now known to be related to T1D. Cytotoxic T-lymphocyte 
antigen (CTLA-4) gene on chromosome 2 leads to an increase in T-cell self-reactivity thereby 
increasing the risk of autoimmune disorders. Protein tyrosine phosphatase non-receptor 22 
(PTPN22) on chromosome 1 appears to increase the negative regulation of T- cell activation. 
Interleukin 2 receptor alpha (IL2RA) on chromosome 10 encodes the IL-2 receptor complex and 
thereby controls the production of regulatory T-cells. Interferon induced with helicase C 
domain 1 (IFIH1) on chromosome 2 is believed to be involved in releasing interferon-gamma, 
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leading to apoptosis of virally-infected β cells; the GG genotype is associated with shorter time 
to overt diabetes than the GA or AA genotypes.9-12 
2.1.2.2 Risk Factors 
Type 1 diabetes has very few established risk factors. Having the genes for islet cell 
autoimmunity, and having a first degree relative with T1D, point to a strong genetic 
component, yet most cases of T1D are diagnosed among individuals with no family history of 
the disease.  
Proposed environmental triggers include exposure to the Epstein-Barr virus, 
cytomegalovirus, coxsackievirus or the mumps virus. It is believed that infection with these 
agents either stimulates the body’s autoimmune response to attack the islet cells, or it may be 
that these viruses directly infect the pancreas, leading to beta cell destruction. Low levels of 
vitamin D have been offered as a risk factor, supported by the increased rates in northern 
countries with lower sunlight. Contradicting this theory, however, is that early exposure to 
dairy products such as cow’s milk, a good source of vitamin D, appears to be associated with an 
increased risk of T1D. Evidence seems to support an increased risk of T1D as maternal age 
increases, with the highest risk in children born to mothers age 45 and older.13 According to the 
Mayo Clinic website, babies born with jaundice or who develop respiratory infections within the 
first week after delivery may also have an increased risk of developing T1D 
(http://www.mayoclinic.org/diseases-conditions/type-1-diabetes/basics/risk-factors/con-
20019573). 
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Figure 2.1.1 Conceptual framework of type 1 diabetes pathogenesis, effects and complications 
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2.2 TYPE 2 DIABETES 
Previously known as non-insulin-dependent diabetes, type 2 diabetes (T2D) refers to the 
condition in which the body becomes resistant to insulin and fails to properly utilize glucose. 
Type 2 diabetes is by far the most commonly diagnosed type, accounting for 90-95% of all 
diabetes cases.3 Even though it is most frequently diagnosed among adults age 45 and older, 
T2D is becoming increasingly common among younger adults, even among children. The rise in 
obesity and sedentary lifestyle in these age groups is blamed for this disturbing trend. 
2.2.1 Epidemiology 
Over the past thirty years, the number of newly diagnosed cases of T2D among adults aged 20 
and older has tripled, increasing from 493,000 in 1980 to more than 1.9 million in 2012.2 Data 
from the 1980 and 2010 Behavioral Risk Factor Surveillance System (BRFSS) show that adults 
age 18-44 have experienced the greatest percentage increase in newly diagnosed T2D cases, 
from 1.7/1000 in 1980 to 4.6/1000 in 2010. Adults over age 65 continue to have the highest 
overall T2D incidence rate, increasing from 6.2/1000 in 1980 to 12.4/1000 in 2010. The most 
recent national diabetes fact sheet estimates that half of all new T2D cases in 2010 were 
diagnosed in adults between 50 and 64 years of age, with roughly 21% of new cases diagnosed 
in adults aged 65 and older.2 Type 2 diabetes affects males and females equally, with an 
estimated 13 million males (11.8%) and 12.6 million females (10.8%) over the age of 20 living 
with T2D.   
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In contrast to T1D, non-Hispanic whites have the lowest prevalence of T2D (7.1%), based 
on 2007-2009 US survey data.2 Non-Hispanic blacks have the highest prevalence (12.6%) over 
this same time period. Prevalence among Hispanics approaches that of Non-Hispanic blacks 
(11.8%); prevalence is estimated at 8.4% among Asian Americans.2,3 
2.2.2 Etiology 
Like type 1 diabetes, type 2 diabetes is a complex disease with no single cause. T2D typically 
develops insidiously over a number of years. Both lifestyle behaviors, which are generally 
considered modifiable, and environmental factors, generally considered less-modifiable, 
contribute to the development of T2D.   
2.2.2.1 Genetics 
Type 2 diabetes is a complex disease with multiple risk factors and a strong genetic component. 
Identical twin studies of T2D generally show greater than 70% concordance, indicating a 
moderate genetic contribution to T2D risk.11 Genome-wide association studies (GWAS) have 
identified more than 70 genes influencing development of T2D.14 Even though a large number 
of genes are identified, their effect size is small (OR 1.1-1.2), indicating that more genes remain 
to be identified. Furthermore, most (96%) GWAS studies to date have concentrated on 
Caucasian populations, so the risks conferred by these genes cannot be generalized to other 
races/ethnicities; GWAS studies are underway to investigate the heritability of T2D in other 
populations.14 
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2.2.2.2 Risk Factors 
Unlike T1D, multiple risk factors are known for T2D, with increasing age and overweight/obesity 
considered the primary risk factors. Other strong risk factors include race, family history of T2D, 
abdominal adiposity and physical inactivity or sedentary lifestyle. Women who develop 
gestational diabetes or who deliver a baby weighing more than nine pounds have an increased 
risk of developing T2D, as do these offspring. Having “pre-diabetes” or insulin resistance, 
impaired glucose tolerance, hypertension, dyslipidemia, cardiovascular disease and polycystic 
ovary syndrome (PCOS) also increase the risk of developing T2D. Recently, depression has 
become recognized as both a risk factor for, and a consequence of, type 2 diabetes.15 
Importantly, many of these risk factors tend to co-occur; individuals with higher combinations 
of these risk factors have a greater risk of developing T2D than does a person with only one or 
two factors. 
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Figure 2.2. Conceptual framework of type 2 diabetes pathogenesis, effects and complications 
 
2.2.3 Prevention and Intervention 
Currently, type 1 diabetes can only be managed (although some may consider pancreatic 
transplantation a ‘cure’), while T2D is considered to be a mostly preventable disease. Results 
from the Diabetes Prevention Program (DPP) and several other international intervention trials 
show that lifestyle changes, such as dietary changes, modest weight reduction and greater 
physical activity can prevent or delay the development of T2D among high-risk individuals.16-19   
In some individuals with T2D, the disease can be managed through diet and lifestyle 
alone although most will eventually require oral agents to maintain glucose regulation. For a 
percentage of T2D cases, oral agents cease to adequately manage the disease after a number of 
Metabolic 
Syndrome 
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years. These individuals eventually require exogenous insulin in addition to or in place of their 
oral medication(s).20 Interest is growing to determine if early insulin treatment in T2D patients 
significantly improves glycemic control and lowers long-term complication rates, with recent 
trials exploring whether early therapy with insulin or Exenatide® better protect against diabetes 
complications.21-24 
2.3 OTHER TYPES OF DIABETES MELLITUS 
The vast majority, approximately 95%, of diabetes mellitus cases fall in the type 1 or type 2 
classifications. Gestational diabetes (GD) develops in 2-10% of pregnancies each year in the 
U.S., with African-American, Native American and Hispanic women more likely to develop the 
condition compared to non-Hispanic Caucasian women.3 While GD usually resolves post-
delivery, some 5-10% of women do not recover and are diagnosed with T2D shortly after their 
delivery. As mentioned earlier, GD is a risk factor for T2D, with between 35-60% of women 
diagnosed with GD going on to develop T2D within 20 years. Children of women with GD are 
also at higher risk of developing T2D.  
Other rare types of DM are related to specific conditions or diseases. These make up 
only 1-5% of all diabetes cases. Examples include pancreatectomy, chronic pancreatitis, cystic 
fibrosis, pancreatic cancer, glucagonoma, pheochromocytoma, Cushing’s Syndrome, Wolfram 
Syndrome and congenital lipoatrophic disorders.25-31 
15 
3.0  DIABETES MELLITUS COMPLICATIONS 
People with T1D or T2D may develop the same complications, but the onset and progression 
differ by diabetes type as well as by individual variability. Complications can be classified as 
chronic or acute as well as by micro- or macrovascular nature. It is possible that the 
pathophysiology of complications differ by type but further studies are needed to determine 
the mechanisms contributing to the development of complications. This section will discuss the 
well-known complications related to diabetes mellitus. 
3.1 CHRONIC COMPLICATIONS 
Long-term exposure to hyperglycemia adversely affects numerous body systems although great 
variability exists between rates of these complications. Individual differences in disease control 
efforts, duration of disease, age at disease onset and presence/control of comorbidities (e.g. 
hypertension, dyslipidemia, depression and anxiety) all contribute to the development and 
severity of diabetes-related complications. These complications can be divided into 
microvascular and macrovascular conditions. Generally, T1D is more commonly associated with 
microvascular complications while macrovascular complications occur more frequently among 
those with T2D.     
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3.1.1 Microvascular Complications 
Chronic hyperglycemia damages small blood vessels throughout the body. The most common 
diabetes-related microvascular complications are retinopathy, nephropathy and neuropathy. 
For individuals with T1D, these conditions are typically diagnosed many years after the onset of 
diabetes. For many with T2D, it is not uncommon for patients to show early signs of at least one 
of the three above-mentioned conditions at the time of their T2D diagnosis.  
Diabetic retinopathy is the leading cause of blindness among adults ages 20-74 in the 
United States.32 This is a progressive condition, characterized by growth of new blood vessels 
along the retina and often associated with a build-up of fibrous tissue between the vessels and 
the retina. These new blood vessels are prone to hemorrhaging, leading to macular edema and 
increased risk of glaucoma, all of which can lead to partial or complete permanent blindness. 
Diabetes duration appears to be the strongest predictor of retinopathy.33 Within 15 years of 
their diagnosis, 25-50% of patients with T1D develop some degree of retinopathy; the condition 
affects virtually 100% of T1D patients within 30 years of diagnosis.34 The prevalence of non-
proliferative retinopathy is somewhat lower in T2D than in T1D, affecting approximately 20-
30% of T2D patients within 15 years of diagnosis. According to Crawford et al. (2009), 
proliferative retinopathy was found in only 3% of T2D patients compared to 17% of T1D 
patients 11 years post-diagnosis.34 
Diabetic nephropathy  in the forms of intercapillary glomerulonephritis, nodular diabetic 
glomerulosclerosis or Kimmelstiel-Wilson syndrome occurs in 20-30% of those with T1D or 
T2D.35 In its earliest stage, termed microalbuminuria, low but abnormal levels of albumin can 
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be detected in urine samples. Glomerular filtration function continues to decline at a variable 
rate, ranging from a loss of 2-20 ml/min/yr., depending on individual factors.36 Confirmation of 
overt nephropathy (ON) occurs when urine protein levels surpass 300 mg/day.35  
According to the 2004 American Diabetes Association (ADA) position statement, 80% of 
T1D patients with microalbuminuria will progress to ON within 10-15 years if they do not 
receive some type of intervention. Among T1D patients with ON, 50% will progress to end stage 
renal disease (ESRD) within 10 years, and in more than 75% within 20 years, unless they receive 
some type of targeted intervention.35 Microalbuminuria is present in 20-25% of T2D patients at 
time of diagnosis, due to the long latency between the biological onset and diagnosis of T2D.36 
Without specific intervention, roughly 20-40% of T2D patients will progress from micro-
albuminuria to ON over a 20 year period. Unlike T1D patients, however, only 20% of T2D 
patients with ON will progress to ESRD within 20 years of the onset of nephropathy. This may 
be due to the high mortality rate related to cardiovascular disease (CVD) among T2D patients; 
as T2D-related CVD mortality rates fall, there may be a related increase in ESRD in this 
population.35  
Diabetic neuropathy is a common microvascular complication affecting nerve function. 
Several types exist, affecting different areas of the nervous system; these can be focal or 
diffuse. The most common types are distal symmetric polyneuropathy (DSP) and neuropathies 
involving the autonomic nervous system.37 Roughly half of those with DSP are asymptomatic; 
these individuals are at a greater risk of unrecognized injuries to the extremities, resulting in 
greater risk for amputations. Symptomatic individuals describe burning or “electrical” pain or 
numbness in the feet, legs and/or hands, with intensification of pain at night.32 Those with an 
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autonomic neuropathy are at an increased risk of morbidity and mortality, particularly those 
with cardiac autonomic neuropathy (CAN).37 Other organ systems can also be affected, leading 
to “gastroparesis, constipation, diarrhea, anhidrosis, bladder dysfunction, erectile dysfunction, 
exercise intolerance, resting tachycardia, silent ischemia, and even sudden cardiac death.”32 
The exact etiology of diabetic neuropathy remains unclear, but exposure to chronic 
hyperglycemia, tissue ischemia, oxidative stress and accumulation of advanced glycation end-
products (AGEs) all potentially contribute to the development of diabetic neuropathy.32  
3.1.2 Macrovascular Complications 
Exposure to chronic hyperglycemia and resultant AGEs, as well as chronic inflammation and 
oxidative stress, damage large blood vessels throughout the body, primarily via atherosclerosis. 
Plaques accumulate throughout the arteries, leading to reduced blood flow and increased 
pressure against the arterial walls. An acute vascular event will occur should one of these 
lesions rupture.32 Because people with T2D are more likely to also have metabolic syndrome 
with high risk factors for cardiovascular disease, such as central adiposity, dyslipidemia and 
hypertension, they have a greater risk of suffering from diabetes-related macrovascular 
complications compared to those with T1D.38 Results from the United Kingdom Prospective 
Diabetes Study (UKPDS) show that tight control of cardiovascular risk factors decreased 
mortality from T2D-related conditions by 32%, two-thirds of which were related to 
cardiovascular disease.39  
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Coronary artery disease (CAD) is the leading cause of death in people with T2D.40 In fact, 
the risk of a first myocardial infarction (MI) in those with T2D is equivalent to the risk of a 
second MI in people without diabetes. Those with T2D are also more likely to die from a first MI 
compared to people without diabetes.41 Among T1D patients, CAD is highly associated with 
increased mortality, with evidence of an association between chronically elevated blood 
glucose and an increased risk of fatal CAD.42 This same study also found that lower insulin dose, 
in addition to many standard risk factors for cardiovascular disease, was associated with a 
greater prevalence of non-fatal CAD.42 
Cerebrovascular disease (CVD) includes stroke and transient ischemic attack (TIA). Data 
from the Baltimore-Washington Cooperative Young Stroke Study found more than a ten-fold 
higher risk for stroke among DM participants younger than age 44 compared to those without 
diabetes.43 Additionally, those with DM are more likely to die from a stroke compared to 
individuals without diabetes. Furthermore, individuals with DM who survive a stroke are more 
likely to experience another stroke and have more than triple the risk of developing stroke-
related dementia compared to individuals without diabetes.44 
Peripheral artery disease (PAD) occurs due to reduced blood flow to the extremities. It is 
particularly common in the legs and is highly associated with intermittent claudication (pain 
when standing or walking).45 Diabetes doubles to quadruples the risk of developing PAD and 
this reduced blood flow in the legs is associated with a 20-fold increased risk of lower extremity 
amputations among adults age 65-74 years.44 Controlling glycemic levels and treating 
dyslipidemia and hypertension significantly lower the risk of PAD and other macrovascular 
complications in patients with DM.44 
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3.2 ACUTE COMPLICATIONS 
Most of the acute DM complications result from severe hyperglycemia: diabetic ketoacidosis 
(DKA), hyperosmolar hyperglycemic state (HHS) and lactic acidosis (LA). HHS primarily affects 
those with T2D while DKA primarily occurs among those with T1D. Both types may be affected 
by LA. Hypoglycemic events are most common among T1D patients but can sometimes occur in 
T2D patients attempting tight glucose control.  
Diabetic Ketoacidosis (DKA) occurs in the absence of insulin, e.g. in people with T1D, 
because the body cannot properly utilize glucose for energy. Starving tissues signal the liver to 
increase the production of glucose, leading to hyperglycemia. The kidneys work to remove the 
excess glucose through the urine, causing water and salts to also be excreted; this process is 
termed osmotic diuresis. This becomes a cycle leading to dehydration, polydipsia and polyuria. 
Eventually, the liver begins to burn fatty acids for fuel (lipolysis), with the end result being a 
build-up of ketone bodies in the blood, causing the blood pH to drop (acidosis). If left 
uncorrected, DKA is life-threatening, causing coma, seizures and cerebral edema. DKA is fairly 
common among those with T1D, often being the presenting symptom leading to a diagnosis of 
T1D in youth. The condition may occur on rare occasions in those with T2D, such as during 
periods of extreme stress or severe illness. 
Hyperosmolar Hyperglycemic State (HHS) may present after prolonged periods of 
hyperglycemia among people with DM, particularly T2D. This condition was formerly known as 
hyperosmolar non-ketotic coma or non-ketotic hyperosmolar coma. HHS is similar to DKA in 
that hyperglycemia leads to dehydration and depletion of solutes. Unlike DKA, ketone bodies 
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are usually not present in HHS. Untreated, HHS can result in coma, seizures and death. Most 
cases of HHS occur in individuals suffering from an illness such as pneumonia, influenza, stroke 
or heart failure.  
Lactic Acidosis refers to a type of metabolic acidosis defined by “a large anion gap, low 
pH of arterial blood, substantial reduction of bicarbonate levels and increased lactic acid levels”  
and is usually diagnosed when pH drops below 7.37 and lactic acid levels rise over 5 mmol/L.46 
Once a somewhat common and often fatal complication related to the medication phenformin, 
LA has become quite rare in DM patients, estimated at 3.3 cases per 100,000 patient years, and 
is now most commonly diagnosed among individuals using the oral antidiabetic drug 
metformin.46 In rare instances, LA can co-occur with DKA in patients with T1D, and with HHS in 
patients with T2D. It seems to be more common among DM patients who abuse alcohol, 
perhaps due to liver damage, but the exact cause is unknown.45 
Hypoglycemia refers to low blood glucose (< 70 mg/dL) and is a frequent complication 
among those using insulin or the oral drugs sulfonylurea and glinide.47 DM patients able to 
recognize symptoms of hypoglycemia can usually reverse the low glucose level with no adverse 
effect. If, however, the individual is hypoglycemic unaware or cannot access food/drink or 
another source of glucose, the blood glucose can drop to dangerous levels, leading to “severe” 
hypoglycemic events. In such an event, the individual needs assistance to reverse the low 
glucose levels (e.g., glucagon injection). Some may lose consciousness and many require 
hospitalization to correct glucose levels. Hypoglycemia occurs much more frequently among 
those with T1D than with T2D, with the incidence of severe hypoglycemic events ranging from 
115-320 per 100 patient years for those with T1D compared to 35-70 per 100 patient years for 
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those with T2D.47 The most common complaint associated with hypoglycemia is short-term 
neurological impairment that appears to resolve shortly after establishing normoglycemia.48,49 
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4.0  TYPE 1 DIABETES AND BRAIN STRUCTURE 
The brain parenchyma is comprised of two types of tissue, described by their color: gray and 
white matter.  
White matter (WM) forms the bulk of the deep brain. It consists mainly of axon fibers 
and glial cells. Glial cells serve to support and protect neurons. Cerebral axons are enveloped in 
myelin, an insulating layer of oligodendrocytes. This white, fatty myelin sheath, from which WM 
derives its name, allows saltatory conduction of nerve impulses. Damaged myelin impedes 
impulse transmission with resultant deficits in cognitive and/or physical function (e.g., balance, 
speech) as evidenced by demyelinating neurodegenerative diseases such as multiple sclerosis.  
Cerebral gray matter (GM) is comprised of neuronal cell bodies, dendrites, astrocytes 
and oligodendrocytes supplied by an intricate capillary network. It is distributed primarily along 
the brain surface although there are sub-cortical GM structures: the thalamus, hypothalamus, 
subthalamus, basal ganglia, hippocampus, amygdale and the olfactory nucleus. Gray matter 
structures are also found in the cerebellum: the dentate, fastigial, globose and emboliform 
nuclei, and in the brain stem: the substantia nigra, red nucleus, olivary and cranial nerve nuclei. 
Even though research has linked gray matter volume with a number of outcomes including 
mobility,50 cognitive function,51,52 addiction,53 mental disorders54 and mood disorders, GM 
damage remains an area of active research with many unknowns. For example, multiple 
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sclerosis research previously focused on WM damage and only in the past year have 
researchers determined it also affects cerebral GM.55 This research hopes to contribute to 
understanding several of these unknowns. For example: does an association exist between gray 
matter volume and cognitive dysfunction in middle-aged adults with T1D?; if present, is the 
effect of GM volume global or focal?; could microstructural measures of gray matter integrity 
such as GM diffusivity and/or cerebral blood flow identify individuals at risk of cognitive 
dysfunction who may benefit from a pharmaceutical or lifestyle intervention?     
4.1 TYPE 1 DIABETES AND CEREBRAL SMALL VESSEL DISEASE 
As discussed previously, T1D causes both microvascular and macrovascular complications (see 
Sections 3.1.1, 3.1.2). These are systemic vascular effects; cerebral blood vessels are not 
immune to the effects of T1D. Indeed, cerebral macrovascular damage leading to an increased 
risk of hemorrhagic stroke in individuals with T1D is well recognized.43,56 Conversely, cerebral 
microangiopathy in T1D is not well-studied and deserves further investigation.  
Increasing age and hypertension have been established as the major risk factors for 
cerebral small vessel disease (SVD).57 Hyperglycemia has also been identified as an important 
contributor to the development of SVD not only in the brain, but in the kidneys and eyes as 
well.58 Even though hypertension and hyperglycemia cause impaired vascular tone (i.e., vessel 
stiffening), the mechanisms by which these factors damage cerebral small vessels are 
heterogeneous and not fully understood; Figure 4.1 presents a simplified proposed mechanistic 
pathway by which these factors affect brain structure and function. Hyperglycemia causes 
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oxidative stress which leads to endothelial dysfunction and resultant tissue hypoperfusion.59 
Similarly, hypertension results in vessel wall stiffening, endothelial dysfunction and 
hypoperfusion. Cerebral small vessel damage compromises the blood-brain-barrier. Chronic 
hypoperfusion leads to loss of neurons60 and oligodendrocytes61 and glial activation.62 
Hypoperfusion causes acute closing of pre- and post- capillary sphincters and in the longer 
term, causes microemboli to develop, clogging capillary beds and eventually a loss of 
capillaries.57   
 
Figure 4.1 Proposed pathophysiological pathways for diabetes-related changes in brain 
structure and resultant changes in brain function. 
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4.2 ASSESSING BRAIN STRUCTURE USING NEUROIMAGING 
The etiology of many important disorders of the central nervous system remains elusive. For 
some diseases, like stroke, the most important risk determinants have been identified but 
better prevention and therapeutic approaches are needed to reduce the continued high 
incidence and mortality, especially in selected racial, ethnic and socioeconomic groups. Evolving 
new technologies for studying disease etiology, pathologies and host susceptibility provide 
potential opportunities to define these conditions, to understand their etiology and to respond 
with effective prevention and treatments. Specifically, the application of advanced imaging 
methodologies can facilitate the phenotype’s characterization earlier in the course of the 
disease, can improve causal inference in observational epidemiological studies and can enable 
accurate monitoring of response to therapy.   
Evolving technologies alone, however, are not sufficient to advance our understanding 
of the etiology and pathogenesis of disorders of the central nervous system. It is essential to 
understand how to apply such technology in the context of carefully characterized populations, 
especially those with larger sample size and unique characteristics, i.e. higher or lower 
incidence of disease, that are followed in studies which are rigorously conducted and designed.   
4.3 ASSESSING CEREBRAL WHITE MATTER HEALTH USING NEUROIMAGING 
Studies show that T1D patients tend to have smaller WM volumes compared to their non-T1D 
peers.63-68 White matter volume, however, is not the best indication of brain function. Other 
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neuroimaging measures provide a better assessment of white matter integrity at both the 
micro- and macro-structural levels. 
4.3.1 White Matter Hyperintensities 
White matter hyperintensities (WMH) serve as a macrostructural marker of cerebral small 
vessel disease. WMH appear as bright areas on T2-weighted fluid attenuated inversion recovery 
(FLAIR) images.69,70 Although sometimes located deep in the white matter, they are more 
frequently noted at the periventricular caps and rims.70 WMH are associated with advanced 
microvascular disease70-72 and represent a heterogeneous set of conditions such as gliosis,  
demyelination, myelin pallor70,72,73 or post-inflammatory water retention in the interstitial 
space.74  
Cerebral WMH are common MRI findings among adults over age 65,75 with a prevalence 
rate ranging from 60-100%.76,77 Advancing age is the strongest predictor of WMH, with 
hypertension and hyperglycemia important contributors.58,70,75,77 Even though the exact nature 
of WMH cannot be determined by MRI alone (e.g., demyelination vs. gliosis), these lesions are 
not benign. Brain imaging studies in elderly populations demonstrate that the presence of 
WMH is associated with increased rates of stroke, disability, depression, dementia and 
death.70,72,78,79 The implications of WMH presence in adults ages 40-50 remains controversial, 
with prevalence estimates ranging from 0-50%.80-82 Because they are not common findings in 
adults at this age range, few studies exist that investigate WMH in healthy adults younger than 
age 60.   
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4.3.2 Fractional Anisotropy 
Diffusion tensor imaging (DTI), a neuroimaging technique based on the three-dimensional 
diffusion of water molecules, is useful in assessing WM integrity at the microstructural level.83 
In unrestricted environments, water molecules diffuse freely in random directions (isotropic 
diffusion). In restricted environments, diffusion is largely unidirectional; this is known as 
anisotropic diffusion.83 Myelinated bundles of axons in cerebral white matter restrict water 
movement, with healthy myelin allowing diffusion parallel to the axons (axonal diffusivity) and 
prohibiting diffusion perpendicular to the axons (radial diffusivity). Axonal and radial diffusivity 
values are used to calculate the fractional anisotropy (FA) for each voxel of cerebral white 
matter.  
FA is a scalar (0-1) measure that describes the magnitude, orientation and direction of 
diffusion. Low FA values are interpreted as areas of poor myelin integrity, low fiber density or 
axonal damage. Importantly, DTI assumes that all the fibers within each voxel travel in the same 
direction. In reality, fibers within voxels often cross, bend and otherwise change directions. This 
creates a challenge when interpreting changes in FA values; does a reduction in FA truly 
represent WM damage or is it merely an artifact caused by crossing or kissing fascicles in the 
same voxel?  
DTI requires a minimum of six diffusion directions to estimate the diffusion tensor, from 
which FA is calculated. Researchers now prefer to use 32-64 directions to improve the signal to 
noise ratio, but this does not overcome the issue of crossing/bending fibers.84 Alternative 
imaging protocols that do not rely on estimating a diffusion tensor, such as diffusion spectrum 
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imaging85 and high angular resolution diffusion imaging (HARDI)86 provide a solution to the 
crossing fiber issue. As researchers continue to refine and cross-validate these methods, they 
may replace the current DTI protocol as the standard tool to analyze cerebral WM health.  
DTI also assumes that each voxel depicts only one tissue type. In reality, an estimated 
30-50% of voxels classified as being WM also contain other tissue types, i.e., gray matter and/or 
cerebrospinal fluid (CSF).87 The presence of multiple tissue types in the same voxel causes what 
is known as partial volume effects. Because of their isotropic diffusion, contamination by GM or 
CSF will cause a spurious reduction in FA.88 To overcome partial volume effects on FA, image 
acquisition parameters can be adjusted to reduce the influence of partial volume effects on FA 
values. Using smaller voxel sizes and increasing directions, for a higher signal-to-noise ratio, are 
easily employed strategies to deal with partial volume effects.87 In addition, use of a shorter 
repetition time (TR) and a minimum diffusion weight (b value) greater than zero have been 
shown to reduce the effects of CSF contamination in calculating FA values.89 
4.3.3 Type 1 Diabetes and White Matter Hyperintensities 
Relatively few MRI studies have examined the prevalence of WMH in middle aged adults with 
T1D 90-97 and these yield conflicting results. Out of the five case-control studies comparing WMH 
in participants with vs. without T1D,90,92,95-97 only Dejgaard et al.90 found a significant between-
group difference in WMH prevalence.92,93,95,97 In one study comparing WMH between patients 
with T1D and T2D, a significantly greater number of deep WMH were detected among T2D 
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compared to T1D participants.98 While their presence does relate to suboptimal brain health, 
the exact effects of WMH on brain function remain to be determined.   
4.3.4 Type 1 Diabetes and Fractional Anisotropy 
Only three studies were found using DTI in T1D populations,99-101 with two of these from the 
same group and using the same T1D population.99,100 All three reported significantly lower 
fractional anisotropy (FA) among T1D participants compared to non-DM controls, suggesting 
reduced WM integrity in those with T1D. In a group of 73 children (mean age 16.8 years) with 
T1D, an increasing frequency of severe hyperglycemic episodes was significantly related to 
lower FA in the superior parietal lobe whereas FA in this same region significantly increased 
with increasing frequency of hypoglycemic episodes.101 In a study of 25 adults with T1D, mean 
age 45 years, Kodl et al. (2008) reported a significant association between older age, longer 
diabetes duration and higher A1c and lower FA values in the optic radiation and posterior 
corona radiata; longer disease duration was also significantly related with lower FA in the 
splenium.99 Moreover, reduced FA was associated with worse performance on the Rey -
Osterreith Complex Figure, copy task, and the Grooved Peg Board test, both of which involve 
sensory motor integration and therefore provide some indication of cerebral white matter 
health.99 
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4.4 ASSESSING CEREBRAL GRAY MATTER HEALTH USING NEUROIMAGING 
4.4.1  Gray Matter Volume 
Loss of brain neurons and/or their connections results in smaller gray matter volume, known as 
GM atrophy. This can be visualized on MRI as enlarged ventricles, widening sulci and cortical 
thinning. Loss of GM can be global or focal and is highly associated with increasing age102 
although GM atrophy appears to occur earlier or at a faster rate in many conditions, such as 
multiple sclerosis,103 hypertension104 and migraines.105 Despite being especially well-studied in 
relationship to dementia, with over 1000 articles returned from a recent Ovid search combining 
the terms “dementia” and “brain atrophy”, the exact mechanisms and implications of GM 
atrophy are not yet fully understood.  
4.4.2 Type 1 Diabetes and Gray Matter Volume 
Studies differ regarding the relationship between T1D and GM. Seven studies report 
significantly smaller GM volume (overall and in specific regions) in T1D participants compared 
to non-DM controls.66,67,98,100,106-108 One study reported larger hippocampal volumes in T1D 
participants compared to non-DM controls.109 Five studies reported no difference in GM 
volume between T1D and non-DM controls63,68,92,93,110 and one study found enlarged ventricles 
in T1D participants with early disease onset (diagnosed younger than age seven) compared to 
those with a T1D diagnosis after age seven.94 
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Severe hypoglycemic episodes were believed to be the major cause of reduced GM 
volume in people with T1D, but recent studies point to chronic hyperglycemia and DKA as being 
more detrimental to GM development.63,66,93,107 Differences in population characteristics, such 
as age at time of T1D diagnosis, duration of T1D and exclusion of those with any T1D-related 
complications, may contribute to the lack of consistency between study results. 
4.5 ASSESSING CEREBRAL BLOOD FLOW USING NEUROIMAGING 
4.5.1 Arterial Spin Labeling 
The brain requires a regulated flow of blood in order to provide oxygen and other nutrients to 
brain cells and to remove metabolic by-products. Cerebral blood flow (CBF) refers to the 
perfusion rate, usually in ml of blood/100g brain tissue/minute. Positron emission tomography 
(PET), single photon emission computed tomography (SPECT) and dynamic susceptibility 
contrast (DSC) have been historically utilized in CBF studies and clinical practice, but these 
invasive methods require use of a radiotracer. A newer method, arterial spin labelling (ASL) is 
rapidly gaining favor as a non-invasive method to analyze CBF without the use of radioisotopes 
and with no concerns of nephrotoxicity.111  
Limitations of ASL must be considered, especially as it is a newer imaging technique. In 
particular, ASL has a relatively low signal-to-noise ratio which could cause detection problems 
in clinical settings, i.e., in populations suffering from diseases related to reduced cerebral blood 
flow.111  Variations in image acquisition (i.e., pulsed vs. continuous vs. pseudo-continuous ASL) 
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and differences in pre- and post-processing software protocols make it difficult to compare 
results across studies. These can be minimized with the use of a validated automated pipeline; 
by using a 3-D fast spin echo rather than 2-D echo-planar single shot sequence, signal-to-noise 
ratio is maximized while distortions and artifacts are minimized.112 
4.5.2 Type 1 Diabetes and Arterial Spin Labeling 
Only one study was found utilizing ASL in a population of adults (mean age 40 yrs.) with T1D.113 
Mangia et al. (2012) report that hypoglycemic unaware T1D participants demonstrated a 
blunted increase in thalamic blood flow during early hypoglycemia (using hyperinsulinemic 
clamp) compared to individuals without T1D. They suggest that their findings implicate the 
thalamus in coordinating a counter regulatory response to hypoglycemia113 but additional ASL 
studies are needed to corroborate this finding. Studies should also explore the effects of long-
term T1D on global and regional CBF, its clinical significance and T1D-related risk factors related 
to reduced CBF. To date, no cognitive studies in adults with T1D utilizing ASL have been 
published. 
In summary, a variety of modalities exist to examine changes in brain structure at the 
macro- and microstructural levels. It is theorized that microstructural changes precede 
macrostructural brain changes. That is, microstructural changes occur earlier in T1D cerebral 
pathology while macrostructural changes become detectable after years of damage. Other than 
acute insults such as stroke or traumatic brain injury, changes to cerebral structure that cause 
symptomatic changes in brain function (i.e., cognitive dysfunction) gradually progress over time 
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until such a point as they become visible on MRI, e.g., WMH. Additionally, markers of each 
technique are influenced by a complex interaction of T1D-specific risk factors (e.g., chronic 
hyperglycemia, severe hypoglycemia, insulinemia) and provide different implications regarding 
functional outcomes (Figure 5). No study has been identified that has conducted a thorough 
multi-modal investigation of brain structure and function among a population with long-
standing T1D as is proposed in this research. 
 
 
Figure 4.2.0. Conceptual framework of type 1 diabetes pathogenesis and its effects on the brain 
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5.0  TYPE 1 DIABETES AND BRAIN FUNCTION 
In contrast to T2D, which is a recognized risk factor for dementia, less is known about the 
relationship between cognition and T1D.114-117  Animal models of T1D demonstrate a 
deleterious effect of diabetes on the central nervous system118-120  and studies report mild 
deficits in information/psychomotor processing test scores in youth with as compared to youth 
without T1D (note: these scores, while lower, are still within the “normal” range). A growing 
body of literature demonstrates that T1D negatively affects cognitive function in adults with 
T1D68,92,94,99,107,121-125 but the mechanisms of this relationship remain unclear. Further 
complicating the matter is the effect of advancing age, a risk factor in itself for cognitive 
dysfunction. Identifying factors contributing to cognitive deficits in T1D remains an important 
area of research, especially as individuals with T1D are now living well into older age yet remain 
under-represented in T1D studies. 
5.1 COGNITIVE DOMAINS AND TESTS 
For the purposes of this paper, four broad areas (domains) of cognitive function will be 
considered: intelligence, executive function which encompasses information processing and 
psychomotor speed, memory and other (attention, visual perception, language).  Researchers 
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often further divide or aggregate these domains, resulting in difficulties when attempting to 
compare cognitive function across studies. For instance, some studies differentiate between 
visual perception and visual-spatial ability126 while others consider the two as a single 
domain.127,128 Additionally, a multitude of neuropsychological tests exist to assess function in 
each domain, further complicating comparisons of results across different studies.129 A 
complete listing of every neuropsychological test available would be impractical; rather, a list 
and short explanation of the instruments used for this research is presented in the appendix 
(Appendix A). 
5.1.1 Type 1 Diabetes and Cognitive Dysfunction 
Type 1 diabetes is most often associated with mild to moderate deficits in information 
processing speed68,92,93,96,99,124,127 and attention.68,93,96,124 Wessels et al. (2007) reported 
significantly poorer performance in the visual-spatial domain among T1D participants without 
retinopathy compared to the non-T1D control group68 while Brands et al. (2006) found the 
opposite; they report better performance on the Rey-Osterrieth Complex Figure by T1D 
participants compared to non-T1D controls (mean difference 0.56; 95% CI 0.13, 0.98).92 The 
participants in the Brands et al. (2006) study were 20 years older on average than those in the 
Wessels et al. (2007) study (61 yrs. vs. 42 yrs. of age, respectively) with equivalent levels of 
education.68,98   
Only one study with brain imaging and neuropsychological testing published within the 
past 10 years66 found a marginally significant difference in overall intelligence between T1D 
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participants and non-DM controls based on test scores from the Wechsler Abbreviated Scale of 
General Intelligence; the effect size was small (mean difference = 3.03; p=0.05). Two recent 
meta-analyses report similarly small yet statistically significant deficits in general intelligence in 
adults127 and children81 with T1D compared to non-T1D controls. Both reported significantly 
worse performance on tests of information processing speed, attention (visual and sustained), 
cognitive flexibility and visual perception domains, with no statistically significant between 
group differences noted regarding memory and learning domains.127,128 
Brismar et al. (2007) conducted an extensive study to identify factors that might predict 
cognitive impairment in adults with T1D.126 They found that T1D duration was significantly 
related to poorer performance in the following domains: psychomotor speed, memory, 
executive function (reflects control and management of other cognitive processes) and overall 
score.126 Younger age of T1D onset was related to worse performance in these domains: 
general intelligence, verbal ability, working memory, attention and processing speed; 
hypertension was associated with worse performance in these domains: memory, visual 
perception; BMI was related to worse performance in these domains: general intelligence and 
processing speed. Female sex predicted poorer scores for psychomotor speed tasks. 
Nephropathy was related to worse performance on tasks of psychomotor speed (excluding 
Pegboard) and retinopathy was related to worse performance on tasks of executive function.126 
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6.0  SUMMARY 
Worldwide incidence and prevalence rates of DM continue to increase annually. The 
International Diabetes Federation estimates that well over 30 million people in the U.S., and 
more than 220 million people in India and China, will be living with DM by the year 2030.5,14 
Many individuals with DM develop severe and often disabling complications, resulting in high 
medical, personal and societal costs. In addition, DM increases the risk of mortality; diabetes 
continually ranks as one of the top 10 leading causes of death in the U.S., with experts 
cautioning that DM is underreported on death certificates.2,3,130 
Over the last few decades, advances in treatment and management of the disease have 
improved the life expectancy of DM patients, especially those with T1D. Whereas pre-19702, 
few T1D patients survived beyond middle age, those diagnosed after 1970 can expect to live 
almost as long as someone without diabetes (69 yrs. vs. 72 yrs., respectively).131 These longer-
lived T1D patients brought to light a previously under-recognized complication of DM – 
deleterious effects on the central nervous system (CNS) such as cerebral grey matter atrophy, 
compromised integrity of cerebral white matter and an increased prevalence of cognitive 
dysfunction in adults at a younger-than-expected age. Unlike the body of literature assessing 
these conditions in children and young adults, relatively few studies have investigated these 
conditions in older adults living with T1D since childhood, and the results remain equivocal. 
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Determining the prevalence of white matter hyperintensities and cognitive dysfunction in 
middle-aged adults with childhood onset T1D, identifying risk factors related to these outcomes 
and employing a multi-modal neuroimaging approach to comprehensively examine the effects 
of T1D on brain structure and function in an aging T1D population are the objectives of this 
research. Raising awareness about these CNS complications and identifying its risk factors 
should enable clinicians and patients with T1D to design strategies to better manage this 
condition and minimize the negative impacts of this disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
7.0  METHODS 
The research proposed herein seeks to heighten the awareness that T1D negatively impacts 
brain structure and function to such a degree that they gain the same attention as other well-
recognized complications of T1D, e.g. blindness and kidney failure. To do so, the following gaps 
in knowledge will be addressed: (1) Is long-term exposure to T1D related to changes in cerebral 
white matter integrity as assessed by the presence of white matter hyperintensities in middle-
aged adults with T1D since childhood, and if so, which factors contribute to the presence of 
WMH? (2) Does long-term exposure to T1D negatively impact cognitive function? If so, which 
cognitive tests/domains are most affected and which factors are associated with T1D-related 
cognitive dysfunction? (3) Do MRI measures explain the presence of cognitive dysfunction in 
middle-aged adults with childhood-onset T1D? How do these MRI measures relate to cognitive 
test scores? How do age, disease duration and other factors affect T1D-related cognitive 
dysfunction? 
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7.1 AIMS 
Specific Aim 1: Determine if white matter hyperintensities (WMH), a measure of cerebral white 
matter health, occur more frequently among middle-aged adults with a childhood-onset of T1D 
compared to similarly-aged adults without T1D.  
Hypothesis 1: Middle-aged adults with childhood-onset T1D will have a greater burden of WMH 
compared to similarly-aged adults without T1D. 
Hypothesis 2: Among those with T1D, poor glycemic control, a history of high blood pressure 
and the presence of diabetes-related microvascular complications will be related to a greater 
burden of WMH. 
Hypothesis 3 (exploratory): The associations described in H2 will be stronger among those 
younger than age 50 compared to those older than age 50 at time of MRI, with age being the 
strongest predictor of WMH in the older group. 
Specific Aim 2: Investigate differences in neurocognitive task scores between middle-aged 
adults with childhood-onset T1D compared to similarly-aged adults without T1D. 
Hypothesis 1: Participants with T1D will perform worse in tasks assessing executive 
function/information processing compared to similarly-aged adults without T1D.  
Hypothesis 2: Between-group differences in task scores (effect sizes) will be larger in this 
population of middle-aged adults compared to effect sizes noted in pediatric and young adult 
T1D studies.  
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Hypothesis 3: Among T1D participants, poor glycemic control, longer disease duration, history 
of high blood pressure, prevalent depressive symptoms and prevalent microvascular 
complications will be associated with a higher prevalence of cognitive dysfunction. 
Specific Aim 3: Examine the relationship between cognitive dysfunction and cerebral micro- and 
macrostructural measures in middle-aged adults with childhood-onset T1D. 
Hypothesis 1: Measures of early changes to brain structure, i.e., reduced cerebral blood flow, 
will be related to the presence of cognitive dysfunction in this population of middle-aged adults 
with childhood-onset T1D.  
Hypothesis 2: Poor glycemic control, history of high blood pressure, and prevalence of 
microvascular complications will be associated with lower CBF in middle-aged adults with 
childhood-onset T1D.   
7.2 STUDY POPULATIONS 
A cross-sectional design, comparing a population of middle-aged adults with T1D to a similarly-
aged population without T1D was used to answer the research questions put forth in this 
document. 
7.2.1 Type 1 Diabetes Population  
Data from a subset of participants (N=106) from the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) Study will be analyzed to answer specific aims. Individuals with childhood-
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onset T1D (< age 17 at diagnosis), diagnosed or seen within one year of their diagnosis at the 
Children’s Hospital of Pittsburgh (all diagnosed between 1950 and 1980) were invited to 
participate in the EDC. A total of 658 patients, living within 100 miles of Pittsburgh, were 
enrolled in the EDC and underwent a baseline assessment between 1986 and 1988. For the first 
10 years after their baseline exam, EDC participants underwent a complete physical exam and 
provided survey information every two years. After this time, participants completed mail-in 
questionnaires every two years for another eight years. A complete physical exam occurred in 
2004-2006. 
Notifications of the brain imaging study were sent to all EDC participants expected at 
the 2010-2012 EDC clinic visit. Out of 263 potential participants, 157 replied with interest in the 
MRI study. Of those, 112 were found to be eligible for MRI, 106 of whom were successfully 
scheduled and underwent brain imaging, neuropsychological testing and an abbreviated 
physical exam. Of the 106 with MRI data: 
• nine had poor/no FLAIR image, resulting in N=97 for analyses of WMH (Aim 1).  
• 11 did not complete the neuropsychological test battery, resulting in N=95 for 
analyses of cognitive dysfunction (Aims 2, 3).  
• 13 had missing neuropsychological test scores or incomplete MRI sequences, 
resulting in N=93 for the multi-modal neuroimaging assessment of cognitive 
dysfunction (Aim 3). 
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7.2.2 Comparison Population without Type 1 Diabetes 
Individuals from the University of Pittsburgh’s MRI Study of Pre-Hypertensive adults (MR Hyper) 
study, free of T1D, served as a comparison group to address Aims 1 and 2. Details of the MR 
Hyper study have been previously described.132 In brief, to study the effects of vascular risk 
factors on cerebral blood flow and cognition, 414 middle-aged adults living in the Pittsburgh area 
were screened to participate in this study. Of those, 110 did not meet blood pressure inclusion 
criteria (either too high or too low), 60 declined to participate and 14 withdrew, yielding a study 
population of 230 pre-hypertensive adults, mean age 46 years. Brain MRIs were acquired from 
2010 - 2013. To mirror the EDC racial distribution, only Caucasians were included in these 
analyses. At time of MRI, biological and lifestyle data were collected for MR Hyper participants 
using methods comparable to those for EDC patients. SIF and HbA1c, however, were not 
available for these participants. Details of MR Hyper exclusion criteria are provided in Appendix 
C. 
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8.0  MANUSCRIPT 1: WHITE MATTER HYPERINTENSITIES IN MIDDLE-AGED ADULTS WITH 
CHILDHOOD-ONSET TYPE 1 DIABETES: PREVALENCE AND CONTRIBUTORS 
8.1 ABSTRACT 
Cerebral white matter hyperintensities (WMH), common features among adults age 65 and 
older, are indicative of microvascular diseases and increase the risk of stroke, depression, 
dementia, disability and death. Accrual of WMH significantly increases with older age, but it 
may be delayed by intervening on vascular factors. As patients with type 1 diabetes live longer, 
it is important to identify factors to prevent WMH. We determined prevalence and correlates of 
WMH in 97 middle-aged adults with childhood-onset type 1 diabetes participating in the 
Pittsburgh Epidemiology of Diabetes Complications Study since 1989 (age and duration: 49 and 
41 years; 48% female), using high-resolution imaging at 3Tesla. Data from 81 adults without 
type 1 diabetes served as a comparison group (mean age 48 years; 53% female). Those with 
type 1 diabetes had significantly larger volumes of WMH than controls (0.214% vs. 0.003%, 
respectively) independent of age, blood pressure or lipid levels. In univariate logistic regression 
models among those with type 1 diabetes, significant predictors of WMH > the median (0.001% 
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± .003%) were older age (OR=1.11, for each year), longer diabetes duration (OR=1.11, for each 
year), older age at diagnosis (OR=3.53 for age> 7), ever smoking cigarettes (OR=3.12), prevalent 
cardiac autonomic neuropathy (OR=2.52) and peripheral polyneuropathy (OR=2.94). Although 
these associations were independent of diabetes duration, only smoking and peripheral 
polyneuropathy remained significant after adjustment for age. Glycemic control (HbA1c current 
and historic, skin intrinsic fluorescence) did not significantly predict WMH among the full 
cohort. These findings indicate that childhood-onset diabetes contributes to earlier WMH 
development, and that older age and smoking may further accelerate WMH accrual among 
middle-aged patients with diabetes. Further studies to clarify the relationship between 
peripheral neuropathy and central nervous system disturbances are warranted.   
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8.2 INTRODUCTION 
A striking feature of type 1 diabetes is that patients develop brain abnormalities commonly 
observed in much older adults without diabetes.133 In addition to brain atrophy and infarcts, 
some children and young adults with type 1 diabetes develop cerebral small vessel disease, 
detected on magnetic resonance imaging (MRI) as white matter hyperintensities (WMH).133 While 
cerebral WMH are common findings among non-diabetic adults over age 65,75 with a prevalence 
ranging from 60-100%,76,77 these lesions are not benign; they are associated with increased rates 
of depression, disability, stroke, dementia and death.79,134-138 Uncommon before age 65, WMH 
are not routinely studied in younger adults. Initial evidence suggests that antihypertensive 
therapy may reduce progression of WMH.72. We contend that type 1 diabetes increases the risk 
of WMH development, and at a younger than expected age, thereby deserving greater attention 
in patients with type 1 diabetes, many of whom now survive well beyond age 50.  
In addition to advancing age, many WMH risk factors overlap with characteristics of 
diabetes, particularly hypertension, hyperglycemia72,139 and physical inactivity.139,140 Chronic 
exposure to these shared conditions may predispose type 1 diabetes patients to develop WMH in 
excess of the 0-50% prevalence reported in middle-aged adults without diabetes.80-82 Given 
patients’ increased life expectancy131 and the 3% annual increase in T1D incidence,141 
determining the prevalence of and risk factors for WMH related to this disease deserve prompt 
investigation. 
Few studies have explored the prevalence of WMH in middle-aged adults with T1D90-97 and 
the relationship between WMH with older age and cardiovascular risk factors remains unstudied. 
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Moreover, results to date have been inconsistent. In studies comparing WMH in participants with 
and without type 1 diabetes,90,92,95-97 only one90 found significantly greater WMH in cases than 
controls. A major limitation of these prior studies is their use of visual, semi-quantitative ratings 
of WMH, obtained at lower resolution, which best capture advanced WMH and may 
underestimate smaller lesions. Volumetric measures of WMH obtained at high resolution are 
needed to quantify WMH and identify correlated factors in type 1 diabetes patients. 
This study’s goals are to estimate the prevalence of WMH in middle-aged patients with 
type 1 diabetes and to characterize their WMH risk profile. Hypotheses include that adults with 
T1D have greater WMH compared to similarly-aged adults without T1D. We also tested whether 
blood pressure and other known WMH risk factors contribute to any between-group difference. 
Additionally, analyses explored relationships between WMH and diabetes-specific as well as 
general health factors collected over a 20-year span prior to MRI. 
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8.3 METHODS 
All study procedures received local IRB approval prior to study initiation. All participants provided 
informed consent prior to undergoing procedures. 
8.3.1 Study Populations 
Type 1 diabetes participants were drawn from the Pittsburgh Epidemiology of Diabetes 
Complications Study (EDC), an ongoing, prospective study of individuals with childhood-onset 
(diagnosed < 17 years) type 1 diabetes. All EDC participants, diagnosed between 1/1/50 and 
5/31/80 and seen within one year of diagnosis at Children’s Hospital of Pittsburgh, underwent a 
baseline assessment (1986 – 1988) when the mean age was 28 years and the average diabetes 
duration was 19 years. After their baseline visit, EDC patients were followed with biennial 
exams for 10 years, thereafter completing biennial questionnaires. An additional physical exam 
occurred in 2004-2006 (18-yr follow-up). A total of 263 locally-resident EDC participants 
contacted for the 2010-2012 exam were invited to participate in this MRI study. Of these, 157 
did not undergo imaging:  81 were not interested, 37 were ineligible for MRI and 39 did not 
reply or did not show for their MRI. The remaining 106 (mean age 48 years, 50% female, 98% 
Caucasian) underwent brain imaging between December 2010 and December 2012. Due to poor 
or no WMH imaging, nine were excluded from analyses, yielding an analytical sample of n=97 
(Figure 8.1). 
Non-type 1 diabetes population: Adults without type 1 diabetes from the University of 
Pittsburgh’s MR Hyper Study served as a comparison group. Details of the MR Hyper Study have 
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been previously described.132 In brief, to study the effects of vascular risk factors on cerebral 
blood flow, 414 middle-aged adults living in the Pittsburgh area were screened to participate in 
this study. Of those, 110 did not meet blood pressure inclusion criteria (either too high or too 
low), 60 declined to participate and 14 withdrew, yielding a study population of 230 pre-
hypertensive adults, mean age 46 years; full exclusion criteria are presented in Appendix C. Brain 
MRIs were acquired from 2010 – 2013 when participants also completed a neuropsychological 
test battery with many of the same tasks as administered to the EDC participants. To mirror the 
EDC racial distribution, only Caucasians were included in these analyses. At time of MRI, biological 
and lifestyle data were collected for MR Hyper participants using methods comparable to those 
for EDC patients. SIF and HbA1c, however, were not available for these participants. 
8.3.2 Covariates 
Diabetes-specific variables: For EDC participants, the following were collected at each physical 
exam from baseline to time of MRI: insulin dose (average daily units/Kg body weight); HbA1c 
(using saline-incubated blood samples and cation-exchange microcolumn chromatography 
prior to October 1987, using high-performance liquid chromatography through 2004-2006, 
and thereafter using the  DCA 2000 analyzer); estimated glucose disposal rate (an estimate 
of insulin sensitivity based on a regression equation derived from insulin clamp studies)142; 
use of insulin pump (yes/no); and fasting serum glucose. 
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Repeated assessment of HbA1c at every exam allowed the calculation of an average 
HbA1c over the duration of the EDC study. “A1c months”, a variable combining cumulative 
degree and duration of glycemic exposure, was also assessed (see 143 for details).   
Skin intrinsic fluorescence (SIF), a measure which partially reflects advanced glycation end 
products (AGEs) in the skin, was assessed at MRI. A skin fluorescence spectrometer (SCOUT 
DS®) noninvasively measured the skin of the left volar forearm. Details on the device and SIF 
calculations are discussed elsewhere.144 
Severe hypoglycemia history was assessed in 1990-92, when patients self-reported loss of 
consciousness due to hypoglycemia over the previous two years. 
Diabetes-related complications: Prevalence of complications was ascertained in 2004-2006. 
While this was an average of five years prior to MRI, these were the most recent EDC 
physical exam data available for analyses. 
Renal disease refers to microalbuminuria (MA), overt nephropathy (ON) or End Stage 
Renal Disease. ON was defined as the presence of an albumin excretion rate >200 μg/min in at 
least 2 of 3 timed urine collections and MA as an albumin excretion rate between 20-200 
μg/min in at least 2 of 3 urine samples. 
Coronary artery disease (CAD) was defined as myocardial infarction (Minnesota Codes 1.1 
or 1.2), fatal CAD (determined by review of death records and family interview) or angiographic 
evidence of 50% or more stenosis. CAD also included angina diagnosed by the clinic physician 
and/or ischemic ECG changes (Minnesota Codes: 1.3, 4.1-4.3, 5.1-5.3, 7.1). 
Neuropathies: Distal symmetric polyneuropathy (DSP) was determined by medical history 
and clinical examination using established protocols, i.e. the symptoms and signs consistent 
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with DSP, and reduced deep tendon reflexes. DSP was further determined as ‘confirmed’ using 
the Vibratron II to detect vibratory threshold. Cardiac autonomic neuropathy (CAN) was 
determined by heart variation during deep breathing and by heart rate and blood pressure 
response to standing. 
Retinopathy: Eye exams were done using three standard field stereo fundus 
photographs. Photographs were read at the Madison Reading Center in Wisconsin and graded 
using the Early Treatment Diabetic Retinopathy Study classification, with a grade of 60 or higher 
in one eye or a grade less than 60 but with panretinal photocoagulation scars consistent with 
laser therapy indicating proliferative retinopathy.145 
Biological risk factors: Hypertension was defined as any blood pressure reading >140/90 
mmHg or ever reporting use of antihypertensive medication from baseline through day of MRI. 
Blood pressure: Three seated blood pressure readings were taken with a random-zero 
sphygmomanometer on day of MRI, with an average of the second and third readings used, per 
the Hypertension Detection and Follow-up Program Protocol.  
Cholesterol: SYNCHRON CX® Systems was used to measure non-fasting total cholesterol 
and high-density cholesterol (HDLc) at time of MRI. Non-HDL cholesterol was calculated as 
(total cholesterol – HDLc). 
Serum creatinine levels were measured at time of MRI. 
Apolipoprotein E (ApoE) status was ascertained in 2004-2006. 
Body mass index (BMI) was calculated based on the participants’ weight and height at 
time of MRI (kg/m2). 
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Lifestyle/Behavioral risk factors: 
Smoking status was self-reported as current, past or never smoking 100 cigarettes and 
was dichotomized as ever vs. never smoking based on information obtained through 2004-
2006. 
Alcoholic beverage consumption was dichotomized as any vs. no alcohol in the past week 
based on participant self-report in 2004-2006. 
Physical activity for the past week was determined via Paffenbarger self-report 
questionnaire in 2004-2006. Responses were used to estimate energy expenditure (kcal). 
Brain MRI protocol. Both cohorts underwent brain MRI in a 3Tesla Siemens Trio TIM scanner 
located in the Magnetic Research Center at the University of Pittsburgh. A T1-weighted 3D 
sequence (MPRAGE: TR/TI/FA = 2300/900/9, Resolution 256, Grappa 2), acquisition time 7.5 
minutes, was used to attain grey matter (GM) and white matter (WM) volumes. For WMH, a T2-
weighted FLAIR sequence (TR/TE = 9002/56 ms Ef; TI = 2200 ms, NEX = 1) was used with an 
interleaved acquisition; 48 slices (3mm, no gap). 
Markers of macro-structural measures: An automated WMH segmentation method was 
used.69 First, skull and surrounding soft tissue were stripped from the underlying brain on T1-
weighted images. This map was used to remove brain from skull in the corresponding T2 FLAIR 
images at the same voxel size. Clustered WMH, based on voxel intensities on T2 FLAIR images, 
were then derived. Total brain volume constituted the sum of volumes of GM, WM and 
cerebrospinal fluid, obtained using an automated labeling pathway. For EDC patients, 
normalized GM volume was computed as a percentage [(GM volume/intracranial 
volume)*100]; this variable was not calculated for MR Hyper participants. 
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8.3.3 Statistical Analyses 
Group differences were assessed using t-test for normally-distributed continuous variables, 
Fisher exact test for categorical variables and Wilcoxon rank test for non-normal data. 
Demographic and other factors potentially related to WMH were compared between EDC 
patients by MRI status (Table 8.1), between EDC and MR Hyper participants  (Table 8.2), 
between EDC patients by WMH burden (Table 8.3) and between EDC patients by age < or > 50 
(Supplementary Table 8.1). Tobit censored regression (data not shown) was performed on the 
combined populations (EDC and MR Hyper) to determine if case status predicted WMH volume 
independently of other factors.146 
In analyses restricted to EDC patients, WMH volume was dichotomized as either < or > 
the EDC median of 0.00111 ± 0.0031%, corrected for intracranial volume. Factors that differed 
significantly by WMH burden were tested using logistic regression models. Because older age is 
the strongest risk factor for WMH in aging studies, two approaches were applied to control for 
the effects of age on WMH in EDC patients. Models were first conducted adjusting for age at 
MRI then stratified by the EDC median age of 50, using age-group specific median values of 
WMH (M age group<50 = 0.00108 ± 0.0032%; M age group>50 = 0.00166 ± 0.0028%). 
To examine survival bias effects on these associations, analyses were repeated excluding 
the 18 EDC patients diagnosed before 1965, as mortality was relatively negligible for those 
diagnosed post-1965 (15%) compared to those diagnosed prior to 1965 (44%). 
Analyses were conducted using SAS 9.3 and SPSS 21. 
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8.4 RESULTS 
Compared to the 157 patients without MRI (Table 8.1), the 106 EDC patients with MRI were 
significantly younger, less likely to be female, with a lower prevalence of CAD, CAN or 
microalbuminuria and a lower BMI (all p<0.05). 
Compared to MR Hyper participants (Figure 8.2, Table 8.2), EDC patients had almost 
sixty times greater WMH volume (p<0.0001). This difference remained significant (p<0.0001) 
after excluding the 32 EDC patients with hypertension (mean WMH = 0.0019%) or when 
excluding the prominent EDC outlier (mean WMH = 0.0019%). WMH risk profiles differed 
significantly between cohorts (Table 8.2). Compared to MR Hyper participants, EDC patients 
had significantly higher glucose and lower physical activity levels, but EDC patients also had 
lower diastolic blood pressure, total cholesterol, non-HDL cholesterol and were less likely to 
report consuming alcohol. No covariates modified the between-group difference in WMH; in 
Tobit censored regression models (not shown), having type 1 diabetes significantly predicted 
greater WMH volume independently of any factors that differed between the two cohorts 
(coefficient = 0.0021%, p<0.0001). 
Among EDC patients, high WMH burden, defined as WMH > 0.0011%, the EDC median, 
was significantly and positively associated with age, disease duration, SIF, prevalence of CAN, 
prevalence of DSP and smoking status (Table 3). WMH burden was not significantly associated 
with usual markers of glucose control, including any A1c measure or fasting glucose at MRI (all 
p>0.50; Table 8.3). Associations of WMH burden with other risk factors for age-related WMH 
(e.g., systolic blood pressure at MRI or averaged across EDC study years, diastolic blood 
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pressure, hypertensive history, non-HDL cholesterol, physical activity or alcohol consumption) 
were also non-significant (all p>0.10; Table 8.3).  
Associations between WMH burden and SIF, the prevalence of CAN or DSP and ever 
smoking cigarettes were overall similar after adjustment for age (Table 4) or duration (Table 
8.5), with the exception of SIF. The association of WMH burden with SIF was attenuated and 
non-significant (p>0.10) after adjustment for age (Table 8.4).   
The interaction term of SIF with age predicting WMH burden was statistically significant 
(p=0.008) while interaction terms with age and CAN (p=0.80), DSP (p=0.06) and smoking 
(p=0.70) were non-significant.  
In models stratified by age 50 at MRI, WMH burden was associated with SIF among 
those > but not those < age 50 (duration-adjusted Odds Ratios, [95% confidence intervals]: 
1.30 [1.06, 1.60], p=.012 and .98 [.84, 1.14], p=.76, respectively). Among those > age 50, the 
association of WMH with SIF remained significant and substantially unchanged (1.29 [1.00, 
1.66], p=.048) after adjustment for characteristics associated with older age in this sample, 
i.e. disease duration, prevalence of CAN, DSP and proliferative retinopathy, overall SBP and 
non-HDL cholesterol (Supplementary Table 8.1). Further adjustment for diastolic blood 
pressure, age at diagnosis or diagnosis pre/post 1965 did not modify these associations (not 
shown). In the subgroup > age 50, WMH was not associated with CAN, DSP or smoking (all 
p>0.05). In contrast, WMH burden was significantly associated with CAN and smoking history 
among those < age 50 (Supplementary Table 2). Results for those diagnosed 1965 and later 
were similar to the subgroup < age 50; that is, associations were significant for CAN, DSP and 
smoking but not for SIF (Supplementary Table 3). 
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8.5 DISCUSSION 
Applying high-resolution neuroimaging along with careful characterization of diabetes factors in 
this large sample of middle-aged adults revealed a remarkably high WMH prevalence in 
participants with type 1 diabetes (EDC patients). This study identified a profile of factors related 
to WMH, consisting of SIF, neuropathies and smoking, and the pattern of associations differed 
by age. These findings indicate that childhood-onset diabetes can accelerate WMH 
development and that cerebral WMH begin to accumulate in patients with type 1 diabetes 
earlier and/or faster than expected based on age alone. While WMH should be considered an 
important complication of diabetes, its accrual may be prevented or delayed via strict glycemic 
control, particularly for older adults, and possibly by tobacco avoidance. Preventing WMH could 
have beneficial effects on overall brain health, especially for patients entering their sixth 
decade of life in whom disease-related brain changes overlap with age-related brain changes. 
Brain imaging studies147-149 show continued myelination and development of new WM tracts 
connecting cortical regions during adolescent years, with an additional late myelination wave in 
the fourth decade of life. Glycemic control during these important years may help compensate 
for WM abnormalities that had already developed earlier among diabetes patients. 
WMH in adults with type 1 diabetes has received initial attention, but results have been 
inconsistent. One small case-control study90 applied volumetric WMH measures similar to those 
of our study, finding WMH in 69% of type 1 diabetes cases vs. 12% of age-matched controls. 
Other case-control studies applying crude measures of WMH92,95 found non-significant between-
group differences while two other studies96,97 reported an absence of WMH in both type 1 
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diabetes and control participants. Methodologies used to ascertain WMH varied across studies 
and may explain contradictory findings. Visual rating scales used in these prior studies are less 
accurate at detecting smaller lesions compared to volumetric assessments of WMH150-152 as 
utilized in our study. In addition to neuroimaging methodologies, selective exclusion criteria may 
further explain the discrepant findings of WMH prevalence; two studies95,96 excluded participants 
with complications such as CAD, neuropathy, nephropathy and hypertension. It is reasonable to 
expect that studies conducted among “healthier” type 1 diabetes patients would detect a fewer 
WMH, but such individuals unlikely represent the typical adult with long-standing diabetes. 
Among EDC patients in this study, long-term hyperglycemia as indicated by higher SIF, 
was related to higher WMH burden, especially for older patients. SIF is a novel, non-invasive 
measure of AGEs in the skin, partially reflecting systemic glycosylation. The half-life of skin AGEs 
has been estimated at 15 years,153 thus SIF provides glycation information in terms of years 
compared to months as seen with A1c values. The association between SIF and WMH may 
reflect the negative impact hyperglycemia may have on brain health, pointing to SIF as a 
potential biomarker of underlying WMH. Importantly, SIF increases with age even among those 
without diabetes;154 we found that SIF was significantly higher in the older compared to the 
younger subgroup (26.61 ± 4.96 and 22.58 ± 3.83 respectively, p<0.001). We noted that older 
age modified the association between SIF and WMH and that the relationship between WMH 
and SIF differed by age, as indicated by the significant interaction term of SIF by age predicting 
WMH burden. SIF was the only factor significantly related to WMH burden in patients > 50 but 
was not related to WMH among those < age 50. Since older age also predicts high WMH 
burden,61,139 it is possible that longer exposure to hyperglycemia, as indicated by higher SIF, 
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combined with older age, can further compromise brain health in patients with type 1 diabetes 
entering their sixth decade of life. Another explanation for the stronger SIF WMH association in 
older adults is if older patients had been exposed to more severe hyperglycemia compared to 
the younger patients, which would have precipitated a more rapid WMH accrual. This, 
however, seems unlikely as all  EDC patients exhibited fair to good glycemic control, with a 20-
year A1c average of 8.25% (Table 8.1) and control was similar for the younger vs. older 
subgroups (20-year mean A1c: 7.93% ± 0.89 and 8.21% ± 1.05, p=0.16, respectively). These 
findings indicate the need to monitor SIF and myelination in type 1 diabetes patients via 
longitudinal neuroimaging studies and to consider using SIF as a biomarker of underlying WMH 
development. 
The associations between neuropathies and WMH burden found in this study are also 
novel. Although there is a biological plausibility for associations between neuropathies in the 
central, peripheral or autonomic nervous systems, these associations have not been examined 
in detail. Most prior studies excluded patients with neuropathy92,95,96 or had very low 
prevalence of neuropathy.91 The clinical relevance and overall strength of these associations 
need further study, especially in relationship with other behavioral risk factors. For example, we 
noted that neither CAN nor DSP remained significantly associated with WMH after adjusting for 
smoking. In multivariable models (Tables 8.4, 8.5), smoking tripled the odds of high WMH 
independent of age, disease duration or neuropathies. These results were stronger for the 
younger versus the older subgroup. Studies indicate that smoking increases the risk of WMH in 
older adults without diabetes155,156 yet only one study examined smoking and WMH in adults 
with type 1 diabetes,95 finding no significant relationship between the two. The participants of 
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this prior work were younger (average age 32 years), with disease duration almost half that 
observed in our study, even when our observations were restricted to those < age 50. It is 
possible that smoking may contribute to higher WMH during a certain window of time, making 
age an important factor. It cannot be ignored that some risk factors exert a stronger effect on 
the development of brain abnormalities that differs by age groups. 
This study’s negative findings also deserve attention. First, no association between WMH 
and concurrently measured levels of blood pressure, lipids or fasting glucose levels were found. 
Moreover, the difference in WMH volume between EDC and MR Hyper participants was not 
explained by factors associated with higher prevalence of WMH in older populations, including 
blood pressure, lipids or glucose levels.70,71,77,155,157-160  It is possible that long-term exposure to 
diabetes may have a greater effect on WMH than traditional vascular factors. Of note, these 
traditional factors were measured concurrently with WMH, whereas WMH develops over 
several years of “incubation”. Once cerebral WMH become manifest, these factors may no 
longer play a substantial role. This is consistent with a recent animal study showing that 
diabetes has a greater effect than hypertension on neurodegeneration in the rat brain.161 
Negative findings may also reflect the small range of blood pressure and lipids in both studies, 
which were especially well controlled for the EDC patients; they presented with lower DBP and 
higher lipid levels, with lower alcohol consumption, compared to MR Hyper participants. 
Smoking history was similar between cohorts. While SIF predicted WMH burden, no other 
glycated hemoglobin measures were significantly related to WMH. This is consistent with 
previous studies91,92,95,154 and underscores the importance of moving beyond A1c to measure 
glycemic control in diabetic patients. Similar to our negative finding, previous studies reported 
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no significant association between severe hypoglycemia and WMH,92,93,95 91-93,95-97 although 
animal studies show hypoglycemia inhibits oligodendrocyte development and apoptosis of 
oligodendrocyte precursor cells.162 CAD, microalbuminuria and proliferative retinopathy were 
not significantly related to WMH burden, similar to results of earlier studies.91,92,95,97 No 
association was detected between WMH and age at diagnosis. Two studies found associations 
with WMH and “early” age at diagnosis92,94, with one defining early diagnosis as prior to age 
eight94 while the other defined early diagnosis as prior to age 18.92 It is possible that this sample’s 
range of ages at diagnosis was insufficient to detect an association. 
Strengths of this study include the use of a high resolution neuroimaging protocol and 
volumetric assessment of WMH. Patients were drawn from a well-defined cohort of adults with 
long-standing type 1 diabetes, with more than 20 years of follow-up data. Any EDC participant 
interested in and eligible for the MRI study was allowed to participate, making the study 
findings generalizable to patients with a similar duration of childhood-onset type 1 diabetes. 
Limitations of this study include the cross-sectional nature of the brain imaging and the 
verification of diabetes complications roughly four years prior to MRI. A survivor bias is present 
in that these patients have survived with diabetes and are therefore different from patients who 
died before the MRI study. The EDC patients participating in this MRI study are, in general, much 
healthier than the parent EDC cohort. These limitations, however, should underestimate the 
true prevalence of WMH in type 1 diabetes patients, making these findings even more 
important. Prospective brain imaging studies with accurate, early assessments of severe hypo- 
and hyperglycemic events are needed to better understand WMH in individuals with childhood-
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onset type 1 diabetes. Studies with larger sample sizes and wider age ranges are needed to fully 
examine the contribution of chronological age and age of diabetes onset on WMH development. 
In light of these findings, prevention of WMH in patients with childhood-onset type 1 
diabetes should focus on long-term glycemic control and behavioral factors associated with 
vascular disease. In particular, efforts to deter the use of tobacco products could significantly 
delay the development and/or progression of WMH. In addition, with chronic poor glycemic 
control increasing the risk for diabetic neuropathies, improved patient education combined 
with early, intense interventions to lower blood glucose levels may also prevent or delay the 
development of WMH. 
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8.6 TABLES AND FIGURES 
Table 8.6.1. Characteristics of Pittsburgh Epidemiology of Diabetes Complications Study (EDC) 
participants by MRI status. Data are from EDC exam cycle 10 (2004-2006) unless otherwise 
noted 
 
 
EDC 
 no MRI 
n=157 
EDC  
with MRI 
n=106 
p- 
value 
 Values presented are N (%) or Mean ± SD 
Brain imaging  WMH volume (mm3) † 1  -- 0.214±0.31 -- 
Demographic 
factors  
Age (years)  45.8±7.6 43.7±7.1 0.03 
Female  99 (63.0%) 54 (50.9%) 0.05 
Diabetes-
specific 
variables 
Duration (years) 37.0±7.1 35.6±6.4 0.12 
HbA1c monthly estimate  (AU) 3 1040.0±484.2 957.0±378.0 0.15 
HbA1c (%) (mmol/mol) 7.4±1.3 (58±14.2) 7.4±1.5 (58±16.4) 0.99 
Mean HbA1c (%) (mmol/mol) 3  8.5±1.2 (70±13.1) 8.5±1.0 (70±10.9) 0.81 
Age at diagnosis (years)  8.8±4.0 8.1±4.1 0.16 
Diagnosis after 1/1/1965  113 (72.0%) 86 (81.1%) 0.09 
Severe hypoglycemia in 1988-1992 2 33 (29.0%) 21 (22.8%) 0.32 
Diabetes 
complications 
Coronary artery disease   47 (30.5%) 18 (17.0%) 0.01 
Cardiac autonomic neuropathy  57 (54.3%) 48 (45.7%) 0.006 
Distal symmetric polyneuropathy  85 (59.9%) 51 (49.0%) 0.09 
Microalbuminuria 96 (66.2%) 56 (53.3%) 0.04 
Proliferative retinopathy  87 (58.4%) 52 (49.5%) 0.16 
Biological risk 
factors 
Fasting glucose (mg/dL)  167.1±73.0 174.4±77.1 0.51 
Systolic blood pressure (mmHg)  116.6±17.1 113.3±16.3 0.15 
Diastolic blood pressure (mmHg)  64.9±9.5 66.4±11.4 0.31 
Study 20-yr average SBP (mmHg)3 114.6±10.8 111.9±11.6 0.06 
Ever high blood pressure  # 29 (18.8%) 15 (14.2%) 0.32 
Body Mass Index (kg/m2)  27.7±4.8 26.5±4.3 0.04 
ApoE4 allele status 24, 34, 44 32 (30.2%) 35 (23.2%) 0.21 
Behavioral 
risk factors 
History of ever smoking cigarettes 3 60 (38.2%) 30 (28.4%) 0.11 
Physical activity, past week (Kcal) ‡ 784 (336-1663) 994 (420-1964) 0.18 
† (WMH Volume/Total brain volume) * 100 
‡ Data presented are median (Interquartile range) 
# SBP > 140 or DBP > 90 or report of ever using antihypertensive medication at any EDC physical exam 
1 = Measure taken 2101-2013; 2 = Measure taken 1990-1992; 3 = Ever, average or cumulative measure from 
baseline through cycle 10 exam (2004-2006) 
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Table 8.6.2 Characteristics of participants with type 1 diabetes (Pittsburgh Epidemiology of 
Diabetes Complications Study, T1D) and participants without type 1 diabetes (Pittsburgh MR 
Hyper Study, no T1D) at time of MRI (2010-2013) unless otherwise noted 
 
 
 
 
 
 
 
  T1D 
N=97 
No T1D 
N=81 
p-value 
  Values presented are N (%) or Mean ± SD 
Brain imaging WMH volume (%) † 0.214 ± 0.31 0.004 ± 0.01 <0.0001 
Demographic 
factors 
Age (years)  49.5 ± 6.9 48.1 ± 7.3 0.1996 
Female 47 (48%) 43 (53%) 0.5510 
Biological 
factors 
Fasting glucose (mg/dL)  176.3 ± 86.9 92.3 ± 20.4 <0.0001 
Systolic blood pressure (mmHg)  118 ± 15 117 ± 10 0.6848 
Diastolic blood pressure 
(mmHg)  65 ± 9 77 ± 7 <0.0001 
Ever high blood pressure # 32 (33%) 5 (6%) <0.0001 
Body Mass Index (kg/m2)  27.1 ± 4.6 27.7 ± 6.0 0.4849 
Behavioral 
factors 
History of ever smoking 
cigarettes 2 33 (34%) 37 (46%) 0.1253 
Physical activity in past week 
(Kcal) ‡1 1092 (504-1999) 779 (616-3173) 0.0253 
† (WMH Volume / Total brain volume )* 100 
‡ Data presented are median (Interquartile range) 
# For T1D participants: SBP > 140 or DBP > 90 or report of ever using antihypertensive medication 
at any EDC physical exam; for MR Hyper participants without T1D, past history of hypertension 
based on self-report at time of MRI 
FOR T1D (EDC) PARTICIPANTS: 1=measure taken 2004-06; 2=ever, cumulative or average from 
baseline through time of MRI 
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Table 8.6.3 Characteristics of participants with type 1 diabetes (Pittsburgh Epidemiology of 
Diabetes Complications Study), grouped by low vs. high white matter hyperintensity burden 
(WMH < or > group median) at time of MRI (2010-2012) unless otherwise indicated 
 
Low WMH† 
< 0.1113 
n=49 
High WMH† 
> 0.1113 
n=48 
p- 
value 
 Values presented are N (%) or Mean ± SD 
Brain imaging WMH volume (%)
 †  0.072 ± .031 0.358±0.384 <0.0001 
Normalized grey matter volume (%) ^ 33.80 ± 2.00 33.60 ± 2.51 0.6453 
Demographic 
factors  
Age at MRI (years)   47.3 ± 6.0 51.7 ± 7.1 0.0014 
Female  22 (45%) 25 (52%) 0.5446 
Diabetes-
specific 
variables 
Duration (years)  39.5 ± 4.2 43.2 ± 7.6 0.0041 
Skin intrinsic fluorescence (AU) 1 23.12 ± 4.01 25.67 ± 5.19 0.0106 
HbA1c monthly estimate (AU) 3 1119.1 ± 466.1 1116.1 ± 461.1 0.9748 
HbA1c at time of MRI (%) 
(mmol/mol)   
7.70±1.26 
(61±13.8) 
7.55±1.29 
(59±14.1) 0.5934 
Mean HbA1c (%) (mmol/mol) 3 8.14±1.02 (65±11.1) 
8.03±0.96 
(64±10.5) 0.6128 
Age at diagnosis (years)  7.9 ± 4.4 8.5 ± 4.0 0.4233 
Diagnosis after 1/1/1965  48 (98%) 31 (65%) <0.0001 
Any severe hypoglycemia (1988-
1992) 2 6 (14%) 13 (30%) 0.1175 
Diabetes 
complications 
Coronary artery disease  2 9 (18%) 6 (13%) 0.5759 
Cardiac autonomic neuropathy 2  15 (31%) 28 (58%) 0.0133 
Distal symmetric polyneuropathy 2 14 (29%) 30 (63%) 0.0020 
Microalbuminuria 2 21 (43%) 29 (60%) 0.1053 
Proliferative retinopathy 2  21 (44%) 31 (65%) 0.0647 
Biological risk 
factors 
Fasting glucose (mg/dL)  171.5 ± 83.36 181.0 ± 90.97 0.5991 
Systolic blood pressure (mmHg)  117.6 ± 15.5 118.6 ± 14.4 0.7305 
Diastolic blood pressure (mmHg)  66.7 ± 9.0 63.9 ± 9.5 0.1432 
Study 20-yr average systolic blood 
pressure (mmHg)4 110.7 ± 8.5 113.6 ± 10.2 0.1284 
Ever high blood pressure  # 12 (252%) 20 (42%) 0.1290 
Body Mass Index (kg/m2)  27.7 ± 4.9 26.5 ± 4.4 0.2274 
ApoE4 allele status 24, 34, 44 16 (33%) 11 (23%) 0.3660 
Behavioral 
risk factors 
History of ever smoking cigarettes 4 11 (22%) 22 (46%) 0.0189 
Physical activity in past week (Kcal) ‡2 994 (504-1868) 1151 (504-2371) 0.4585 
† (WMH volume / total brain volume) * 100   ‡ Data presented are median (Interquartile range) 
^ (GMV/ICV)*100     # SBP > 140 or DBP > 90 or report of ever using antihypertensive medication at any 
EDC exam    1=measure taken 2006-2008; 2=measure taken 2004-06; 3=measure taken 1990-92; 4=ever, 
cumulative or average measure from baseline through time of MRI 
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Table 8.6.4 Logistic regression models for participants with type 1 diabetes (Pittsburgh 
Epidemiology of Diabetes Complications Study) showing the independent effects of diabetes-
related factors on the odds of high white matter hyperintensity burden (> cohort median of 
0.1113%) when controlling for age at MRI and specified factor(s) 
 
 
 
 
 
 
 
 
Model 1 2 3 4 5 1+3+5 
 Odds Ratio (95% Confidence Limits) and Wald p-value 
Age at MRI 
(years) 
1.12 
(1.04, 1.20) 
.002 
1.10 
(1.02, 1.18) 
.015 
1.10 
(.1.02, 1.18) 
.013 
1.08 
(1.00, 1.17) 
.060 
1.12 
(1.04, 1.20) 
.003 
1.10 
(1.02, 1.18) 
.012 
Skin Intrinsic 
Fluorescence 
 1.09 
(.98, 1.21) 
.132 
   -- 
Cardiac 
Autonomic 
Neuropathy 
  2.61 
(1.02, 6.71) 
.046 
  2.20 
(0.82, 5.87) 
.116 
Distal  
Symmetric 
Neuropathy 
   2.62 
(0.95, 7.26) 
.064 
 -- 
Ever smoking 
100+ 
cigarettes 
    2.98 
(1.12, 7.91) 
.001 
2.57 
(.94, 7.02) 
.066 
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Table 8.6.5 Logistic regression models for participants with type 1 diabetes (Pittsburgh 
Epidemiology of Diabetes Complications Study) showing the independent effects of diabetes-
related factors on the odds of high white matter hyperintensity burden (> cohort median of 
0.1113%) when controlling for diabetes duration at MRI and specified factor(s) 
Model 1 2 3 4 5 1+3+4+5 
 Odds Ratio (95% Confidence Limits) and Wald p-value 
Diabetes 
duration  
(years) 
1.11 
(1.03, 1.19) 
.008 
1.09 
(1.01, 1.18) 
.033 
1.09  
(1.01, 1.18) 
.029 
1.07 
(.98, 1.16) 
.137 
1.11 
(1.03, 1.20) 
.009 
1.07 
(.98, 1.16) 
.143 
Skin Intrinsic 
Fluorescence 
 1.10 
(1.00, 1.22) 
.059 
   -- 
Cardiac 
Autonomic 
Neuropathy 
  2.96 
(1.18, 7.44) 
.021 
  1.71 
(0.58, 4.99) 
0.329 
Distal  
Symmetric 
Neuropathy 
   3.06 
(1.14 8.21) 
.026 
 2.49 
(.80, 7.80) 
.116 
Ever smoking 
100+ 
cigarettes 
    3.03 
(1.16, 7.90) 
.023 
2.84 
(1.02, 7.88) 
.046 
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Figure 8.6.1 Flow chart showing recruitment of participants with type 1 diabetes from the 
Epidemiology of Diabetes Complications Study (EDC) parent cohort for the MRI study 
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Figure 8.6.2 Plot of white matter hyperintensity volume (WMH, % of total brain volume), by age 
at MRI, for Pittsburgh Epidemiology of Diabetes Complications (EDC) participants with type 1 
diabetes (green) and MR Hyper participants without type 1 diabetes (blue) 
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Figure 8.6.3 Left: FLAIR image of 49 y.o. female without type 1 diabetes, no visible WMH;  
Right: FLAIR image of 49 y.o. female with type 1 diabetes since age 10 with noticeable WMH 
(black arrows) at ventricular rims, caps as well as in deep tissue  
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Table 8.6.6 Characteristics of participants with type 1 diabetes (Pittsburgh Epidemiology of 
Complication Study) by age < or > 50 years at time of MRI, 2010-2012, unless otherwise noted 
 Age <50 at MRI n=53 
Age > 50 at MRI 
n=44 
p- 
value 
 N (%), Mean ± SD or Median (Interquartile Range) 
Brain Imaging 
WMH volume (%) 0.164 ± .319 0.273 ± 0.279 0.0764 
Normalized grey matter (%)* 33.92 ± 2.30 33.42 ± 2.19 0.2831 
Demographic 
factors  
Age at MRI (years)  44.4 ± 4.0 55.6 ± 4.1 <0.0001 
Female  22 (42%) 25 (57%) 0.1563 
Diabetes-
specific 
variables 
Duration (years)  37.6 ± 4.3 45.7 ± 5.6 <0.0001 
Skin intrinsic fluorescence (AU) † 22.58 ± 3.83 26.61 ± 4.96 <0.0001 
HbA1c monthly estimate (AU) ‡ 1130.5 ± 470.1 1102.5 ± 455.4 0.7680 
HbA1c at time of MRI 
(%)(mmol/mol)  7.79 ± 1.30 (63±14.2) 
7.43 ± 1.24 
(56±13.6) 0.1771 
Mean HbA1c (%)(mmol/mol) ‡ 8.21 ± 1.05  (66±11.5) 7.93 ± 0.89 (64±9.7) 0.1531 
Age at T1D diagnosis (years)  6.8 ± 4.0 9.9 ± 3.9 0.0002 
Diagnosis after 1/1/1965  52 (98%) 27 (61%) <0.0001 
Any severe hypoglycemia ‖ 11 (26%) 8 (19%) 0.6040 
Diabetes 
complications§ 
Coronary artery disease   7 (13%) 8 (18%) 0.5784 
Cardiac autonomic neuropathy  14 (27%) 29 (66%) 0.0002 
Distal symmetric 
polyneuropathy  11 (21%) 33 (75%) <0.0001 
Microalbuminuria  26 (49%) 24 (55%) 0.6843 
Proliferative retinopathy  22 (42%) 30 (68%) 0.0141 
Biological risk 
factors 
Fasting glucose (mg/dL)  183.1 ± 97.1 168.1 ± 73.0 0.3979 
Systolic blood pressure 
(SBP)(mmHg)  115.8 ± 14.1 120.9 ± 15.5 0.1101 
Diastolic blood pressure (mmHg)  68.4 ± 7.9 61.5 ± 9.5 0.0003 
Mean SBP over EDC study 
(mmHg) ‡ 110.2 ± 8.8 114.6 ± 9.7 0.0237 
Ever hypertensive  ¶ 13 (25%) 19 (44%) 0.0517 
Body Mass Index (kg/m2)  27.9 ± 4.8 26.1± 4.3 0.0516 
ApoE allele status 24, 34, 44 § 14 (26%) 13 (30%) 0.8213 
Behavioral risk 
factors 
Ever smoking 100+ cigarettes ‡ 15 (28%) 18 (41%) 0.2050 
Physical activity in past week 
(Kcal) § 1228 (756-2634) 784 (364-1860) 0.1632 
* (Grey matter volume / Intracranial volume) * 100 
† Measure taken at 2006-2008 exam 
‡ “Ever”, average or cumulate measure from EDC baseline through time of MRI 
§ Measure taken at 2004-2006 exam 
‖ Based on 1990-1992 exam questionnaire when participant self-reported experiencing any hypoglycemic events 
resulting in loss of consciousness over the previous two years  
¶ SBP > 140 or DBP > 90 or report of ever using antihypertensive medication at any EDC physical exam   
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Table 8.6.7 Logistic regression models showing independent effects of diabetes-related factors 
on high white matter hyperintensity burden (> age-group specific WMH median) for 
participants with type 1 diabetes, stratified by age 50 at MRI, controlling for duration 
Ag
e 
> 
50
 a
t  
M
RI
, W
M
H 
m
ed
ia
n=
0.
16
6 
%
 
Model 1 2 3 4 5  
 Odds Ratio (95% Confidence Limits) and Wald p-value 
Diabetes 
duration  
(years) 
1.14 
(1.01, 1.29) 
.040 
1.15 
(1.00, 1.33) 
.048 
1.14 
(1.00, 1.30) 
.045 
1.11 
(.98, 1.27) 
.113 
1.15 
(1.01, 1.31) 
.030 
-- 
Skin Intrinsic 
Fluorescence 
 1.30 
(1.06, 1.60) 
.012 
   -- 
Cardiac 
Autonomic 
Neuropathy 
  1.83 
(.46, 7.24) 
.387 
  -- 
Distal  
Symmetric 
Neuropathy 
   4.35 
(.74, 25.61) 
.104 
 -- 
Ever smoking 
100+ 
cigarettes 
    2.40 
(.60, 9.64) 
.219 
-- 
Ag
e 
< 
50
  a
t  
M
RI
,  
W
M
H 
m
ed
ia
n=
0.
10
8 
%
 
Model 1 2 3 4 5 1+3+5 
Diabetes 
duration  
(years) 
0.99 
(.87, 1.13) 
.910 
0.99 
(.87, 1.13) 
.882 
1.00 
(.87, 1.15) 
.998 
0.98 
(.86, 1.13) 
.806 
0.99 
(.86, 1.14) 
.914 
1.00 
(.86, 1.16) 
.974 
Skin Intrinsic 
Fluorescence 
 .98 
(.84, 1.14) 
.764 
   -- 
Cardiac 
Autonomic 
Neuropathy 
  6.11 
(1.40, 26.60) 
.016 
  6.15 
(1.32, 28.63) 
.021 
Distal  
Symmetric 
Neuropathy 
   3.48 
(.77, 15.74) 
.106 
 -- 
Ever smoking 
100+ 
cigarettes 
    4.38 
(1.12, 17.04) 
.033 
4.40 
(1.03, 18.75) 
.045 
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Table 8.6.8 Logistic regression models among participants diagnosed with type 1 diabetes on 
or after 1/1/1965 from the Pittsburgh Epidemiology of Diabetes Complications Study 
showing the effects of diabetes-related measures and complications on high white matter 
hyperintensity burden (>cohort median of 0.107%) 
Model 1 2 3 4 5 1+3+4+5 
 Odds Ratio (95% Confidence Limits) and Wald p-value 
Diabetes 
duration  
(years) 
1.02 
(.90, 1.20) 
.978 
1.00 
(.89, 1.11) 
.948 
0.97 
(.5, 1.09) 
.566 
0.96 
(.85, 1.08) 
.505 
1.01 
(.90, 1.13) 
.912 
.96 
(.84, 1.09) 
.491 
Skin Intrinsic 
Fluorescence 
 1.08 
(.97, 1.20) 
.158 
   -- 
Cardiac 
Autonomic 
Neuropathy 
  5.28 
(1.84, 15.13) 
.002 
  2.82 
(.81, 9.89) 
.105 
Distal  
Symmetric 
Neuropathy 
   3.80 
(1.31, 11.05) 
.014 
 2.41 
(.65, 8.96) 
.189 
Ever smoking 
100+ 
cigarettes 
    3.54 
(1.25, 9.98) 
.017 
3.08 
(.98, 9.63) 
.054 
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9.0  MANUSCRIPT 2: COGNITIVE FUNCTION IN LONG-TERM SURVIVORS OF CHILDHOOD-
ONSET TYPE 1 DIABETES 
9.1 ABSTRACT 
Adults with type 1 diabetes (T1D) are now more likely to live longer, but the combined effects 
of older age and T1D on cognitive function remains unknown. We assessed the correlates of 
cognitive dysfunction among middle-aged adults with childhood-onset T1D compared to adults 
without T1D. During 2010-2013, 97 adults with childhood-onset T1D, participating in the 
Pittsburgh Epidemiology of Diabetes Complications Study (mean age 49 + 7 years; mean 
duration 41 + 6 years; 51% female, 98% Caucasian) and 138 similarly-aged adults without T1D 
(mean age 49 + 7 years; 55% female, 100% Caucasian) completed an extensive 
neuropsychological evaluation to test performance in executive function, psychomotor speed, 
memory and other domains. After controlling for education, significant between-group 
differences were found for scores on the North American Adult Reading Test (NAART), Digit 
Symbol Substitution Test (DSST), Grooved Pegboard (peg) and Rey Osterrieth Complex Figure 
copy task (ROCF-c), with standardized effect sizes (Cohen’s d) ranging from 0.6-0.9. Between-
 75 
group score differences were not explained by other factors (age, blood pressure, history of 
high blood pressure). Furthermore, compared to participants without T1D, a greater 
percentage of participants with T1D had test scores > 1.5SD worse than “expected” (i.e., 
compared to published normative scores), with such scores indicative of clinically relevant 
dysfunction.  Among those with T1D, linear regression models showed that worse performance 
on the DSST, peg and ROCF-c tests was associated with poorer glucose control (higher skin 
intrinsic fluorescence [SIF]) and with prevalent microvascular complications (distal symmetric 
polyneuropathy, proliferative retinopathy and overt nephropathy). No factors examined were 
related to NAART score. These results suggest that the early, small effects of T1D on 
information processing and executive control intensify with advancing age and that prevalent 
microvascular complications may indicate worse cognitive function in middle-aged adults with 
childhood-onset T1D.  
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9.2 INTRODUCTION 
Individuals with childhood-onset type 1 diabetes (T1D) develop mild cognitive dysfunction128,163-
165 at a much earlier age than occurs among the general population.166,167 Because of the 
increased life expectancy for individuals with T1D, they now suffer longer with this 
complication.168 Despite the known association between increasing age and cognitive 
dysfunction,169 the majority of T1D-related cognitive dysfunction studies focus on children and 
young adults. Consequently, the role of aging on cognitive dysfunction among middle-age 
adults with childhood-onset type 1 diabetes remains unknown. This issue deserves immediate 
attention as cognitive dysfunction negatively impacts quality of life for those with the condition 
as well as for their caregivers170 with high direct and indirect costs.171 
In their 2005 meta-analysis, Brands et al. report that adults with T1D demonstrate mild 
to moderate (Cohen’s effect size, d, 0.2-0.7) deficits in tasks assessing executive function, 
attention, intelligence and psychomotor speed domains while learning and memory domains 
appear preserved.127 Importantly, this meta-analysis included studies of individuals with adult-
onset T1D. Since the influence of age at diagnosis on the development of cognitive dysfunction 
remains equivocal, including studies with mixed populations (i.e., childhood vs. adult onset) 
limits the ability to make conclusions regarding cognitive dysfunction in adults with childhood-
onset T1D. Furthermore, the study populations tended to be relatively young; only seven out of 
42 studies had a mean population > 40 years of age. This under-representation of older 
individuals highlights the need for additional studies of aging adults with childhood-onset T1D 
to better understand the combined effects of diabetes and advancing age on cognitive function.  
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Additionally, the mechanisms underlying the development and progression of T1D-
related cognitive dysfunction remain unclear. Current studies underscore an important 
relationship between chronic hyperglycemia and cognitive dysfunction.165,172-174 One proposed 
mechanism is via chronic hyperglycemia leading to endothelial dysfunction59 with resultant 
development of microvascular complications (e.g., retinopathy, neuropathy and nephropathy). 
These conditions are associated with an increased risk of cognitive dysfunction in people with 
type 1 diabetes.126,127,175,176 Shared pathophysiology may explain this relationship; that is, 
chronic hyperglycemia may have the same deleterious effects on cerebral microvasculature as 
it has on small blood vessels elsewhere in the body (kidney, retina, etc.) thereby leading to T1D-
related cognitive dysfunction.163 An additional possibility is that sustained exposure to 
hyperglycemia at a level below that which would cause diabetic ketoacidosis (DKA) may result 
in a state of subclinical cerebral edema, with unknown consequences on cognitive function.177 
This research aims to characterize cognitive function in middle-aged adults with 
childhood-onset T1D. Relationships between diabetes- and health-related factors and 
neurocognitive test scores will be explored. We hypothesize that overall cognitive test scores 
will be worse among participants with T1D compared to similarly-aged adults without T1D and 
that greatest between-group differences will be found in tasks assessing executive function and 
information processing. Among those with T1D, hyperglycemia, high blood pressure and 
prevalent microvascular complications will be associated with worse cognitive performance.  
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9.3 METHODS 
All study procedures received local IRB approval prior to study initiation. All participants provided 
informed consent prior to undergoing procedures. 
9.3.1 Study Populations 
Type 1 diabetes participants were drawn from the Pittsburgh Epidemiology of Diabetes 
Complications Study (EDC), an ongoing, prospective study of individuals with childhood-onset 
(diagnosed < 17 years) T1D. All EDC participants, diagnosed between 1/1/50 and 5/31/80, were 
seen within one year of diagnosis at Children’s Hospital of Pittsburgh and underwent a baseline 
assessment (1986 – 1988) when the mean age was 28 years and the average diabetes duration 
was 19 years. After their baseline visit, participants were followed with biennial exams for 10 
years, thereafter completing biennial questionnaires. An additional physical exam occurred in 
2004-2006. Out of 263 locally-resident participants invited to participate in this cognitive study, 
159 replied with interest. Of these, 47 were ineligible for MRI (a requirement to participate in the 
neurocognitive study) due to metallic implants/objects or claustrophobia, leaving 112 eligible for 
MRI. Fifteen participants did not complete the neuropsychological battery, given between 2010 
and 2013, yielding an analytical sample size of N=97 (Figure 9.6.2). 
Non-type 1 diabetes comparison population: Adults without type 1 diabetes, from the 
University of Pittsburgh’s MR Hyper Study, served as a comparison group. Details of the MR 
Hyper Study have been previously described.132 In brief, to study the effects of vascular risk 
factors on cerebral blood flow, 414 middle-aged adults living in the Pittsburgh area were 
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screened to participate in this study. Of those, 110 did not meet blood pressure inclusion criteria 
(either too high or too low), 60 declined to participate and 14 withdrew, yielding a study 
population of 230 pre-hypertensive adults, mean age 46 years; full exclusion criteria are 
presented in Appendix C. Participants completed a neuropsychological battery (2011-2013) which 
included a large number of the same tests as used the EDC Study, with the exception of the 
Logical Memory and Block Design tasks. To mirror the EDC racial distribution, only Caucasians 
(n=138) were included in these analyses. At the time of cognitive testing, biological and lifestyle 
data were collected for MR Hyper participants using standard methods comparable to those for 
EDC participants. SIF and HbA1c, however, were not available for these participants. 
9.3.2 Covariates 
Diabetes-specific variables: The following variables were collected at each physical exam from 
EDC baseline to time of cognitive testing: fasting serum glucose and HbA1c (using saline-
incubated blood samples and cation-exchange microcolumn chromatography prior to October 
1987, using high-performance liquid chromatography through 2004-2006, and thereafter using 
the DCA 2000 analyzer). Repeated assessment of HbA1c at every exam allowed the calculation of 
an average HbA1c from EDC baseline through time of neurocognitive testing.  
 Skin intrinsic fluorescence (SIF), a measure which partially reflects advanced glycation end 
products (AGEs) in the skin, was assessed during the 2006-2008 EDC exam. A skin fluorescence 
spectrometer (SCOUT DS®) noninvasively measured the skin of the left volar forearm. Details on 
the device and SIF calculations are discussed elsewhere.144 
 80 
Diabetes-related complications: Prevalence of complications was ascertained during the 2004-
2006 exam; this occurred on average five years prior to neuropsychological testing. 
 Renal disease refers to microalbuminuria (MA), overt nephropathy (ON) or End Stage 
Renal Disease. ON was defined as the presence of an albumin excretion rate >200 μg/min in at 
least 2 of 3 timed urine collections and MA as an albumin excretion rate between 20-200 μg/min 
in at least 2 of 3 urine samples. 
 Coronary artery disease (CAD) was defined as myocardial infarction (Minnesota Codes 1.1 
or 1.2), fatal CAD (determined by review of death records and family interview) or angiographic 
evidence of 50% or more stenosis. CAD also included angina diagnosed by the clinic physician 
and/or ischemic ECG changes (Minnesota Codes: 1.3, 4.1-4.3, 5.1-5.3, 7.1). 
 Neuropathies: Distal symmetric polyneuropathy (DSP) was determined by medical history 
and clinical examination using established protocols, i.e. the symptoms and signs consistent with 
DSP, and reduced deep tendon reflexes. DSP was further determined as ‘confirmed’ using the 
Vibratron II® to detect vibratory threshold. Cardiac autonomic neuropathy (CAN) was determined 
by heart variation during deep breathing and by heart rate and blood pressure response to 
standing. 
Retinopathy: Eye exams were done using three standard field stereo fundus photographs. 
Photographs were read at the Madison Reading Center in Wisconsin and graded using the Early 
Treatment Diabetic Retinopathy Study classification, with a grade of 60 or higher in one eye or a 
grade less than 60 but with panretinal photocoagulation scars consistent with laser therapy 
indicating proliferative retinopathy.145 
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Biological risk factors: Hypertension was defined as any blood pressure reading >140/90 mmHg or 
ever reporting use of antihypertensive medication from EDC baseline through day of 
neurocognitive testing; for the MR Hyper participants, high blood pressure was defined as blood 
pressure >140/90 mmHg on the day of the MRI (those with a history of hypertension or chronic 
use of antihypertensive medication were ineligible for the MR Hyper Study). Use of 
hypertension medication is available from study entry to time of MRI for EDC participants. 
Blood pressure: Three seated blood pressure readings were taken with a random-zero 
sphygmomanometer on day of neurocognitive testing, with an average of the second and third 
readings used, per the Hypertension Detection and Follow-up Program Protocol.  
Cholesterol: SYNCHRON CX® Systems was used to measure non-fasting total cholesterol 
and high-density cholesterol (HDLc) at time of neurocognitive testing. Non-HDL cholesterol was 
calculated as (total cholesterol – HDLc). 
Apolipoprotein E (ApoE) status was ascertained in 2004-2006 for EDC participants and at 
time of neurocognitive testing for MR Hyper participants. 
Body mass index (BMI) was calculated based on the participants’ weight and height at 
time of neurocognitive testing (kg/m2). 
Lifestyle/Behavioral risk factors: 
Smoking status was self-reported as current, past or never smoking 100 cigarettes and 
was dichotomized as ever vs. never smoking based on information obtained through time of 
neurocognitive assessment. 
Physical activity for the past week was determined via self-report from the Paffenbarger 
Physical Activity Questionnaire178 in 2004-2006 for EDC participants and at time of 
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neurocognitive testing for the MR Hyper participants. Responses were used to estimate energy 
expenditure (kcal). 
9.3.3 Neuropsychological Testing 
The following cognitive tests were administered to participants from both studies. More 
information regarding each test is provided in Appendices A and B. 
1. North American Adult Reading Test (NAART) 
2. Rey Osterrieth Complex Figure (ROCF) 
3. Rey Auditory Verbal Learning Test (RVLT) 
4. Four Word Short Term Memory (4WSTM)  
5. Digit Symbol Substitution Test (DSST), number complete in 90 seconds 
6. Trail Making Test A and B (TMTA, TMTB), time to complete 
7. Wechsler Adult Intelligence Scale (WAIS) Block Design 
8. Verbal Fluency – FAS and Animals Tests 
9. Stroop Color-Word Test (Golden version) 
10. Grooved pegboard, dominant hand, time to insert pegs 
 
Neuropsychological tests were administered by one trained study staff member to ensure 
consistency between participant experiences. Tests were scored by trained study staff unaware 
of participant cognitive status. 
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9.3.4 Statistical Analyses 
Groups (T1D, no T1D) were assessed for differences in population characteristics using t-test for 
continuous variables, Fisher exact test for categorical variables and Wilcoxon rank sum test for 
highly skewed data. Mean and percent differences in raw cognitive test scores were compared 
by T1D status, controlling for years of education. Standardized effect sizes were computed 
using Cohen’s d (2t/√df),179 classified as small (d<0.2), moderate (0.21<d<0.5) or large 
(d>0.51).180 Indicator variables were created for each task to show whether cognitive any test 
score was > 1.5SD worse than published normative data.27-30 Analyses were repeated excluding 
all participants with a history of high blood pressure (SBP > 140 mmHg, DBP > 90 mmHg) or self-
report use of anti-hypertensive medication. 
Cognitive test scores that differed significantly (education adjusted p<0.001) between 
groups (T1D, no T1D) were used as dependent variables (DV) in linear regression models. To 
test the contributions of T1D status and other factors on cognitive test scores, factors (with the 
exception of serum glucose due to its correlation with group status) that differed between 
groups (p<0.05) entered step-wise regression models. Multicollinearity was deemed severe if 
the variance inflation factor (VIF) > 2.5; any factor(s) reaching this VIF were not included in the 
same model. Adjusted R2 was used to identify the most parsimonious models.  
 In order to identify diabetes-specific factors significantly related with cognitive function, 
further analyses were restricted to participants with T1D. Unadjusted standardized betas 
between each diabetes variable of interest with each DV were reported. Factors significantly 
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associated with each DV (p<0.05) were further tested to examine how first adjusting for years 
of education then further adjusting for age affected the relationship. 
All analyses were conducted using SAS 9.3 and SPSS 21. 
9.4 RESULTS 
Groups did not significantly differ (p>0.05) regarding age at neurocognitive testing or sex 
distribution (Table 9.6.1). Serum glucose and history of high blood pressure were statistically 
significantly (p<0.05) higher among participants with T1D compared to those without T1D. 
Years of education, diastolic blood pressure and physical activity were statistically significantly 
lower for participants with T1D compared to those without T1D. The groups did not 
significantly differ in regards to systolic blood pressure, ApoE4 status or smoking history (Table 
9.6.1).  
Between group differences were observed for tasks assessing premorbid IQ, 
psychomotor speed, executive function and visuo-spatial construction, but not for memory 
(Table 9.6.2). In particular, participants with T1D performed significantly worse (education 
adjusted p<0.05) than those without T1D on NAART (number correct), DSST (number complete 
in 90 seconds), Grooved Pegboard (time to insert pegs, dominant hand), Trail Making Test B 
(time to complete), Trail Making Test B:A ratio and the ROCF-copy tasks. Effect sizes for these 
tasks were large, with d ranging from 0.5-0.9 (Table 9.6.2, Figure 9.6.3). Group differences in 
scores for other tasks were not statistically significant (education adjusted p>0.05), with small 
to moderate effect sizes, (d=0.1-0.3).  
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Between group differences were also observed when comparing test scores to 
published norms. Compared to participants without T1D, a higher percentage of participants 
with T1D scored at least 1.5SD worse than published normative data. Greater between-group 
differences were seen for the DSST, Grooved Pegboard and ROCF-copy tasks as compared to 
other tasks (Figure 9.6.1). 
 In linear regression models, having T1D (Table 9.6.3, unadjusted model) explained 8% of 
the between-group difference in NAART score, 11% of DSST score difference, 13% of pegboard 
score difference and 12% of ROCF-copy score difference. Years of education explained another 
23% of difference in NAART score but only explained an additional 2-5% of group differences in 
scores for DSST and ROCF-copy; education did not contribute to group differences in Grooved 
Pegboard scores (Table 9.6.3, education adjusted model). History of high blood pressure was 
included in the most parsimonious model for each DV even though it was only weakly 
associated with the outcome. Diastolic blood pressure was included only in the parsimonious 
model for NAART score while physical activity was included in the most parsimonious models 
for Grooved Pegboard and ROCF-copy. The combination of factors explained an additional 5% 
of the variance in NAART score, 3.4% of the variance in Grooved Pegboard score and less than 
1% of the variance in DSST or ROCF-copy scores  over the education adjusted model (Table 
9.6.3, most parsimonious model). 
 In further analyses restricted to participants with T1D, statistically significant 
(unadjusted p<0.05) relationships were seen between DSST, Grooved Pegboard and ROCF-copy 
scores and prevalent distal symmetric polyneuropathy, overt nephropathy and proliferative 
retinopathy (Table 9.6.4). Scores on these three tasks were also significantly related to a 
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measure of chronic hyperglycemia, with worse DSST and ROCF-copy scores being significantly 
associated with higher SIF and worse Grooved Pegboard score being significantly related to 
higher A1c months. Worse DSST score was also significantly related to longer diabetes duration 
and with cardiac autonomic neuropathy. Worse NAART score was not statistically significantly 
related to any of the factors examined, although there was a borderline association with higher 
A1c months (p=0.06) (Table 9.6.4). Except for the relationship between ROCF-copy and 
proliferative retinopathy, all of the relationships remained statistically significant after 
adjustment for years of education.  After further adjustment for age, DSST score remained 
significantly related to distal symmetric polyneuropathy and proliferative retinopathy, Grooved 
Pegboard score remained significantly related to A1c months, distal symmetric polyneuropathy, 
overt nephropathy and proliferative retinopathy, and ROCF-c score remained significantly 
related to SIF and overt nephropathy (Table 9.6.4). No statistically significant associations were 
found between task scores and estimated glomerular filtration rate (eGFR, per the Chronic 
Kidney Disease Epidemiology Collaboration formula,181 data not shown). First order 
relationships between task scores and SIF were independent of smoking history and eGFR (data 
not shown). 
9.5 DISCUSSION 
Similar to studies involving children and young adults with T1D,127,128,165 the largest score 
differences were seen in tasks assessing premorbid IQ, psychomotor speed, executive function 
and visuo-spatial construction. We found larger effect sizes, however, compared to previous 
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studies. In the Gaudieri et al. meta-analysis comparing children with and without T1D,128 no 
effect sizes were greater than 0.2, a ‘small’ effect per Cohen’s classification. The large effect 
sizes found in our study more closely resemble those reported a. meta-analysis of cognitive 
function in adults with T1D; Brands et al. reported significantly worse performance by T1D 
compared to non-T1D participants in overall cognition (Cohen’s d~0.35), intelligence (d 0.4-0.8), 
psychomotor efficiency (d~0.6), attention (d 0.3-0.4), cognitive flexibility (d~0.5) and visual 
perception (d~0.4).127 The studies included in this meta-analysis, however, were not limited to 
adults with childhood-onset T1D; this is, many of the participants in the meta-analyses were 
diagnosed in adulthood, thus obscuring the true effects of childhood-onset T1D on cognitive 
performance. Additionally, we cannot compare task scores directly as each study included in 
the meta-analyses employed a different battery of neurocognitive tasks. Differences in effect 
sizes reported for pediatric128 and adult127 T1D populations suggest that increasing age 
contributes to T1D-related cognitive decline at a faster rate than occurs in non-T1D 
populations.  
   We found no factors to explain the between group difference in NAART score. It is 
possible that the factors influencing NAART performance occurred much earlier in the disease 
physiology, near time of diagnosis, and thus do not appear in this analysis. The effect of these 
early, unknown factors may be so strong that the influence of traditional risk factors on 
cognitive decline (eg., hypertension, hyperglycemia) become non-significant. A life-course 
approach to cognitive function in childhood-onset T1D with repeated neuropsychological 
testing, brain imaging and demographic/biological risk factor assessment would enable us to 
better understand the complex nature of T1D and cognitive function.   
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Cognitive function is believed to steadily increase from childhood into the early 20s, 
remain fairly stable from the 20’s until the 40’s to early 50’s, then begin to decline steadily into 
older age.182 It remains unknown whether childhood-onset T1D prevents the brain from 
reaching its full cognitive abilities or if the decline in cognitive function occurring in late middle-
aged adults occurs at a much earlier age in people with T1D, or possibly a combination of the 
two. Northam et al. demonstrate that in children, T1D exerts measurable effects on cognitive 
function within a few years of diagnosis.183,184 Conversely, no significant declines in cognitive 
test scores (average of 18 years between neurocognitive testing) were reported among adults 
participants in the Diabetes Control and Complications Trial/ Epidemiology of Diabetes 
Interventions and Complications study 48 even though smoking, hypertension and highest 
tertile A1c levels were found to negatively affect learning, memory, spatial information, 
psychomotor efficiency and motor speed.185 While our study is cross-sectional and cannot 
assess cognitive change over time, the differences in cognitive task scores between participants 
with and without T1D suggest accelerated brain aging occurs in people with childhood-onset 
T1D. 
The clinical importance of these results is demonstrated in the comparison of test scores 
to published norms (Figure 1). At least 10-15% of T1D participants scored > 1.5SD worse than 
normative means on NAART, Trails B, Ratio Trails B:A and RVLT interference while almost 20% 
met this degree of impairment on ROCF-copy, 25% on DSST and 45% on Grooved Pegboard. 
Conversely, among non-T1D participants, approximately 12% met this level of impairment on 
NAART and approximately 10% on the Grooved Pegboard; for the remaining tasks, 1-7% of non-
T1D participants scored > 1.5SD from published norms. A score of 1.5SD worse than the 
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published norms is used in aging studies as indication of clinically relevant cognitive dysfunction 
or dementia. The fact that these middle-aged adults with T1D score comparable to older adults 
with dementia indicates an immediate need for intervention and/or assistance. 
In conclusion, this study characterizes cognitive function among middle-aged adults with 
childhood-onset T1D. These exceptional patients have survived into middle age with T1D. They 
are under-represented in T1D studies but as they comprise a rapidly growing proportion of T1D 
patients, they deserve prompt attention in order to prevent or delay progression of 
complications. Other studies have shown that early glycemic control may prevent or delay the 
development of microvascular complications in people with type 1 diabetes. We extend the 
possibility that glycemic control may also benefit cognitive functioning and suggest that 
prevalent distal symmetric neuropathy, overt nephropathy and proliferative retinopathy may 
identify individuals suffering from executive function, psychomotor speed and visuo-spatial 
difficulties. While this study is limited by its cross-sectional nature, it does provide needed 
descriptive information about cognitive status in long-term T1D survivors, giving policy-makers 
an idea of the need for services for such individuals. From a public health perspective, reducing 
cognitive dysfunction in people with type 1 diabetes should correspond with a reduction in 
diabetes-related complications and improved self-care.163 Longitudinal studies including the use 
of repeated brain imaging measures and precise ascertainment of hyper- and hypoglycemic 
events are needed to disentangle the complexities of type 1 diabetes-related cognitive 
dysfunction. 
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9.6 TABLES AND FIGURES 
Table 9.6.1 Characteristics of participants with type 1 diabetes (T1D, from Pittsburgh’s 
Epidemiology of Diabetes Complications study) and without type 1 diabetes (no T1D, from 
Pittsburgh’s MR Hyper Study) at time of neurocognitive assessment (2010-2013) unless 
otherwise noted 
 
 
 
 
 
 
 T1D 
N=97 
No T1D 
N=138 
Values presented are N(%), Mean ±Standard Deviation or Median (Interquartile Range) 
Demographic 
factors 
Age (years)  49.1 ± 6.6 48.7 ± 7.2 
Female 49 (51%) 76 (55%) 
Education (years) 16 (13 - 17) ** 16 (14 - 18) 
Biological  
factors 
Serum glucose pre-cognitive testing (mg/dL)  174.5 ± 86.3 **** 91.3 ± 16.3 
Systolic blood pressure(mmHg)  119.6 ± 15.6 119.4 ± 9.9 
Diastolic blood pressure (mmHg)  66 (60 - 70) **** 80 (74 - 84) 
History of high blood pressure† 37 (38%) **** 11 (8%) 
ApolipoproteinԐ4 status (24, 34, or 44) 29 (30%) 27 (21%) 
Lifestyle 
factors 
Ever smoking 100+ cigarettes 37 (38%) 58 (42%) 
Physical activity in past week (Kcal)# 1092 (420 - 1981) * 1628 (616 - 3008) 
*p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001 
† For T1D participants: SBP > 140 or DBP > 90 or report of ever using antihypertensive medication at any 
EDC physical exam; for participants without T1D, history of high blood pressure based on self-report at 
time of neurocognitive assessment 
# For T1D participants, measure taken 2004-06 
 91 
 Table 9.6.2 Comparison on raw scores for each task in the neuropsychological test battery 
(controlling for years of education) between participants with type 1 diabetes (T1D, Pittsburgh 
Epidemiology of Diabetes Complications Study) and without type 1 diabetes (no T1D, Pittsburgh 
MR Hyper Study) 
* p-value adjusted for years of education 
~ Effect size = Cohen’s d, calculated as 2t/√df to account for unequal variances 
^ Considered an estimate of premorbid IQ 
† Tasks in which a higher score = worse performance; for other tasks, higher scores = better performance 
 
 
 
 
 
 
Domain 
 
Test 
T1D 
Raw Score 
No T1D 
Raw Score 
Raw Score Difference 
(no T1D – T1D) 
Effect 
Size 
Mean ± SD Mean Percent p-value* 
 
d~ 
IQ
^  North American Adult Reading Test       
Number correct  37.1 ± 9.4 43.3 ± 10.3 6.2 -15.0% .0009 0.62 
Ps
yc
ho
-
m
ot
or
 
Sp
ee
d 
Digit Symbol Substitution Test  54.5 ± 13.5 63.4 ± 11.8 8.9 -15.0% <.0001 0.70 
Grooved Pegboard †  88.8 ± 33.2 69.0 ± 17.6 19.8 25.1% <.0001 0.66 
Trail Making Test       
Part A †  27.6 ± 11.9 28.2 ± 13.9 0.6 -1.7% .524 0.05 
Ex
ec
ut
iv
e 
Fu
nc
tio
n 
   
Stroop Color:Word  41.0 ± 9.5 44.2 ± 8.8 3.2 -7.5% .071 0.33 
Trail Making Test       
Part B † 65.4 ± 38.5 53.4 ± 22.3 12.0 16.5% .030 0.46 
Ratio B:A † 2.5 ± 1.4 2.0 ± 0.7 0.5 21.2% .004 0.54 
Verbal Fluency: FAS 44.4 ± 13.8 48.2 ± 11.9 3.7 -7.4% .114 0.29 
Letter Number Sequence  11.0 ± 2.9 11.9 ± 2.8 1.0 -8.2% .055 0.33 
M
em
or
y 
 
Rey Auditory Verbal Learning        
Sum trials 1-5  54.1 ± 8.9 56.0 ± 9.0 2.0 -3.7% .464 0.22 
Interference  6.4 ± 2.6 6.9 ± 1.9 0.5 -7.5% .363 0.24 
Delayed recall  11.0 ± 3.0 11.4 ± 3.0 0.4 -4.0% .664 0.15 
Rey Osterrieth Complex Figure       
Delayed recall  18.6 ± 6.7 19.9 ± 6.6 1.3 -6.6% .410 0.20 
4-Word Short term memory       
5 second list  15.2 ± 3.1 16.3 ± 3.2 1.1 -7.0% .095 0.33 
15 second list  12.3 ± 4.1 13.4 ± 3.8 1.2 -9.2% .172 0.29 
30 second list  10.5 ± 4.5 11.1 ± 4.7 0.6 -5.8% .757 0.13 
O
th
er
 
 
Rey Osterrieth Complex Figure       
Copy 30.7 ± 5.4 33.9 ± 3.4 3.2 -9.9% <.0001 0.87 
Verbal Fluency: Animals 21.7 ± 5.3 23.3 ± 5.5 1.5 -6.5% .146 0.28 
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Table 9.6.3 Linear regression models showing the effects of type 1 diabetes and other 
covariates of interest on cognitive test scores 
Standardized Beta  (SE) p-value 
Outcome: 
NAART 
Unadjusted 
model 
Adjusted for 
education 
Most 
parsimonious 
model 
Fully adjusted 
model 
Type 1 diabetes 
-.294 
(1.33) 
<0.001 
-.197 
(1.17) 
<0.001 
-.255 
(1.61) 
<0.001 
-.246 
(1.71) 
0.003 
Years of education 
.491 
(0.21) 
<0.001 
.531 
(0.21) 
<0.001 
.521 
(0.22) 
<0.001 
Diastolic blood pressure 
-.118 
(0.07) 
0.092 
-.101 
(0.07) 
0.167 
History of high blood 
pressure/using 
antihypertensive 
medication 
-.065 
(1.53) 
0.280 
-.083 
(1.58) 
0.194 
Physical activity (Kcal) 
-.079 
(.000) 
0.170 
Adjusted R2 0.082 0.312 0.362 0.337 
Outcome: 
DSST score 
Unadjusted 
model 
Adjusted for 
education 
Most 
parsimonious 
model 
Fully adjusted 
model 
Type 1 diabetes 
-.332 
(1.67) 
<0.001 
-.297 
(1.70) 
<0.001 
-.260 
(1.82) 
<0.001 
-.230 
(2.49) 
0.014 
Years of education 
.146 
(0.31) 
0.022 
.149 
(0.32) 
0.019 
.152 
(0.33) 
0.023 
Diastolic blood pressure 
-.051 
(0.11) 
0.543 
History of high blood 
pressure/using 
antihypertensive 
medication 
-0.103 
(2.19) 
0.120 
-.121 
(2.34) 
0.101 
Physical activity (Kcal) 
.063 
(.001) 
0.350 
Adjusted R2 0.106 0.121 0.126 0.108 
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Outcome: 
Pegboard 
Unadjusted 
model 
Adjusted for 
education 
Most 
parsimonious 
model 
Fully adjusted 
model 
Type 1 diabetes 
.365 
(3.47) 
<0.001 
0.347 
(3.55) 
<0.001 
.251 
(3.68) 
<0.001 
.338 
(4.66) 
<0.001 
Years education 
-.078 
(0.63) 
0.233 
-.146 
(0.61) 
0.027 
-.139 
(0.61) 
0.038 
Diastolic blood pressure 
.116 
(0.20) 
0.161 
History of high blood 
pressure/using 
antihypertensive 
medication 
0.134 
(4.33) 
0.056 
.081 
(4.50) 
0.269 
Physical activity (Kcal) 
-.124 
(.001) 
0.061 
-.114 
(.001) 
0.093 
Adjusted R2 0.129 0.129 0.163 0.152 
Outcome: 
ROCF copy 
Unadjusted 
model 
Adjusted for 
education 
Most 
parsimonious 
model 
Fully adjusted 
model 
Type 1 diabetes 
-.347 
(0.58) 
<0.001 
-0.297 
(0.57) 
<0.001 
-.214 
(0.65) 
0.002 
-.151 
(0.87) 
0.103 
Years education 
.246 
(0.10) 
<0.001 
.272 
(0.11) 
<0.001 
.263 
(0.11) 
<0.001 
Diastolic blood pressure 
.083 
(0.04) 
0.317 
History of high blood 
pressure/using 
antihypertensive 
medication 
-.119 
(0.75) 
0.081 
-.139 
(0.80) 
0.056 
Physical activity (Kcal) 
.062 
(.000) 
0.328 
.071 
(.000) 
0.268 
Adjusted R2 0.117 0.170 0.176 0.169 
Table 9.6.3 Continued
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Table 9.6.4 Associations between characteristics of participants with type 1 diabetes 
(Pittsburgh Epidemiology of Diabetes Complications Study) and select cognitive test scores. 
Measures taken at time of cognitive assessment (2010-2013) unless otherwise noted 
NAART: North American Adult Reading Test, number correct (max score = 61); DSST: Digit Symbol 
Substitution Test (number correct in 90 seconds); Peg: Grooved Pegboard, time to insert pegs (seconds) 
using dominant hand; ROCF: Rey-Osterrieth Complex Figure (score on copy task); A1c months: 
cumulative glucose control score calculated by multiplying the number of HbA1c units above normal at 
each cycle by the number of months between the midpoints of the preceding and succeeding cycle 
intervals 
1=measure taken 2006-2008; 2=measure taken 2004-2006  
* Remained significant (p<0.05) after adjusting for years of education
** Remained significant (p<0.05) after adjusting for years of education and age at neurocognitive testing 
NAART DSST Peg ROCF 
Standardized Beta (SE), p-value 
Diabetes duration (years) -.006 (0.16), 0.96 -.350 (0.21), <0.001* .212 (0.63), 0.07 -.169 (0.09), 0.10 
Diagnosed > age 8 years .039 (1.95), 0.71 -.178 (2.76), 0.09 .146 (7.62), 0.21 -.035 (1.12), 0.74 
Skin Intrinsic 
Fluorescence (AU)1 -.072 (0.22), 0.51 -.245 (0.30), 0.02
* .229 (0.90), 0.06 -.278 (0.12), 0.01** 
A1c months -.198 (<0.01), 0.06 -.143 (<0.01), 0.17 .287 (<0.01), 0.01** -.039 (<0.01), 0.71 
Coronary artery disease2 .140 (2.64), 0.18 -.066 (3.92), 0.53 -.016 (10.50), 0.89 .099 (1.52), 0.35 
Cardiac autonomic 
neuropathy2 -.151 (2.02), 0.16 -.275 (2.84), 0.01
* .106 (8.17), 0.38 -.161 (1.10), 0.14 
Distal symmetric 
polyneuropathy2 -.070 (1.99), 0.52 -.388 (2.66), <0.001
** .369 (7.72), 0.002** -.257 (1.16), 0.02* 
Overt nephropathy2 .038 (2.52), 0.75 -.252 (3.40), 0.03* .458 (9.55), <0.001** -.241 (1.35), 0.04** 
Proliferative retinopathy2 -.036 (1.95), 0.73 -.338 (2.64), <0.001** .493 (6.68), <0.001** -.205 (1.10), 0.05 
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Figure 9.6.1 Percentage of participants with type 1 diabetes (red bars) and without type 1 
diabetes (black bars) scoring 1.5 or more SD worse than published normative data.  
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Figure 9.6.2 Flow chart showing recruitment of participants with type 1 diabetes from the 
parent Pittsburgh Epidemiology of Diabetes Complications (EDC) Study into the 
MRI/neurocognitive study 
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Figure 9.6.3 Standardized effect sizes of raw score differences between participants with type 1 
diabetes (T1D, Pittsburgh Epidemiology of Diabetes Complications Study) and without type 1 
diabetes (Pittsburgh MR Hyper Study). Sample size for T1D participants in parentheses (N=xx). 
For participants without T1D, N=138 for all tasks except NAART (NAART N=137)  
Standardized Cohen’s d    -1.2        -1.0        -0.8        -0.6        -0.4    -0.2   0.0     0.2 
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NAART correct (N=95) 
DSST (N=94) 
Pegboard (N=76) 
Trails A (N=96) 
Stroop Color:Word (N=73) 
Trails B (N=96) 
Ratio Trails B:A (N=96) 
Sum FAS (N=86) 
LN Sequence (N=95) 
RVLT (sum 1-5) (N=95) 
RVLT (interference)(N=95) 
RVLT (delay)(N=92) 
ROCF (delay)(N=84) 
4WSTM 5 seconds (N=76) 
4WSTM 15 seconds (N=76) 
4WSTM 30 seconds (N=76) 
ROCF (copy)(N=93) 
Animals (N=86) 
Worse   Better 
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10.0  MANUSCRIPT 3: REDUCED CEREBRAL BLOOD FLOW RELATED TO COGNITIVE 
DYSFUNCTION IN MIDDLE-AGED ADULTS WITH CHILDHOOD-ONSET TYPE 1 DIABETES  
10.1 ABSTRACT 
Objective. Employ a non-invasive neuroimaging approach to examine the relationship between 
brain perfusion and cognitive dysfunction in middle-aged adults with childhood-onset type 1 
diabetes. 
Methods. A subset of 93 adults (mean age 49 years, mean diabetes duration 41 years) 
from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC) underwent brain 
neuroimaging and completed a neuropsychological battery between December 2010 and 
January 2103. Cognitive status (cognitive normal vs. cognitive dysfunction) was determined by 
clinical adjudication. Between-group differences were examined using logistic regression 
models, controlling for IQ. 
Results. 32% of participants were classified with cognitive dysfunction. Reduced cerebral 
blood flow to the right middle frontal gyrus and bilateral superior parietal lobes was 
significantly related to cognitive dysfunction; no other neuroimaging markers, either whole 
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brain or region of interest, were significantly related to cognitive dysfunction. Having an ankle-
brachial index (ABI) > 1.3 and being in the lowest vs. highest quartile of physical activity, as 
assessed in 2004-2006, both significantly increased the odds of cognitive dysfunction, however 
only high ABI remained significantly associated with cognitive dysfunction after adjusting for 
reduced cerebral blood flow. 
Conclusion. Cognitive dysfunction in middle-aged adults with type 1 diabetes is related 
to reduced cerebral blood flow, vascular stiffness (as indicated by high ABI) and low physical 
activity. Further studies are needed to investigate the vascular mechanisms underlying these 
associations and whether interventions aimed at preventing vascular stiffness and  increasing 
physical activity would reduce cognitive dysfunction in people with T1D. 
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10.2 INTRODUCTION 
Adults with type 1 diabetes mellitus (T1D) have a higher prevalence of mild to moderate 
cognitive dysfunction compared to similarly-aged peers without diabetes.133,163-165,177,186,187 
Greatest decrements are noted in executive function, psychomotor speed, intelligence, 
attention and visual perception.127,165 In addition, cognitive dysfunction appears at a younger 
age in those with T1D128,164 compared to the general population.166,167 The risk factors and 
neuroanatomical correlates that underlie T1D-related cognitive dysfunction remain unclear and 
deserve further investigation. Studying this relationship among older adults with T1D is 
particularly important since advancing age also negatively affects cognitive function. 
Considering the improved life expectancy of people with T1D,131 research in this area is of 
public health urgency in order to develop strategies to minimize the development and/or 
progression of cognitive dysfunction in adults with childhood-onset type 1 diabetes.  
Among the type 1 diabetes factors that correlate with brain imaging markers, the two 
main candidates are chronic hyperglycemia and high blood pressure because of their known 
effects on cerebral vasculature.58 Both conditions lead to thickening of vessel walls and 
narrowing of the lumen, which causes diffuse ischemic damage, changes in myelin structure, 
loss of axons and necrosis of gray and/or white matter.58 While severe hypoglycemia has long 
been considered a risk factor for the deleterious effects of T1D on the central nervous 
system,188 some studies have failed to prove such an association.126,163 Chronic hyperglycemia, 
however, negatively impacts endothelial function58 and has emerged as a modifiable risk factor 
for T1D-related cognitive dysfunction.189 Even though hypertension plays a major role in age-
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related cognitive decline,58,190 its contribution to T1D-related cognitive dysfunction remains 
unclear, with two studies reporting an association between hypertension and reduced cognitive 
function 126,176 while a third did not.127 
Although gray matter volume and white matter hyperintensities are known correlates of 
cognitive impairment in older adults without T1D,52,70,191 few studies have examined these 
relationships in adults with T1D.  One study reports a relationship between reduced cognitive 
function and smaller cerebral white matter volume68 in adults with vs. without T1D but other 
studies do not support this association.92,95 While middle-aged adults with childhood-onset T1D 
have a higher prevalence of cerebral WMH compared to adults without T1D, (Nunley et al., 
2014, unpublished), studies have not found an association between these lesions and T1D-
related cognitive dysfunction.93-95 The relationship between gray matter volume and cognitive 
function in adults with T1D also remains unknown. Musen et al. conducted a GM voxel based 
morphometry study in young adults with T1D but did not provide results showing correlations 
between cognitive test scores and GM density.192 Other studies report cerebral atrophy (as 
suggested by larger ventricle size) in participants with vs. without T1D but found no significant 
correlations between this marker of atrophy and cognitive dysfunction.92-94,96 One possible 
reason for these discrepancies is that advanced structural changes such as WMH and loss of 
GM volume may not be evident in younger people with T1D who have earlier/milder cognitive 
impairment.193    
Recent advances in imaging technology can assess earlier changes in brain structure as 
compared to WMH or GM volume. Microstructural disruption of gray and white matter 
integrity, as assessed using diffusion tensor imaging (DTI), correlates with poor cognitive test 
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performance on executive function, memory and perception speed tasks in age-related 
cognitive decline.194,195 Two DTI studies have examined the relationship between cognitive 
function and cerebral white matter microstructural integrity in adults with T1D, with both 
reporting lower fractional anisotropy (FA) values in participants with vs. without T1D.99,125 Kodl 
et al. report that lower FA was related to poorer performance on the Rey-Osterreith Complex 
Figure Drawing and grooved pegboard tasks.99 While Van Duinkerken et al. found an association 
between lower FA and lower overall cognitive performance, they did not report associations 
between FA values and individual neurocognitive tests.125    
Cerebral blood flow (CBF) can also detect early indications of compromised brain 
integrity. Lower CBF is associated with mild cognitive impairment and dementia in elderly 
populations.196-198 Unlike other CBF techniques (e.g., positron emission tomography, X-ray 
computed tomography),199 ASL does not require the use of a radiotracer. Rather, 
radiofrequency irradiation is used to magnetically label arterial blood water molecules. Decay 
of the magnetic signal occurs with T1 relaxation.200 The non-invasiveness of ASL makes it a 
more acceptable methodology to research study participants. It also allows CBF imaging in 
patient populations with contraindications for contrast agents. No studies were found that 
examined the relationship between CBF using ASL and cognitive function in adults with T1D.  
Lack of consistency between studies (e.g. differences in duration of disease, glycemic 
control, brain tissue of interest and choice of neuropsychological tests) prevent a complete 
understanding of the effects T1D has on brain structure and function. In addition, most of these 
studies utilized low magnetic field strength (.5 or 1.0 Tesla) which may have limited the ability 
to detect early and/or small changes in the T1D brain. Lastly, only one study examined older 
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T1D participants92 while the remaining studies examined younger adults with  T1D. As such, the 
full effects of T1D on cerebral structure and function, combined with the known effects of 
advancing age on cerebral structure and function, remain to be ascertained.  
This research will explore the possibility of using a non-invasive measure of CBF to 
explain the pathophysiology of early cognitive dysfunction in middle-aged adults with 
childhood-onset T1D. The aim of this research is to 1) determine if cerebral blood flow partially 
explains the presence of clinically-adjudicated cognitive dysfunction in middle-aged adults with 
childhood-onset T1D; and 2) identify potential risk factors for cognitive dysfunction using data 
collected over the 20 years preceding MRI and cognitive testing. The hypotheses are 1) 
clinically-adjudicated cognitive dysfunction will be correlated with reduced cerebral blood flow 
in this population of middle-aged adults with childhood-onset T1D; 2) in these participants with 
childhood-onset T1D, older age, poor glycemic control, diabetes duration and the presence of 
neuropathy and retinopathy will be associated with cognitive dysfunction. 
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10.3 METHODS 
Each study protocol received local IRB approval prior to study initiation. All participants 
completed informed consent prior to undergoing study procedures. 
10.3.1 Study Population 
Participants for this study were drawn from the Pittsburgh Epidemiology of Diabetes 
Complications Study (EDC), an ongoing, prospective study of individuals with childhood-onset 
(diagnosed < 17 years) T1D. All EDC participants, diagnosed between 1/1/50 and 5/31/80 and 
seen within one year of diagnosis at Children’s Hospital of Pittsburgh, underwent a baseline 
assessment (1986 – 1988) when the mean age was 28 years and the average diabetes duration 
was 19 years. After their baseline visit, EDC patients were followed with biennial exams for 10 
years, thereafter completing biennial questionnaires. An additional physical exam occurred in 
2004-2006. A total of 263 locally-resident EDC participants contacted for the 2010-2012 exam 
were also invited to participate in this MRI study. Of these, 157 did not undergo imaging:  81 
were not interested, 37 were ineligible for MRI and 39 did not reply or did not show for their 
MRI. The remaining 106 (mean age 48 years, 50% female, 98% Caucasian) underwent brain 
imaging between December 2010 and December 2012. Due to poor or missing imaging 
sequences, nine individual were excluded from analyses. Another four participants did not 
undergo neurocognitive testing, yielding an analytical sample of n=93 (Figure 10.6.1). 
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10.3.2 Neuropsychological Testing 
The following tasks comprised the neurocognitive test battery. Details of each test are provided in 
Appendix B. 
1. North American Adult Reading Test (NAART)
2. Wechsler Memory Scale-Revised (WMS-R) Logical Memory, Story A
3. Rey Osterrieth Complex Figure (ROCF)
4. Rey Auditory Verbal Learning Test (RVLT)
5. Four Word STM
6. Digit Symbol Substitution Test (DSST), number complete in 90 seconds
7. Trail Making Test A and B (TMTA, TMTB), time to complete
8. Wechsler Adult Intelligence Scale (WAIS) Block Design
9. Verbal Fluency – FAS and Animals Tests
10. Stroop Color-Word Test (Golden version)
11. Grooved pegboard, dominant hand, time to insert pegs
Neuropsychological tests were administered by one trained study staff member to ensure 
consistency between participant experiences. Tests were scored by trained study staff unaware 
of participant cognitive status. 
The clinical adjudication process has been previously described and validated.166 For this 
study, a clinical psychologist with expertise in dementia and a clinical psychologist with 
expertise in cognitive functioning in people with T1D evaluated the cognitive tests and clinical 
history of each patient since the first available record. Using standardized diagnostic criteria 
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from neurocognitive test scores in conjunction with medical and personal histories and brain 
MRIs, they determined the presence of “Cognitive disorder not otherwise specified (NOS)” 
(DSM-IV Code 294.9) for each participant; this category is reserved for cognitive dysfunction 
resulting from the direct physiological effects of some general medical condition (i.e., type 1 
diabetes) and that does not meet DSM-IV criteria for other types of cognitive disorders such as 
delirium or dementia.201 
10.3.3 Covariates 
The following were ascertained at each EDC visit, from baseline (1986-1988) to time of MRI: 
diabetes duration; HbA1c (using saline-incubated blood samples and cation-exchange 
microcolumn chromatography prior to October 1996, using high-performance liquid 
chromatography through 1996-98, and thereafter using the DCA 2000 analyzer); estimated 
glucose disposal rate (eGDR, an indicator of insulin sensitivity); use of insulin pump (yes/no); 
and serum glucose.  
Hemoglobin A1c was also measured at time of MRI. An average HbA1c value was 
calculated over all visits. A measure known as “A1c months” that combines a cumulative 
degree and duration of glycemic exposure was also included (see 143 for specific details).  
Diabetes-related complications  
Prevalence of the following complications was ascertained at the 2004-2006 exam 
which occurred, on average, five to six years prior to MRI: 
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Renal disease refers to either microalbuminuria (MA), overt nephropathy (ON) or End 
Stage Renal Disease (ESRD; dialysis or renal transplantation). ON was defined as the presence of 
renal failure (serum creatinine >5 mg/dl and/or ESRD) or an albumin excretion rate >200 
μg/min in at least 2 of 3 timed urine samples. In the absence of urine collections, a serum 
creatinine >2 mg/dl indicated ON. MA was defined as an albumin excretion rate between 20-
200 μg/min in at least 2 of 3 urine samples.   
Coronary artery disease (CAD) was defined as myocardial infarction (Minnesota Codes 
1.1 or 1.2), fatal CAD (determined by review of death records and, where appropriate, family 
interview), or angiographic evidence of 50% or more stenosis. CAD also included angina 
diagnosed by the clinic physician and/or ischemic ECG changes (Minnesota Codes: 1.3, 4.1-4.3, 
5.1-5.3, 7.1). 
Neuropathy: Distal symmetric polyneuropathy (DSP) was determined by medical history 
and clinical examination using established protocols, i.e. the presence of two or more of: 
symptoms, signs consistent with DSP, or reduced deep tendon reflexes. DSP was further 
determined as ‘confirmed’ using the Vibratron II tester to detect a vibratory threshold above the 
age-specific normal range. Cardiac autonomic neuropathy (CAN) was determined by heart 
variation during deep breathing and by heart rate and blood pressure response to standing and 
was considered present if the mean expiration to inspiration ratio was <1.1. 
Retinopathy: Eye exams were done using three standard field stereo fundus photographs. 
Photographs were read at the Madison Reading Center in Wisconsin and graded using the Early 
Treatment Diabetic Retinopathy Study classification, with a grade of 60 or higher in one eye or a 
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grade less than 60 but with panretinal photocoagulation scars consistent with laser therapy 
indicating proliferative retinopathy.145 
Biological risk factors 
Hypertension was defined as any study blood pressure reading >140/90 mmHg or ever 
reporting use of antihypertensive medication. Ever use of antihypertensive and lipid lowering 
medications were compiled using data from each EDC clinic visit and time of MRI. 
Blood pressure: Three seated blood pressure readings were taken with a random-zero 
sphygmomanometer on day of MRI, with an average of the second and third readings, per the 
Hypertension Detection and Follow-up Program Protocol.202  
Cholesterol: SYNCHRON CX® Systems was used to measure non-fasting total cholesterol 
and high-density cholesterol (HDLc). Non-HDL cholesterol was calculated as HDLc subtracted 
from total cholesterol.  
Ankle-Brachial Index (ABI) was calculated as the ratio between systolic blood pressure 
measured at the posterior tibialis and the upper arm, using measures from the same side 
(usually the right side), during the 2004-2006 exam. ABI was dichotomized as below or above 
1.3 as this has been previously shown to correlate with mortality203 and arterial calcification204 
in people with T1D. 
Apolipoprotein E (ApoE) status was ascertained at the 2004-2006 exam.  
Body mass index (BMI) in kg/m2 was calculated based on the participants’ weight and 
height recorded at time of MRI. 
Skin intrinsic fluorescence (SIF), a marker of advanced glycation end products (AGEs), 
was assessed among T1D participants in 2006-2008. This utilized a skin fluorescence 
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spectrometer (SCOUT DS®) to take a noninvasive measure from the skin of the left volar 
forearm. Details on the device and SIF calculations are discussed elsewhere. 144 
Lifestyle/Behavioral risk factors 
Smoking status was determined at each EDC exam via self-report questionnaire as 
currently, formerly or never smoking 100 cigarettes. Responses were dichotomized as ever vs. 
never smoking using information obtained from baseline through the EDC 2004-2006 exam. 
Physical activity was estimated using the Paffenberger questionnaire during the 2004-
2006 exam. Results were used to calculate energy expenditure over the past week in Kcal. 
10.3.4 Brain Imaging Protocols 
All study participants underwent brain MRI scanning in a 3Tesla Siemens Trio TIM scanner 
located in the Magnetic Research Center at the University of Pittsburgh. A T1-weighted 3D 
sequence (MPRAGE: TR/TI/FA = 2300/900/9, Resolution 256, Grappa 2), acquisition time 7.5 
min, was used to attain grey matter (GM) and white matter volumes. For WMH, a FLAIR 
sequence (TR/TE = 9002/56 ms Ef; TI = 2200 ms, NEX = 1) was used with an interleaved 
acquisition; 48 slices (3mm, no gap). Diffusion-weighted images were acquired using a single 
short spin-echo sequence (TR = 5300 ms, TE = 88 ms, TI = 2500 ms, 90° flip angle, 
256 mm × 256 mm FOV, two diffusion values of b = 0 and 1000 s/mm, 12 diffusion directions, 
four repeats, 40 slices, 3 mm thick, 128 × 128 matrix size, 2 mm × 2 mm × 3 mm voxel size, and 
GRAPPA = 2). A pulsed arterial spin labeling (PASL) sequence was used for perfusion fMRI scans. 
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Interleaved images with and without labeling were acquired using a gradient echo planar 
imaging sequence (TR/TE/TI = 3000/20/1800 ms; flip angle = 90°). The tagging/control duration 
was 0.7 s. 19 oblique slices (thickness/gap = 5/1 mm, field of view = 224 mm × 224 mm, 
matrix = 70 × 70, voxel = 3.2 mm × 3.2 mm × 5 mm) covered the whole brain. All images were 
examined for neurologic abnormalities by a neuroradiologist. 
Neuroimaging measures of interest included whole brain gray matter volume, gray 
matter mean diffusivity, cerebral blood flow, white matter hyperintensities and fractional 
anisotropy of normal appearing white matter. Gray matter diffusivity and cerebral blood flow 
were adjusted for normalized total brain gray matter, computed as (total gray matter / 
intracranial volume x 100). Gray matter volume, blood flow (via ASL) and mean diffusivity (via 
DTI) were extracted from left and right prefrontal cortex (middle frontal gyri), hippocampus, 
superior parietal lobes and anterior cingulated lobes. White matter hyperintensities and 
fractional anisotropy (via DTI) were extracted from left and right superior longitudinal and 
uncinate tracts. These regions and tracts were selected because they are known to be 
vulnerable to high blood pressure and because they are related to impaired executive function 
and memory in older populations without T1D.  
10.3.5 Statistical Analyses 
Participants were categorized by cognitive status (i.e. presence vs. absence of cognitive 
dysfunction) as determined by the adjudication process. For comparison purposes only, this 
classification was compared to an algorithm (Nunley et al. 2014, unpublished) that determined 
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the presence of cognitive dysfunction using published normative data.205-207 Because the clinical 
adjudication process is the gold standard, validated and used in dementia studies, this 
definition of cognitive dysfunction was used for all analyses. For comparative purposes only, 
clinically adjudicated cognitive status was compared to cognitive status determined using an 
algorithm that defined cognitive dysfunction as having at least two test scores worse than 
1.5SD from published normative data (Nunley et al. 2014, unpublished). The two methods 
agreed on 55/108 as being cognitively normal and 27/108 as having cognitive dysfunction 
(Table 10.6.1). 
Group differences were assessed using t-test for continuous variables, Fisher exact test 
for categorical variables and Wilcoxon rank sum test for highly skewed data. For measures last 
assessed at the 2004-2006 EDC exam, models were controlled for the time interval between 
assessment and MRI. Logistic regression was conducted using a reduced sample size of N=68 
with no missing measures (i.e., a subset with complete MRI and risk factors of interest) to test 
for effects of neuroimaging measures and diabetes-related factors on cognitive dysfunction, 
controlling for NAART. Analyses of neuroimaging data of GM volume, GM mean diffusivity and 
cerebral blood flow of gray matter were adjusted for normalized gray matter volume of total 
brain (total brain gray matter volume divided by intracranial volume). 
Analyses were conducted using SAS 9.3 and SPSS 21. 
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10.4 RESULTS 
In this population of middle-aged adults with childhood-onset type 1 diabetes, the clinical 
adjudication process identified 31 of 97 (32%) participants as having cognitive dysfunction. 
Cognitive dysfunction was related with significantly lower NAART scores, a measure of general 
intelligence, and significantly fewer years of education (Table 10.6.1). Participants classified 
with cognitive dysfunction were significantly more likely to have an ankle-brachial index (ABI) > 
1.3 and to report lower physical activity than participants classified as cognitively normal (Table 
10.6.1). These differences remained significant after adjusting for the time interval from 2004-
2006, when these measures were taken, and time of MRI. Trends were observed in CDSP, 
proliferative retinopathy, estimated glucose disposal rate and ever reporting the use of blood 
pressure medications although these differences did not reach statistical significance (Table 
10.6.1).  No significant between-group differences were found in age at MRI, hypertension 
history and/or any measure of poor glycemic control (A1c at time of MRI continuous or > 7.5%, 
A1c average from 1998-2012 continuous or > 7.5% or skin intrinsic fluorescence).  
Cognitive dysfunction and brain imaging. No significant between-group differences were 
detected in whole brain gray matter atrophy, white matter hyperintensities, cerebral blood 
flow, fractional anisotropy of normal appearing white matter or gray matter mean diffusivity 
(Table 10.6.2).  Higher blood flow  measured from the right frontal middle gyrus, and left and 
right superior parietal lobes, was protective against cognitive dysfunction (p-values = 0.049, 
0.041 and 0.037, respectively); further adjustment for sex did not significantly alter these 
relationships. Similar trends were observed for whole brain CBF as well as blood flow measured 
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from  the left anterior cingulate, although these differences were not significant (p-values = 
0.135, and 0.177, respectively). Cognitive dysfunction was not significantly related to regional 
gray matter volume, GM mean diffusivity, FA of normal appearing WM or WMH. 
Risk factors, brain imaging and cognitive dysfunction. In logistic regression models 
controlling for NAART score, low physical activity and high ABI remained significantly associated 
with cognitive dysfunction independently of IQ and time interval between measure assessment 
and MRI. Having an ABI > 1.3 was associated with an eleven-fold increase in the odds of 
cognitive dysfunction (Table 10.6.3, Model 4). Being in the lowest vs. highest quartile of 
physical activity (PA) was associated with a six-fold increase in the odds of cognitive dysfunction 
(Table 10.6.3, Model 3). The effect of PA became non-significant (p=1.00) while high ABI 
remained stable and significant in the model including both factors (Table 10.6.3, Model 5). 
These associations remained unchanged when further adjustments were made for blood flow 
to the right middle frontal gyrus or the superior parietal lobe, bilaterally (Table 10.6.3, Model 5, 
adjusted for CBF).   
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10.5 DISCUSSION 
In this study of middle-aged patients with T1D since childhood, we found that having a higher 
ABI (>1.3) is related to cognitive dysfunction.  Higher ABI is a marker of subclinical vascular 
conditions including atherosclerosis, vessel stiffness and calcification, which are known risk 
factors for cognitive impairment in older adults without T1D.208,209  Vascular stiffness may serve 
as an indicator of early changes to brain structure.210 To our knowledge, the relationship of 
higher ABI with cognitive dysfunction in T1D has not been examined. People with T1D tend to 
have an ABI > 1.3, an indicator of calcification in the lower extremities.211 High ABI is also 
related to medial arterial calcification in adults with T1D, which is a risk factor for stiffness and 
stroke.204 Vessel stiffening can lead to cerebral hypoperfusion, with diffuse subclinical ischemia 
and resultant damage to oligodendrocytes and focal necrosis in gray and white matter, offering 
a mechanistic explanation for the relationship with cognitive dysfunction.   
We also found a relationship between low physical activity and cognitive dysfunction, 
albeit this was weaker. While this relationship is known in the aging literature,212,213 it has not 
been explored with those with T1D. The exact mechanisms of physical activity’s beneficial 
effect on cognition remain unknown but studies show increased neurogenesis, angiogenesis 
and increased growth factors related to cognition.212 Another proposed mechanism is that 
physical activity improves insulin sensitivity, as occurs in type 2 diabetes, and insulin resistance 
is correlated with dementia.214 The marginal relationship between lower estimated glucose 
disposal rate, a measure of insulin resistance, and cognitive dysfunction in this population of 
middle-aged adults with T1D lends support to this theory. 
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In this study, lower cerebral blood flow was related to greater odds of cognitive 
dysfunction, with associations being strongest for the right middle frontal gyrus and bilateral, 
superior parietal lobes. These regions are important for executive function215, attention and 
decision making,216 which are also severely affected in adults patients with T1D (Nunley et al, 
MS2, unpublished and Supplementary Table 2).    
In conclusion, this study shows that utilizing a multi-modal approach to examine the 
neuroanatomical correlates of cognitive dysfunction can advance our understanding of 
cognitive dysfunction for this middle-aged population with long-term T1D. It also underscores 
the relevance of examining markers of cerebral blood flow in addition to more conventional 
markers of structural integrity.  Without longitudinal data, however, we cannot determine if 
these structural changes appeared earlier than expected or whether they have progressed with 
age. Another limitation of the current study is the relatively small sample size and the lag time 
between ascertainment of T1D microvascular complications and brain imaging. While survival 
bias is present in this T1D population and limits the generalizability of these findings, it also 
allows us to study factors related to their ability to survive the damage caused by this disease. 
Further studies are needed to determine if intervening on vascular stiffness and physical 
inactivity may prevent or delay the development of cognitive dysfunction in people with T1D.   
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10.6 TABLES AND FIGURES 
Table 10.6.1 Characteristics of study participants by clinically adjudicated cognitive dysfunction 
status at time of MRI (2010-2013) unless otherwise indicated 
Cognitive Dysfunction  
Yes (N=31) No (N=66) p-value* 
Values are Mean ± SD, N (%) or Median (IQR) 
Population 
Characteristics 
Age, years 49.6 ± 6.2 48.8 ± 6.8 0.5616 
Duration, years 41.8 ± 5.2 40.7 ±6.6 0.4149 
Age at diagnosis, years 7.9 ± 4.6 8.1 ± 4.0 0.7814 
Female 13 (42%) 36 (55%) 0.2814 
Education, years 13 (12-16) 16 (14-17) 0.0021 
NAART score 31.9 ± 10.4 39.5 ± 7.9 0.0009 
Depressive symptoms † 9 (32%) 12 (19%) 0.1670 
24, 34 or 44 allele † 11 (35%) 18 (27%) 0.4780 
Body Mass Index 27.1 ± 5.4 27.5 ± 4.4 0.4962 
Glucose 
control 
HbA1c monthly estimate 1034.7 ± 472.2 1154.0 ± 408.6 0.2055 
HbA1c at MRI > 7.5% 20 (65%) 38 (59%) 0.6608 
HbA1c average 1998-2012 > 7.5%  22 (71%) 41 (63%) 0.4979 
Serum glucose at MRI, mg/dL 182.6 ± 77.8 170.9 ± 90.3 0.5502 
Skin intrinsic fluorescence (AU) ‡ 24.7 ± 4.2 24.5 ± 5.0 0.8716 
Cardiovascular 
factors  
Ankle Brachial Index  > 1.3 † 9 (31%) 4 (7%) 0.0038 
Systolic blood pressure (mmHg) 118.1 ± 16.7 120.3 ± 15.2 0.5186 
Study 20-yr average SBP (mmHg) * 110.5 ± 10.9 113.3 ± 10.6 0.2392 
History of high blood pressure # 14 (45%) 23 (35%) 0.3742 
Lifestyle 
Factors 
Ever smoked 100+ cigarettes ~ 12 (39%) 25 (38%) 0.9999 
Physical activity in past week 
(Kcal) † 
476 (280-1488) 1228 (732-2379) 0.0132 
Diabetes 
Complications 
Coronary artery disease † 4 (13%) 11 (17%) 0.6392 
Cardiac autonomic neuropathy † 12 (41%) 29 (49%) 0.4645 
Confirmed distal symmetric 
polyneuropathy † 
19 (61%) 27 (46%) 0.1713 
Microalbuminuria † 16 (55%) 33 (60%) 0.8260 
Overt nephropathy † 7 (26%) 14 (27%) 0.9440 
Proliferative  retinopathy † 18 (58%) 28 (42%) 0.1301 
† Measure taken  2004-2006; ‡ Measure taken 2006-2008; * average from 1986-88 through 2004-06;  
# Any SBP > 140 OR DBP > 90 OR ever using antihypertensive medication from EDC baseline through 
MRI; ~ “Any” or “Ever” based on self-report from 1986-88 through 2004-2006 
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Table 10.6.2 Results from univariate logistic regression models showing the independent 
effects of cerebral blood flow, after controlling for IQ (NAART score) and normalized gray 
matter volume (total GM volume/Intracranial volume) on the odds of clinically adjudicated 
cognitive dysfunction  
Cerebral Blood Flow (ml/100g tissue/min) OR (95% CL) p-value 
Whole brain 0.94 (0.87, 1.02) 0.135 
Middle Frontal Gyrus, left 0.98 (0.93, 1.05) 0.609 
Middle Frontal Gyrus, right 0.93 (0.86, 1.00) 0.049 
Superior Parietal Lobe, left 0.94 (0.88, 0.99) 0.041 
Superior Parietal Lobe, right 0.93 (0.87, 1.00) 0.037 
Anterior cingulate, left 0.96 (0.90, 1.00) 0.177 
Anterior cingulate, right 0.97 (0.91, 1.02) 0.242 
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Table 10.6.3 Logistic regression models, controlling for NAART, and time interval between 
measure collected (2004-2006) to MRI (2010-2013) showing the independent effects of select 
risk factors on the odds of clinically adjudicated cognitive dysfunction 
1 2 3 
(1 and 2 
3 
adjusted for 
right middle 
frontal 
gyrus  CBF 
3 
 adjusted for 
left superior 
parietal lobe 
CBF 
3 
adjusted for 
right superior 
parietal lobe 
CBF 
Odds Ratio (95% CL) p-value 
Low physical 
activity 
 (q1 v q4) 
6.07 
(1.07, 34.56) 
0.042 
5.64 
(0.72, 44.30) 
0.100 
7.13 
(0.82, 62.18) 
0.076 
9.31 
(0.96, 90.64) 
0.055 
7.46 
(0.82, 68.06) 
0.075 
ABI > 1.3 11.86 
(2.55, 55.20) 
0.002 
12.03 
(2.18, 66.57) 
0.004 
10.64 
(1.65, 68.70) 
0.013 
11.16 
(1.78 , 70.03) 
0.010 
10.41 
(1.69, 64.21) 
0.012 
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Table 10.6.4 Comparison of participants identified as having cognitive dysfunction using the 
clinical adjudication determination vs. the algorithm comparing participant test scores to 
published normative data 
Cognitive Dysfunction  
per Clinical Adjudication N(%) 
Cognitive Dysfunction 
 per Normative Data 
N(%) 
Not Present Present 
Not Present 50 (77%) 8 (27%) 
Present 15 (23%) 22 (73%) 
Total 65 (68%) 30 (32%) 
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Figure 10.6.1 Recruitment flow chart of participants with type 1 diabetes from the parent EDC 
cohort for the MRI/neurocognitive study 
121 
11.0  DISCUSSION, PUBLIC HEALTH IMPORTANCE, FUTURE DIRECTIONS 
This overall goal of this research was to provide evidence in support of deleterious effects of 
childhood-onset type 1 diabetes on brain structure and function. While T1D effects on the 
peripheral nervous system (e.g., distal symmetric polyneuropathy, autonomic neuropathy) are 
well recognized and studied, such is not the case regarding its effects on the central nervous 
system. While CNS effects were once difficult to study in vivo, advances in neuroimaging have 
overcome this obstacle. Even so, relatively few studies over the past two decades have included 
neuroimaging in studies of cognitive performance among adults with T1D. Even fewer studies 
have included middle-aged and older adults who have lived with T1D since childhood. These 
aging individuals with childhood-onset T1D are also experiencing the effects of advancing age 
on cognitive function. Now that people with T1D can expect to live almost as long as those 
without T1D, identifying factors that may help prevent or delay T1D-related cognitive 
dysfunction should be a public health priority.  
To accomplish this goal, the research herein addressed three gaps in knowledge 
regarding brain structure and function in middle-aged adults with childhood-onset T1D: 1) the 
presence of cerebral WMH, a macrostructural measure of WM health; 2) the prevalence of 
cognitive dysfunction; and 3) the brain imaging markers that best correlate with cognitive 
dysfunction in these individual. Diabetes-specific, general health and lifestyle risk factors 
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related to each of these also remain unclear so these were also studied in relationship to each 
gap in knowledge. 
White matter hyperintensities, as a percentage of total brain volume, were almost sixty 
times higher in this T1D population compared to similarly-aged adults without T1D. Among 
participants with T1D, older age, longer T1D duration, higher SIF, a history of smoking, 
prevalent cardiac autonomic neuropathy and distal symmetric polyneuropathy were 
significantly related to high WMH burden. Hypertension, a major contributor to age-related 
WMH, and poor glycemic control were not significantly related to WMH burden.   
In this population of middle-aged adults, childhood-onset type 1 diabetes correlates 
with a higher prevalence of cerebral WMH than would be expected based on age alone. This 
could be due to earlier accrual and/or faster progression of cerebral WMH. The cross-sectional 
nature of this study does not allow investigation of WMH evolution; a longitudinal brain 
imaging study, with first MRI at time of diagnosis, would allow investigation into the 
development and progression of WMH in people with type 1 diabetes from childhood through 
middle-age. Formation of advanced glycation end products resulting from chronic 
hyperglycemia, as measured by SIF, may contribute to the development of WMH, especially in 
older adults with type 1 diabetes. Cigarette use may further exacerbate the development of 
these lesions. WMH deserve further study in people with type 1 diabetes and whether its 
accrual may be prevented or delayed via strict glycemic control, particularly for older adults, 
and possibly by tobacco avoidance. 
Cognitive dysfunction is well-studied in children and young adults with T1D, but few 
studies have examined this condition in older adults with childhood-onset T1D. No studies have 
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yet taken a life-course approach to document the advent and progression of T1D-related 
cognitive dysfunction. Consequently, the best approximation of cognitive dysfunction 
progression in people with T1D is to compare results from pediatric to results from adult 
cognitive studies.  
Gaudieri et al. conducted a meta-analysis on cognitive dysfunction in children.128 
Compared to controls, children with T1D scored worse on tasks assessing intelligence, 
psychomotor/information processing speed, attention/executive function and visual motor 
integration, with all effect sizes < 0.2. No between-group differences were detected in memory 
and learning. Similarly, Brands et al. conducted a meta-analysis on cognitive dysfunction in 
adults.127 Compared to controls, adults with T1D scored worse on tasks assessing intelligence, 
psychomotor/information processing speed, attention, cognitive flexibility (executive function) 
and visual perception, with effect sizes ranging from 0.3 – 0.7. Again, no between-group 
differences were detected in memory and learning. From comparing these two meta-analyses, 
one could conclude that the mild cognitive dysfunction detected in childhood appears to 
progress to moderate dysfunction in young adulthood (most of the study populations included 
in the Brands et al. analysis ranged from early 20s to late 30s). These are not repeated 
measures from the same participants so several assumptions are inherent in making such 
conclusions, but similar results from the few longitudinal cognitive studies also suggest a slow 
progression of cognitive dysfunction.66,173,176,217 
This cross-sectional study found that, compared to middle-aged adults without T1D, 
adults with childhood-onset T1D performed significantly worse on tasks assessing intelligence, 
executive function, information processing and attention. Effect sizes (see Table 9.2) were even 
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greater than those reported by Brands et al. in younger adults,127  ranging from 0.5-0.9. In 
contrast to findings among children and young adults, this population of T1D participants 
scored significantly worse than those without T1D in two assessments of memory, with effect 
sizes > 1.5 (Table 9.2). Chronic hyperglycemia was significantly correlated with cognitive 
dysfunction, prevalent proliferative retinopathy and distal symmetric polyneuropathy, but only 
elevated A1c remained significantly associated with cognitive dysfunction in the fully adjusted 
model.  
The prevalence of cognitive dysfunction in this population of middle-aged adults with 
childhood-onset T1D was twice that observed in adults without T1D. In fact, cognitive 
dysfunction is as prevalent in this population as mild cognitive dysfunction is in much older 
individuals (age 70 and older).190,218 This suggests that advancing age interacts with the effects 
of T1D on cognitive function, with a gradual worsening over time. While memory was affected, 
it was only related to the ability to encode and retrieve complex information, not the type of 
memory deficits associated with Alzheimer’s Disease. Improved glycemic control may prevent 
or delay the development of cognitive dysfunction in people with type 1 diabetes. From a public 
health perspective, reducing cognitive dysfunction in people with type 1 diabetes should 
correspond with a reduction in diabetes-related complications and improved self-care.163 
Longitudinal studies including the use of repeated brain imaging measures and precise 
ascertainment of hyper- and hypoglycemic events are needed to disentangle the complexities 
of type 1 diabetes-related cognitive dysfunction. 
The risk factors and neuroanatomical correlates that underlie T1D-related cognitive 
dysfunction remain unclear and deserve further investigation. Studying this relationship among 
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older adults with T1D is particularly important since advancing age also negatively affects 
cognitive function. Considering the improved life expectancy of people with T1D,131 research in 
this area is of public health urgency in order to develop strategies to minimize the development 
and/or progression of cognitive dysfunction in adults with childhood-onset type 1 diabetes. This 
is the first study to employ a multi-modal neuroimaging approach to examine T1D-relaetd 
cognitive dysfunction. 
This is the first cognitive study to use ASL to measure cerebral blood flow in T1D 
participants. It is also the first study to report a relationship between high ABI (>1.3) and 
cognitive dysfunction as well as between low physical activity and cognitive dysfunction. 
Utilizing a multi-modal approach to examine the neuroanatomical correlates of cognitive 
dysfunction can help understand cognitive dysfunction in this middle-aged population with 
long-term T1D. It also underscores the relevance of examining markers of cerebral blood flow in 
addition to macrostructural integrity. Longitudinal studies, however, are necessary to 
determine if these structural changes appeared earlier than expected or whether they have 
progressed with age. In addition, further studies are needed to investigate the vascular 
mechanisms underlying these associations and whether interventions aimed at preventing 
vascular stiffness and increasing physical activity would reduce cognitive dysfunction in people 
with T1D. 
 
 
 
 
126 
APPENDIX A: BRIEF DESCRIPTIONS AND SCORING CRITERIA FOR NEUROCOGNITIVE TASKS 
COMMON TO BOTH GROUPS (TYPE 1 DIABETES, NO TYPE 1 DIABETES) 
Details of each test administered in the neuropsychological battery. 
1. North American Adult Reading Test (NAART) (measure of general intelligence).
Maximum score = 61. Participant is asked to read a list of words aloud while the test
administrator marks down incorrectly pronounced words. No time limit.
2. Rey Osterrieth Complex Figure (ROCF) copy (measure of visuospatial ability). Maximum
score = 36. Test administrator gives participant a pencil and paper. Participant is told to
look at a picture and copy it onto the paper as accurately as possible and that they will
be asked to draw the same picture again later, from memory. No time limit.
3. Rey Osterrieth Complex Figure (ROCF) immediate recall (measure of memory).
Maximum score = 36. As soon as participant finishes the ROCF copy, the administrator
hands them a blank sheet of paper, saying “I just asked you to draw a design. The design
was up here (pointing to top of page) and you copied it right here (pointing to lower half
of page). I want you to do that again.” No time limit, no other clues provided.
4. Rey Auditory Verbal Learning Test (RVLT) (measure of memory). Maximum score = 75 on
trials 1-5, = 15 on interference trial, = 15 on recall. Test administrator reads a list of 15
words to the participant who then repeats the words back in any order. Administrator
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marks down each word recalled correctly. This is repeated four more times for a total of 
five trials. After the fifth trial, administrator reads a different set of words and asks the 
participant to repeat back as many as they can remember, in any order, again marking 
down each correctly recalled word. After this trial, the administrator asks the participant 
to repeat as many words as they can remember from the first list (trials 1-5), marking 
down the number correctly repeated by the participant. No time limit on these tests. 
5. Digit Symbol Substitution Test (DSST)(measure of psychomotor speed). No maximum 
score. Test administrator points to the top of the sheet and tells participant “Look at 
these boxes. Notice that each has a number in the upper part and a mark or symbol in 
the lower part. Every number has a different mark or symbol”. The administrator points 
to the grid and shows the participant how to fill in the answer sheet by doing three 
number/symbols, then asks the participant to try. Administrator corrects any errors 
during the training. Once the participant clearly understands the task, they are told to 
start at a specific box and to fill out as many squares, in order, as possible until told to 
stop. Administrator marks the numbers completed at 30, 60, 90, 120, 150, 180, 210, 
240, 270 and 300 second intervals, although number completed in 90 seconds was used 
for these analyses. 
After the grid has been filled in, the administrator takes away the key and hands the 
participant a box with all numbers (1-9) and asks the participant to fill in the matching 
symbols from memory. 
6. Trail Making Test, time limit of 300 seconds for each test. For each test, participant is 
first shown a brief sample by test administrator. 
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a. Test A (TMTA)(measure of psychomotor speed) Test administrator has 
participant draw a line connecting dots, from 1 through 25, in numeric order and 
as quickly as possible. 
b. Test B (TMTB)(measure of executive function). Test administrator has participant 
draw a line connecting dots, from 1 through 13 and A through L, alternating 
sequentially between number and letter (1-A-2-B-3-C…13) as quickly as possible. 
7. ROCF delayed recall (measure of memory). Maximum score = 36. Test administrator 
gives participant a sheet of paper and asks them to remember the design they drew 
earlier and to draw it in the bottom half of the page as neatly and accurately as they 
can. No time limit. 
8. RVLT delayed recall (measure of memory). Maximum score = 15. Test administrator asks 
participant to remember the list of 15 words read earlier and to repeat back as many as 
they can in any order. No time limit. 
9. Block Design (measure of visuospatial skills). Maximum score = 51. Test administrator 
shows participant a group of blocks telling them “See these blocks? They are all alike; on 
some sides they are all red, on some all white and on some they are half red and half 
white.” After showing the participant how to put the blocks together to make a design 
and the participant indicates they understand the task, the participant is given a paper 
with xx different designs and asked to arrange the blocks to match each of these 
designs. Correct scores are given for completely matching each desired design. Trial is 
discontinued after three consecutive errors with no time limit. 
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10. Verbal Fluency (also known as FAS or Controlled Word Association Test)(measure of 
executive function). No maximum score. Participant is asked to name as many words as 
they can, excluding proper nouns and numbers, for each of the letters “F”, “A” and “S” 
then asked to name as many animals as they can. Each trial continues for 60 seconds 
before the administrator requests the next sequence. 
11. Four Word Short Term Memory (4WSTM)(measure of verbal memory).  Maximum score 
= 60. Test administrator reads aloud four unrelated words at the rate of one word per 
second.  This is immediately followed by a three-digit number.  As soon as the number is 
heard, the subject begins counting backwards by threes until the examiner says ‘stop.’   
At that point, the subject is asked to recall the words.   
12. Stroop Color Word Test (Golden version) (measure of executive function). No maximum 
raw score. Time limit of 45 seconds for each test component. 
a. Words: Participant is asked to read a list of words down a column (red, green, 
blue repeated randomly in five columns of 20 rows) as fast as possible, then 
move to the next column and the next column until time expires. No errors are 
marked. If the participant makes a mistake, the administrator interjects by saying 
“wrong” or ‘no” and the participant corrects them self then continues reading. 
b. Colors: A series of colored XXX in red, blue and green appear in five columns of 
20 rows. Participants are to read down the columns, naming the color of the 
XXX, as quickly as possible. No errors are marked. If the participant makes a 
mistake, the administrator interjects by saying “wrong” or ‘no” and the 
participant corrects them self then continues reading. 
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c. Color-Word (sometimes called ‘interference’): The three words “red”, “green” 
and “blue” are printed in red, green and blue either matching or not matching 
the word. again in 5 columns of 20 words each. Participants are told to say the 
COLOR of the ink, not the printed WORD, reading down columns as quickly as 
possible. No errors are marked. If the participant makes a mistake, the 
administrator interjects by saying “wrong” or ‘no” and the participant corrects 
them self then continues reading. 
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The order of tests is presented below.   
Cognitive Test Battery Session: 
 
Opening Monologue/Introduction to Cognitive Testing Session 
North American Reading Test 
Story Memory 
Rey Complex Figure (Copy + Immediate Recall) 
Rey Auditory Verbal Learning Test (Learning trials, interference and short recall) 
Digit Symbol Substitution Test (with incidental recall) 
Trail Making Test 
Letter-Number Sequencing 
Block Design Test 
Story Memory – Delayed Recall  
Rey Complex Figure – Delayed Recall 
Rey Auditory Verbal Learning Delayed Recall 
Four Word STM Test 
Stroop Color Word Test 
Verbal and Category Fluency 
Grooved Pegboard 
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Opening Monologue/Introduction to the Cognitive Testing Session 
 
“This session will take about an hour and half.  Do you know anything about the tests we’ll be 
doing today?  We’re going to do a number of tests examining things like attention, memory, 
eye-hand coordination, and overall mental and motor efficiency.  I’m going to be asking you 
to do a number of different tasks---like matching symbols to numbers, remembering words 
from a list, and copying a design.  You will find some of these tasks fairly easy, while others 
are quite difficult.  The most important thing is for you to try and do your best on all of the 
tasks.  These tasks have a kind of game-like quality to them, and most people find them 
interesting and challenging.  I hope you will too”. 
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Subject ID __________________ Start Time: _________   Date _____________ 
 
“BEFORE WE BEGIN, I’D LIKE TO ASK YOU A FEW GENERAL QUESTIONS.” 
1. How old are you now?  ________ years 
2. How far did you go through school? ____________  (# years; BA; MA; post graduate) 
3. Which hand do you prefer to write with?  right ; left ; both equally well  
4. Do you have any problems right now using any of your fingers?  Yes ;  No  
Left     Right 
 [if yes]  Which fingers?     L R M I T  T I M R L 
 What’s the problem?  ________________________________________________ 
5. Can you move both wrists freely?  Yes ;  No  
[if not] Which one do you have trouble with?   Right ; Left  
What’s the problem? ________________________________________________ 
6. Do you wear glasses or contact lenses? Yes ; No  
[if yes]    Do you have them with you? Yes ; No  
7. Do you have any problems with your hearing?   Yes ; No  
[if yes]   What’s the problem?  _________________________________________ 
8. Have you taken any medications or drugs in the past 48 hours?  [List drug, approximate 
quantity, reason for taking drug, and time] 
__________________________________________________________________ 
__________________________________________________________________ 
9. Have you had any beer or other alcohol within the past 48 hours? 
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Beer:  No  ;  Yes  [when] ____________   Quantity ____________ 
Wine:  No  ;  Yes  [when] ____________   Quantity ____________ 
Hard Liquor: No  ;  Yes  [when] ____________   Quantity ____________ 
10. Have you smoked any cigarettes within the past 48 hours?  No ; Yes : number ___ 
11. Have you ever had a head injury where you lost consciousness?  No ; Yes : If yes, 
what happened, and when? How long were you ‘out’? > 30 mins   No ; Yes  
         Has this happened on more than one occasion?  Please explain.  
_____________________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
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Subject ID __________________ Date _________________ 
 
NORTH AMERICAN ADULT  
READING TEST (NAART)  
 
 
This task requires subjects to read a list of 61 irregularly spelled words (debt; gauge; leviathan) 
and pronounce them.  It provides an excellent estimate of premorbid verbal intelligence which 
is quite resistant to the effects of acquired brain damage.  Raw scores can be converted into 
estimated verbal, performance, and full scale IQ scores 219.   
 
Administration:  Hand the subject the page consisting of 3 columns of words.  Say “This page 
contains a list of words that I want you to read out loud, beginning here (point to ‘debt’) and 
continuing down this column and on to the next.  I must warn you that there are many words 
that you probably won’t recognize; in fact, most people don’t know them, so just guess at 
these.  Please read them loudly enough and slowly enough so that I can follow you.  OK?  Go 
Ahead!”  
 
NOTE:  Put a check by the word if the pronunciation is accurate; if wrong, put an x by the word.  
 
Scoring:  Add up the number of INCORRECT responses and use the Conversion Table for 
Calculation of NAART Score to get the NAART score.   
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NAART Number INCORRECT words ____________ 
 
NAART Score ___________ 
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Subject ID __________________ Date ____________________ 
STORY MEMORY –  IMMEDIATE RECALL 
 
Story recall is among the most widely used clinical measures of memory. For this study only the 
first story of the Logical Memory subtest of the WMS-R will be used.  The examiner reads the 
story to the subject in a clear voice. Immediately after hearing the story, the subject is asked to 
retell the story from memory. The story should be read with adequate volume and clarity for 
the subject to understand during the presentation. No repetitions are permitted. 
 
Administration: 
 “Now I am going to read you a little story. Listen carefully, because when I am through, I 
want you to tell the story back to me, just the way your heard it.  Are you ready?”   
As this is the first test in the session, the subject may be anxious or nervous.  Please make sure 
the subject is concentrating and ready to attend to the story before you begin reading. 
 
Story should be read (next page) slowly and naturally, and not in a monotone, and while the 
examiner is looking down at this page. 
 
 “Now tell the story back to me the very best you can.” 
 [Record response verbatim:  After the subject is apparently finished, if recall is not complete 
the examiner should probe, without making eye contact, by asking “Anything else?” and note 
(Q).   
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Then say:   “Later on I will ask you to tell me this story again, so try not to forget it” 
 
 
Scoring criteria: 
 
Record the subject’s responses on the response form in a legible and decipherable manner. 
Scoring is deferred until after the examination is done.  The story consists of 25 units.  On the 
score sheet labeled ‘Logical Memory I’ underline or circle each unit that is successfully recalled.  
Then total the units recalled and enter the number (0-25) in the space provided.   
 
Examples of acceptable responses are provided in the following pages. 
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Subject ID __________________ Date ____________________ 
 
REY COMPLEX FIGURE COPY  (with immediate and delay recalls) 
 
Begin by giving the subject the test sheet and a pencil with an eraser.   
Administration of Copy: “I want you to copy this design. Go ahead and draw it right here.  
Make it as neat and accurate as you can.” [and point to the lower section of the answer 
sheet].   “Later on I will ask you to draw it again for me, from memory.”  There is no time limit, 
and erasing is permitted.  If the subject asks “does it have to be perfect,” say something to the 
effect that “You should try your best – try to make it look like the one on the page.”   
 
Administration of Immediate Recall:  After completion of the Copy, hand subject the answer 
sheet and point to the lower half of the page and say “I just asked you to draw a design.  The 
design was up here [point to upper half of page] and you copied it right here [point to lower 
half of page].  I want you to do it again.”  Do not provide any other cues. 
 
 
Copy Score _____________ (0-36) 
 
Immediate Recall Score _______________ (0-36)
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Subject ID __________________  Date ________________ 
 
REY AUDITORY VERBAL LEARNING TEST 
 
“I am going to read a list of words.  Listen carefully, because after I stop, I want you to say 
back to me as many words as you can remember.  It doesn’t matter in what order you repeat 
them.  Just try to remember as many as you can.” 
Read words at the rate of 1 word / second.  Following presentation of the list, ask the subject to 
recall as many words as they can remember and record them by checking under “recall 1.” 
Then say, “Now I’m going to read the same list again, and once again when I stop I want you 
to tell me as many words as you can remember, including words you said the first time.  It 
doesn’t matter in what order you say them.  Just say as many words as you can remember, 
whether or not you said them before.” 
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Test Recall again (#2) and repeat for 3 more study/test trials 
List A Recall A1 Recall A2 Recall A3 Recall A4 Recall A5 List A 
Dxxx      Dxxx 
Cxxxxx      Cxxxxx 
Bxxx      Bxxx 
Cxxxxx      Cxxxxx 
Sxxxx      Sxxxx 
Pxxxxx      Pxxxxx 
Mxxx      Mxxx 
Gxxxxx      Gxxxxx 
Hxx      Hxx 
Fxxxxx      Fxxxxx 
Nxxx      Nxxx 
Txxxxx      Txxxxx 
Cxxxx      Cxxxx 
Hxxxx      Hxxxx 
Rxxxx      Rxxxx 
 
TOTAL   A1________   A2________  A3________ A4________ A5________  
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Subject ID____________     Date _______________ 
 
Following Recall 5, say, “Now I’m going to read a second list of words.  This time, again, you 
are to say back as many words of this second list as you can remember.  Again, the order in 
which you say the words does not matter.  Just try to remember as many as you can.” 
List B Recall B1 
Dzzz  
Rzzzzz  
Bzzz  
Szzz  
Szzzz  
Mzzzzzzz  
Gzzzzzz  
Tzzzz  
Czzzz  
Bzzz  
Lzzz  
Gzz  
Pzzzzz  
Czzzzz  
Fzzz  
TOTAL    _____________ 
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Following the recall of this list, say “Now I want you to tell me as many words as you can from 
the first list that I read to you” (RecallA6) 
List A Recall A6 
Dxxx  
Cxxxxx  
Bxxx  
Cxxxxx  
Sxxxx  
Pxxxxx  
Mxxx  
Gxxxxx  
Hxx  
Fxxxxx  
Nxxx  
Txxxxx  
Cxxxx  
Hxxxx  
Rxxxx  
 Total         _____________ 
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Subject ID __________________  Date ____________________  
 
DIGIT SYMBOL SUBSTITUTION TEST 
   
Administration:  Point to the key at the top of the answer sheet and say “Look at these boxes.  
Notice that each has a number in the upper part and a mark or symbol in the lower part.  
Every number has a different mark or symbol.” Point to the grid below and say, “Here just the 
numbers are written.  I would like you to fill in the symbol that is paired with each number, 
like this….” Demonstrate the first 3 numbers and say, “Now you try it up to here,” while 
pointing out the heavy dark line separating the sample area from the test items. 
Correct any errors made on the sample.  When the subject clearly understands the task, point 
to the “2” and say,” “Now I want you to begin here [point] and fill in as many squares as you 
can without skipping any.  When you get to the end of the row, just go on to the next row.  
Ready?  Go!”  If the subject stops at the end of the first line and does not immediately go on to 
the second line or row, say “Go on to the next row.”  If the subject omits any, say, “Do them in 
order” or “Don’t skip any.”  If the subject attempts to erase, say, “Don’t erase – just go on!” 
 
Number of symbols completed within each 30 second interval: 
 
30” ________;      60” ________;   90”  ________; 120” ________;   150” _________; 
 
180” _______;    210” ________; 240” _________;  270” ________;   300” _________. 
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Total time to complete grid:  ________ seconds.        ____________________________ 
[At the end of every 30 second interval, mark       ADMINISTER ENTIRE TASK 
on grid below the item completed by subject.]   Do Not Stop at End of 90 sec!!! 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wechsler Adult Intelligence Scale-Revised.  Copyright © 1955 by Harcourt Assessment, Inc. 
Adapted and reproduced by permission.  All rights reserved.   
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Subject ID __________________ Date ____________  
 
DIGIT SYMBOL - INCIDENTAL RECALL 
 
 
Incidental Recall:  [Hand subject small grid] and say “Now I’d like to see how many of these 
symbols you can remember.” 
 
  
1  2  3  4  5  6  7  8  9  
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Subject ID __________________  Date _______________ 
 
TRAIL MAKING TEST 
         
Trails A – Sample:  “I want you to draw a line connecting the numbers in order from 1 to 2 to 3 
to 4” [trace path from number to number] “and so on, until you reach the end” [point].  “Do it 
as quickly as you can.  Ready?  Go.”  Begin timing promptly, watch for errors and correct them 
immediately. 
 
TIME  ____________  ERRORS ____________ 
 
Trails A – Test:  “Now I want you to do the same thing.  this time there are more numbers” 
[hand Trails A sheet to subject]  “so you would connect 1 to 2 to 3 to 4” [very quickly trace 
path]  “and so on all the way to the end of 25” [point].  “Neatness does not count.  Remember, 
work as quickly as you can, and be sure to do the numbers in order.  Ready?  Go.” 
 
 
TIME  ____________  ERRORS ____________ 
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Trails B – Sample: “This one is a little different.  It has both numbers and letters and I want 
you to alternate – number, letter, number, letter, both in order.  So you would start at 1 and 
draw a line from 1 to A”, [trace path], “from A to 2, from 2 to B, from B to 3, from 3 to C, and 
so on, until you reach the end” [point].  “Remember, go number, letter, number, letter as 
quickly as you can.  Ready?  Go!” 
TIME  ____________  ERRORS ____________ 
Trails B – Test:  “Now I want you to do the same thing.  This time there are more numbers and 
letters” [hand Trails B sheet to subject].  “Start here at 1 and draw a line from 1 to A, from A to 
2, from 2 to B, from B to 3, from 3 to C” [trace path], “and so on until you reach the end at 13” 
[point to 13].  “Remember to do the numbers and letters in order by alternating number, 
letter, number, letter.  Do this as quickly as you can.  Ready?  Go!”  
TIME  ____________  ERRORS ____________ 
Correction Cues: 
Step 1: “Stop!  Put your pencil here!” 
Step 2: “What comes next?” 
Step 3:  “After ____ comes ?????” 
Step 4: “Remember:  number, letter, number, letter.  What’s next here?”   
                  ______________________ 
        
          DISCONTINUE TESTS  
          AFTER 300 SECONDS 
         ______________________ 
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TRAIL MAKING 
 
Part A 
 
 
 
 
 
 
 
 
SAMPLE 
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TRAIL MAKING 
 
Part B 
 
 
 
 
 
 
 
 
SAMPLE 
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Subject ID _______________________ Date _____________________   
 
LETTER NUMBER SEQUENCING 
“I am going to say a group of numbers and letters.  After I say them, I want you to tell me the 
numbers first, in order, starting with the lowest number.  Then tell me the letters in 
alphabetical order.  For example, if I say B-7, your answer should be 7-B.  The number goes 
first, then the letter.   If I say 9 –C – 3, then your answer should be 3 – 9 – C, the numbers in 
order first, then the letters in alphabetical order.  Let’s practice.” 
For each of the practice strings on answer sheet, first read the string at the rate of 1 number or 
letter per second, and then pause, waiting for the subject’s response.  If incorrect, first correct 
to ensure the subject understands, and then go to the next string.  If correct, simply reinforce, 
and go on to next string. 
 6 – F  _________ 6 – F 
 G – 4  _________ 4 – G 
 3 – W - 5 _________ 3 – 5 – W 
 T – 7 – L __________ 7 – L – T 
 1 – J – A __________ 1 – A – J 
 
Following completion of the practice strings, proceed to test item 1.  Record all responses on 
the answer sheet.  Administer all 3 trials at each string length. 
 
“Now let’s try these….” 
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Subject ID __________________  Date ___________________ 
 
BLOCK DESIGN TEST –WAIS-R 
“Now I am going to ask you to make some designs.  See these blocks?  They are all alike:  on 
some sides they are all red, on some all white, and on some they are half red and half white.” 
(Turn blocks to show the different sides.)  “I am going to put some blocks together to make a 
design.  Watch me.” (Make the first design.  Give participant four scrambled blocks.  Leave your 
design intact.)  “Now, make one just like I did here.  Tell me when you are finished.”  (If the 
subject rotates the design at all, correct them before moving on to the next trial.  After that, 
any rotation of 30° or more makes the trial incorrect, even if placement is otherwise correct.) 
 
“This time, I want you to put the blocks together to look like the designs I show you on these 
pictures.  Tell me when you are finished with each one.” 
 
Discontinue after any three consecutive errors 
 
 
 
12.0  Total Score ______  (0-24)
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Subject ID __________________  Date ___________________ 
 
STORY MEMORY – DELAY  
Administration: 
Delayed recall of the story should be about 20 minutes after the initial presentation.  If 20 
minutes has not elapsed, or if 30 minutes or more has elapsed, continue with the test but 
record this time on the score sheet. 
“A while ago I read you a story.  I want you to tell me that story again.  As much as you can 
remember, even if you’re not completely sure.”  [After recall is apparently complete, probe 
with “Anything else?” and note Q.]  If the subject cannot remember anything from the story, 
the examiner should say “It was a story about a woman who was robbed”, and indicate the cue 
on the answer sheet. 
 
“Tell me everything you can about the story” 
 
 
 
Scoring: 
 
Follow the scoring criteria for Immediate Recall and record the score at the bottom of the score 
sheet labeled ‘Logical Memory II’. 
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Subject ID __________________  Date ___________________ 
 
DELAYED REY FIGURE  
13.0   
14.0  Hand subject the answer sheet and point to the lower half of the page and say “A few minutes 
ago I asked you to draw a design.  The design was up here [point to upper half of page] and you copied 
it right here [point to lower half of page].  I want you to draw it again.  Make it as neat and as 
accurate as you can.”  Do not provide any cues, except to say that they just copied it a few minutes 
ago. 
  
 
 
REY FIGURE DELAYED RECALL SCORE _____________ (0-36)
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Subject ID __________________ Date _________________ 
REY AUDITORY VERBAL LEARNING TEST - DELAY 
 “A while ago I read a list of words to you several times, and you had to repeat back the words.  
Tell me the words from that list.”  Do not cue the subject in any way; if asked, you can indicate 
that it was the first list of words.”   [If asked, subjects do NOT have to recall the words in 
order.] 
List A Recall A7 
Dxxx  
Cxxxxx  
Bxxx  
Cxxxxx  
Sxxxx  
Pxxxxx  
Mxxx  
….  
….  
 
DELAYED  
RECALL TOTAL  ___________ 
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Subject ID __________________  Date ___________________   
 
STROOP TEST – ANSWER SHEET  TASK 1 - WORDS 
[Hand subject page 1 – words]  “This is a test of how fast you can read the words on this page.  
After I say ‘begin’ I want you to read down the columns starting with the first one [point to 
the leftmost column] and then continue without stopping down the remaining columns in 
order [run hand down remaining columns], until I say STOP.  If you make a mistake, I will let 
you know, by saying ‘whoops’ or ‘wrong.’  Correct yourself and continue without stopping.  
Remember to read the words as quickly and as accurately as you can.  If you get to the end 
before I say STOP, go back to the beginning and start over.  Ready?  Begin!” 
 
Allow the subject 45 seconds.  Mark on your answer sheet (by circling the word), just where 
they were when time was called. 
 
RED BLUE GREEN RED BLUE 
… … … … … 
 
Stop after 45 seconds 
STROOP WORDS SCORE = ________ 
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Subject ID __________________  Date ___________ 
         
TASK 2 - COLOR 
 
APPENDIX A“This next task is a little different.  Again, I want you to start in column one, but this time 
you will be identifying the colors red, green, and blue, as quickly as you can.  Can you tell these colors 
apart?  O.K.  Remember, if you make a mistake, I will tell you.  Correct yourself and then continue 
until I tell you to stop.  Ready?  Go!”  Begin timing. 
 
BLUE RED BLUE GREEN RED 
--- --- ---- ---- ---- 
 
Stop after 45 seconds  
 
STROOP COLOR SCORE = ________ 
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Subject ID __________________  Date ____________ 
      
TASK 3 – COLOR/WORD 
 
[“Hand subject page three – Color/Word]. “This page is similar to the page you just finished, 
but this time I want you to name the color of the ink the words are printed in, ignoring the 
word that is printed.  For example [point to the first item of the first column], this is the first 
item.  What would you say?”  
 
[If incorrect, examiner should say] “No, that is the word that is spelled there.  I want you to 
say the color of the ink the word is printed in.  Try this one [point to the next item].” 
 
[If correct, say]  “Good.  You will do this page just like the others, starting with the first 
column [point] and then going on to complete the page.  Any questions?  Get ready.  Go!” 
 
BLUE RED BLUE GREEN RED 
… … … … … 
     
15.0  Stop after 45 seconds 
STROOP INTERFERENCE SCORE = ________ 
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Subject ID __________________ Date ____________________ 
 
FOUR WORD SHORT-TERM MEMORY TEST 
This test measures the ability of the subject to hold small amounts of verbal information in 
memory for several seconds.  On each trial, four unrelated words are read to the subject at the 
rate of one word per second.  This is immediately followed by a three-digit number.  As soon as 
the number is heard, the subject begins counting backwards by threes until the examiner says 
‘stop.’   At that point, the subject is asked to recall the words.  The purpose of the mental 
arithmetic task is to prevent the subject from rehearsing the words during the retention 
interval.  Three retention intervals will be used:  5, 15, and 30 seconds.   
Administration:  this test is introduced by saying, “I’m going to read you four words, which I 
would like you to try to remember.  In order to make your task more difficult, however, after I 
read the fourth word, I’m going to read a 3-digit number, like 100.  As soon as I read you that 
number, I want you to begin counting backwards from it by threes as rapidly and as 
accurately as you can.  I want you to continue doing that until I tell you to stop.  When I say 
STOP, you tell me what the four words are.  Do you understand?” 
You should then ask, “How good are you at counting backwards by threes?  Let’s try it.  Start 
from 100.”  Have the subject practice counting from 100 to 70.  Correct the subject as 
necessary, and give encouraging feedback.  More than just one counting-practice trial may be 
necessary; the memory task itself should not be initiated until you are certain that the subject is 
counting as efficiently as s/he can. 
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Before beginning the first test trial, you may wish to quickly review the instructions.  Thus: 
 
“Before we begin, I want to quickly review what you’ll be doing.  First, you’ll hear 4 words – 
and I want you to try to remember those.  Then you’ll hear a number – and I want you to 
count backwards from it by threes.  After a while, I’ll tell you to stop, and you’ll tell me the 
words.” 
Introduce the first test trial by saying, “Here are the first four words I want you to try to 
remember.” and read them at a rate of 1 word per second.  You should not make eye contact 
with the subject while reading the words or waiting for the subject’s response.  In reading these 
words, the pitch of the voice should drop somewhat with the last word in each series.  
Following the last word, the examiner pauses 2 seconds and says, “100…” and waits for the 
subject to begin counting.  If the subject fails to begin, you should cue with “97…”  If that fails, it 
may be necessary to cue again with “94…”  At the end of the 5 second retention interval you 
should say “Stop!” and if the subject does not spontaneously produce the words, ask “What 
were the four words?” 
Following the subject’s response, introduce trial 2 by saying “Let’s try these.  Ready?” and read 
the words. 
Before beginning trial 4, warn the subject that different three-digit numbers will now be used:  
“Now we will be counting from a number other than 100.  Whatever number I say, that’s the 
one you start counting from.  Ready?”  Subsequent trials should be introduced with “Let’s try 
these” or “ready?” or some similar warning. 
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FOUR WORD SHORT-TERM MEMORY TEST - page 3 
 
It is important to monitor the subject while s/he is counting backwards.  Subjects should be 
counting as quickly as possible (i.e., the rate should be such that you are convinced that they 
are not rehearsing the words).  At the end of a trial you may want to say something like “I’d like 
you to try to count a little faster next time.”  During a trial, you may wish to say something like 
“Faster” and move your hands in an emphatic manner.  While we ask the subject to count both 
rapidly and accurately, s/he is not penalized for making occasional counting errors.  If many 
errors are made (often a sign that the subject is merely generating words randomly), you 
should make a comment to the effect that “You should try to count as accurately as you can.”  
If no response has been made by the subject 5 seconds or so after you have said “Stop”, ask 
“what are the words?”  If no response is forthcoming, or if the subject reports that s/he 
doesn’t know, that should be noted (DK), and the next trial administered. 
If the subject asks whether the words have to be recalled in order, you can say that that is not 
necessary.   
If the subject says that s/he didn’t hear one or more words, you should make a note on the 
answer sheet and say, “I’m sorry, I can’t repeat the words.” 
Similarly, if the subject misses one or more words on a trial and asks something like “what 
word(s) did I miss that time?” you cannot provide any information; you can only say something 
to the effect that “I’m sorry; I just can’t say.” 
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This task is extremely difficult and frustrating for many subjects.  If it is apparent that the 
subject is becoming upset or anxious, you have an obligation to reassure the subject that 
indeed, this is a difficult task and that many people have trouble, but that they should continue 
and try to do their best. 
 
Recording:  Correct responses should be circled, incorrect responses should be written on the 
line to the right, and the order of all responses indicated with small numbers written 
immediately above the responses. 
 
Discontinuation:  The entire task is given. 
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Subject ID __________________  Date _____________________ 
 
FOUR WORD SHORT- TERM MEMORY TEST 
         
“I’m going to read you four words, which I would like you to try to remember.  In order to 
make your task more difficult, however, after I read the fourth word, I’m going to read a 3-
digit number, like 100.  As soon as I read you that number, I want you to begin counting 
backwards by threes as rapidly and as accurately as you can.  I want you to continue doing 
that until I tell you to stop.  At that point you’ll tell me what the four words are.” 
“How good are you at counting backwards by threes?”  Let’s try it.  Start from 100.”  [provide 
practice] 
“Before we begin, I want to quickly review what you’ll be doing.  First, you’ll hear 4 words – 
and I want you to try to remember those.  Then you’ll hear a number – and I want you to 
count backwards from it by threes.  After a while, I’ll tell you to stop, and you’ll tell me the 
words.”  “Here are the first four words I want you to try to remember…” 
________________________________________________ 
ADMINISTER ALL ITEMS DO NOT SKIP ANY ITEMS 
________________________________________________  
 
[Circle correct words; write incorrect words on line to right; indicate order of recall with small 
numbers above each response.]    The score is the number of words correctly recalled after the 
interference. 
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Subject ID __________________ Date ______________ 
 
GROOVED PEGBOARD 
          
“This is called the grooved pegboard.  The purpose of it is to see how quickly and accurately 
you can work with your hands.  Each peg has a ‘key’ on one side [show subject] which will fit 
into a groove on the hole when the peg is turned the right way” [demonstrate by inserting first 
peg; then remove it]. 
[Two trials are administered:  first dominant, then non-dominant hand.]  “I want you to do this 
with your _____ [right/left] hand.” [give instructions for appropriate hand.  When finished, 
introduce test with non-dominant hand by saying] “Now I want you to use your other hand.” 
Right hand instructions:  “When I say ‘go,’ begin here [point to top left hole from subject’s 
side; sweep hand from left to right] and put the pegs in the holes one at a time, as fast as you 
can, using only your right hand.  If you drop a peg and it goes on the floor, just grab another 
one and keep going.  Any questions?  Ready?  Go!” 
[after all pegs have been inserted]  “Now I would like you to take the pegs out, one at a time, 
with your right hand.  Work as quickly as you can.  Ready?  Go.” 
Left hand instructions:  “When I say ‘go,’ begin here [point to top right hole from subject’s 
side; sweep hand from right to left] and put the pegs in the holes one at a time, as fast as you 
can, using only your left hand.  Any questions?  Ready?  Go!” 
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[after all pegs have been inserted]  “Now I would like you to take the pegs out, one at a time, 
with your left hand.  Work as quickly as you can.  Ready?  Go!” 
In inserting pegs, subjects must pick up the pegs one at a time and should not pig up the first 
peg until the examiner says “go.”  Often a subject will pick up a peg while the examiner is giving 
the directions and will be holding the peg.  Tell subjects that this is not allowed.  Also, 
sometimes subjects begin to insert pegs helter-skelter, rather than in the order (left to right for 
right hand; reverse for left hand) specified in the instructions.  Please encourage them to follow 
the instructions, perhaps by saying “no” and waving one’s hand across the board in the 
specified order while saying something like “go this way” or “put the next one here.” 
Which hand is dominant?      Right ;   Left  
 
Dominant Hand:       Time to insert pegs (sec) ___________ 
 
         Pegs dropped   ___________ 
 
         Time to remove pegs  ___________ 
 
Non-Dominant Hand: Time to insert pegs (sec) ___________ 
 
         Pegs dropped   ___________ 
 
         Time to remove pegs  ___________ 
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Subject ID __________________ Date ____________________ 
 
VERBAL FLUENCY TEST 
 
This test, also known as the “Controlled Word Association Test,” or the “F A S” test, assesses 
the ability of subjects to spontaneously generate a list of words beginning with designated 
letters of the alphabet.  Numerous clinical studies have found performance on this measure to 
be affected by frontal lobe dysfunction – particularly in the dominant hemisphere.  The 
response measure is the number of words produced in 60 seconds.  Three letters will be used:  
F, A, and S. 
Administration:  “I would like you to name as many words as you can beginning with the 
letter ‘F.’  Leave out proper names (like Fred), names of places (like France), and numbers (like 
five).  OK?  I want you to name as many words as fast as you can, till I tell you to stop.  
Ready?  Go!” 
 
Begin timing promptly and write each word as it is given.  60 seconds is allowed per letter.  At 
the end of 60 seconds say, “Time’s up!  Now I would like you to name as many words as you 
can beginning with the letter _________.  Again, no proper names, names of place, or 
numbers.  Ready?  Go!” 
 
Again, record all responses.  At the end of 60 seconds, repeat the instructions for the letter ‘S.’ 
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If, for any letter, the subject begins by giving words that start with a non-designated letter (e.g., 
for ‘F’ the subject begins with a word like ‘breakfast’), s/he should be corrected and reminded 
of the task by repeating the instructions.  On the other h and, if the subject is carrying out the 
task correctly and spontaneously shifts to a different letter (e.g., fish, fin, flounder, cod…), you 
should not correct the subject, but continue to record all responses. 
 
If the subject repeats words that could be homonyms (e.g., son/sun) yet doesn’t indicate to the 
examiner that they are different words, you should ask – but only after that trial is completed – 
something like ‘do you know you repeated the word ‘son’?  Hopefully, with this open-ended 
question the subject will indicate whether it was a true repetition or two different words. 
 
Discontinuation:  The entire task is given. 
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Subject ID __________________ Date _____________________ 
 
VERBAL FLUENCY  
(F, A, S, and Animals) 
 
[Three 60 second trials are administered.  Read the instructions for the letter ‘F’ and record 
each response.  The instructions are subsequently repeated for the letters ‘A’ and ‘S ’.  If the 
subject repeats words which could be homonyms, you should probe [“do you know you 
repeated _____?”] at the end of that trial. 
 
[For ‘F’]  “I would like you to name as many words as you can beginning with the letter ‘F.’  
Leave out proper names (like Fred), names of places (like France), and numbers (like five).  
OK?  Ready?  Go!” 
[For ‘A’ & ‘S’]  “Time’s up!  Now I would like you to name as many words as you can beginning 
with the letter _________.  Again, no proper names, names of place, or numbers.  Ready?  
Go!” 
[‘Animals’] “Now I want you to name all the animals you can think of.  Ready?  Go!” 
 
“F”    “A”    “S”   Animals 
TOTALS   F=______  A=_______   S=_______ 
 Animals=_______          
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Subject ID __________________ Date _________________ 
 
CLINICAL RATING 
 
Examiner __ __     Date __ __/ __ __/ __ __   Clock Time: _________________ 
 
1. How willing was this subject to try his or her best? 
 _____ very willing  _____ somewhat willing 
 _____ not too willing  _____ very unwilling 
 
2. How well did this subject understand the instructions? 
 _____ completely  _____ very well  _____ fairly well 
 _____ not too well  _____ not well at all 
 
3. How much did this subject want to chat about matters unrelated to the session? 
 _____ a great deal – unusually talkative   _____ quite a bit 
 _____ a moderate amount _____ not too much  _____ very little 
 
4. To what extent were you able to maintain control over the session? 
 _____ completely  _____ quite a bit  _____ a moderate amount 
 _____ not too much  _____ very little 
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5. How smoothly did you and this subject work together? 
 _____ extremely smoothly – no strain   _____ very smoothly 
 _____ fairly smoothly  _____ not too smoothly _____ not smoothly at all 
 
6. In general, what was the pace of the session? 
 _____ much faster than average  _____ somewhat faster than average 
 _____ about average    _____ somewhat slower than average 
 _____ much slower than average 
 
7. Overall, how much did distractions and interruptions affect the session? 
 _____ very much  _____ much   _____ somewhat 
 _____ little   _____ very little 
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Subject ID __________________ Date ____________________ 
 
CLINICAL RATING Page 2 
8. To what extent do you feel the information obtained is accurate?  
 _____ completely  _____ mostly   _____ moderately  
_____ somewhat  _____ not very 
 
9. Overall, how would you rate this subject’s anxiety level? 
 _____  not anxious at all  
 _____ somewhat anxious at the beginning, or only intermittently 
 _____ somewhat anxious during much of the session 
 _____ moderately anxious at the beginning, or only intermittently 
 _____ moderately anxious during much of the session 
 _____ extremely anxious at the beginning, or only intermittently 
 _____ extremely anxious during much of the session 
 
10. Overall, how would you rate this subject’s level of depression? 
 _____ not at all depressed 
 _____ mildly depressed 
 _____ moderately depressed 
 _____ severely depressed 
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11. On which particular tasks did this subject appear most anxious?
 ____________________________________________________________________ 
12. On which particular tasks did this subject appear most apathetic? 
 ____________________________________________________________________ 
13. On which particular tasks did this subject appear most angry? 
 ____________________________________________________________________ 
14. Which particular tasks did this subject seem to enjoy the most? 
 ____________________________________________________________________ 
15. During debriefing, what concerns did the subject raise? 
 ____________________________________________________________________ 
16. How did you deal with these concerns? 
 ____________________________________________________________________ 
 ____________________________________________________________________ 
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APPENDIX C: EXCLUSION CRITERIA FOR MR HYPER STUDY 
a. < 35 or > 60 yrs.  
b. Non-english speaking 
c. HTN history or taking medications for HTN. 
d. Regular night shift. 
e. Insulin dependent diabetic. 
f. Any cardiac disease, insulin dependent diabetes, seizure disorder, 
unconscious > 30 mins, amnesia > 24hrs, more than 2 episodes of MTBI, any 
physical or psychological problem you deal with on a daily basis for 3+ 
months,  chronic liver or kidney disease, treatment for cancer in the past 12 
months, serious neuropsychiatric conditions, stroke, multiple sclerosis, brain 
tumor.  
g. Metal in body, refused for an MRI or refused themselves – claustrophobia. 
h. Current pregnancy. 
i. >30% overweight by Metropolitan Life Insurance table standards 
j. Medications – any cardiac medication on a routine basis – exclude and for 
certain categories on a regular basis: anti-anxiety**, narcotics*, antihistamines*, 
sleeping pills**, inhaled medications for asthma, COPD (chronic bronchitis, 
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emphysema) – exclude - */** exceptions are made for those taking less than half 
of the time, but they must abstain for *= 24hrs and ** = 72 hrs.       
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